# Patent

## Title
Antibody polypeptides that antagonize CD40L

## Abstract

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

## Background
REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 14/510,474, filed Oct. 9, 2014, now U.S. Pat. No. 9,228,018, issued Jan. 5, 2016, which is a continuation of U.S. application Ser. No. 13/650,493, filed Oct. 12, 2012, now U.S. Pat. No. 8,895,010, issued Nov. 25, 2015, which claims the benefit of U.S. Provisional Application No. 61/546,800, filed Oct. 13, 2011, and U.S. Provisional Application No. 61/655,110, filed Jun. 4, 2012, which are herein incorporated by reference in their entirety.


SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 23, 2015, is named 200896-0005-03-US_ST25.txt and is 1,222,204 bytes in size.
TECHNICAL FIELD
Antibodies and fragments thereof that target CD40L, compositions comprising the same, and methods of using the same for treatment of diseases involving CD40L activity are provided.
BACKGROUND
CD40 ligand (CD40L), also known as CD154, gp39, TNF-related activation protein (TRAP), 5c8 antigen, or T-BAM, is a trimeric transmembrane protein of the tumor necrosis factor (TNF) superfamily of molecules. CD40L is primarily expressed on activated T cells, as well as on activated leukocytes, eosinophils, basophils, natural killer cells, mast cells, and non-immune cells such as platelets and activated endothelial cells. CD40L also exists in soluble form (sCD40L) that is produced by microsomal stimulus-dependent cleavage of the membrane-bound CD40L. Most of sCD40L in circulation (>90%) is platelet-derived.
CD40L binds CD40, a type I transmembrane glycoprotein belonging to the TNF receptor (TNFR) family. Although all monomeric, dimeric, and trimeric forms of sCD40L can bind to CD40, the trimeric form of sCD40L has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNFR family. The highest expression of CD40 has been observed on antigen presenting cells (APCs), such as B cells, macrophages, and dendritic cells, while lower expression of this receptor is noted on a variety of other cell types, including stromal cells and thymic epithelium. The CD40-CD40L interaction is essential for normal T-B cell interactions, including increased co-stimulation, T-cell priming, cytokine production, antibody-class switching and affinity maturation, and antibody and autoantibody production.
The crucial role of CD40-CD40L interactions in immune and inflammatory responses has made them a promising target for treatment of pathological immuno-inflammatory processes. Blockade of CD40-CD40L interactions by means of specific CD40L monoclonal antibodies (mAbs) successfully prevents allograft rejection in primates and treats autoimmune diseases and atherosclerosis in animal models. Montgomery et al., Transplantation 74: 1365-1369 (2002).
In humans, two different anti-CD40L mAb clones have been used in clinical trials for treatment of different autoimmune diseases. Maribel et al., Mol. Immunol. 45: 937-44 (2008). Monoclonal antibodies, however, can display unusually high incidence of thromboembolic (TE) complications, such as atherothrombotic central nervous system events, myocardial infarction, pulmonary embolism, and deep vein thrombosis. For example, the usefulness of the anti-CD40L mAb clone hu5c8 (anti-CD40L mAb, Biogen) is limited by an unusually high incidence of TE complications. TE by these antibodies is thought to result from the formation of higher-order immune complexes (IC) of the mAbs with membrane-bound CD40L on platelets, or sCD40L shed from platelets, that can ligate and thereby aggregate neighboring platelets via their FcgRIIa receptors, resulting in thrombi formation. The risk of thromboembolism has led to a halt in all ongoing clinical trials. Boumpas et al., Arthritis & Rheumatism 48: 719-727 (2003).
SUMMARY
Anti-CD40L antibody antagonists that are less likely to cause platelet aggregation and thus cause thromboembolism are still needed in a clinical setting. Novel antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides advantageously do not cause platelet aggregation. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, including autoimmune diseases, transplant rejection, and allergic responses. The antibody polypeptides comprise a variable domain. Exemplary antibody polypeptides are in the form of a domain antibody (dAb) that contains a single variable domain. Alternatively, the dAbs can be bi-specific reagents that comprise a second variable domain that can bind another antigen, such as human serum albumin (HSA), for example.
An antibody polypeptide is provided comprising a first variable domain that specifically binds human CD40L, wherein the first variable domain comprises the amino acid sequence of one of the variable domains selected from the BMS2h lineage. Further provided is an isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence of the first variable domain comprises: (a) a CDR1 region which differs from the CDR1 region of BMS2h-572-633 by up to three amino acids, (b) a CDR2 region which differs from the CDR2 region of BMS2h-572-633 by up to three amino acids, (c) a CDR3 region which differs from the CDR3 region of BMS2h-572-633 by up to three amino acids, (d) a FR1 region which differs from the FR1 region of BMS2h-572-633 by up to three amino acids, (e) a FR2 region which differs from the FR2 region of BMS2h-572-633 by up to three amino acids, (f) a FR3 region which differs from the FR3 region of BMS2h-572-633 by up to three amino acids, and (g) a FR4 region which differs from the FR4 region of BMS2h-572-633 by up to three amino acids; and wherein the antibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM. Also provided is an antibody polypeptide, wherein the amino acid sequence of the first variable domain comprises: (a) a CDR1 region which differs from the CDR1 region of BMS2h-572-633 by up to three amino acids, (b) a CDR2 region which differs from the CDR2 region of BMS2h-572-633 by up to three amino acids, and (c) a CDR3 region which differs from the CDR3 region of BMS2h-572-633 by up to three amino acids. Alternatively, the amino acid sequence of the first variable domain can differ from the amino acid sequence of BMS2h-572-633 by up to and including 10 amino acids. Furthermore, the amino acid sequence of the first variable domain can differ from the amino acid sequence of BMS2h-572-633 by up to and including 5 amino acids. The amino acid sequence of the first variable domain can also differ from the amino acid sequence of BMS2h-572-633 by up to and including 2 amino acids. Alternatively, the first variable domain differs from the amino acid sequence of BMS2h-572-633 by 1 amino acid.
Also provided is an antibody polypeptide selected from the lineage group of BMS2h-572, wherein the amino acid sequence of the first variable domain further comprises: (a) a CDR1 region having a sequence Trp-X1-Leu-Met-Gly (SEQ ID NO: 2), wherein X1 is Glu or Gln; (b) a CDR2 region having a sequence Gly-Ile-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQ ID NO: 3); and (c) a CDR3 region having a sequence Lys-X2-Y2-Z2-Ser-Asp-Tyr (SEQ ID NO: 4), wherein X2 is Asp or Glu, Y2 is Ala or Ser, and Z2 is Lys, Asn, or Arg. Also provided is the antibody polypeptide, wherein the amino acid sequence of the first variable domain further comprises: (a) a FR1 region having a sequence Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Asn (SEQ ID NO: 5); (b) a FR2 region having a sequence Trp-X1-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser (SEQ ID NO: 6), wherein X1 is Ala or Val; (c) a FR3 region having a sequence Arg-Thr-Phe-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly (SEQ ID NO: 7); and (d) a FR4 region having a sequence Arg-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8).
Alternatively, the first variable domain of the antibody polypeptide can comprise the amino acid sequence of BMS2h-572-633.
Also provided is an antibody polypeptide selected from the lineage group of BMS2h-719, comprising a first variable domain with the following consensus sequence: Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-X1-Y1-Tyr-Glu-Met-Z1-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-Ser-Ile-Ser-Ser-Asp-Gly-Ser-Phe-Thr-Tyr-Tyr-Ala-A1-Ser-Val-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-B1-Pro-Phe-Thr-Glu-C1-Asp-Tyr-Trp-Gly-His-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 9), wherein X1 is Lys or Asn; Y1 is Arg, Lys, Ser, or Thr; Z1 is Met or Gln; A1 is Asp or Glu; B1 is Asp or Glu; and C1 is Phe, Met, or Leu.
Also provided is an antibody polypeptide selected from the lineage group of BMS2h-503, comprising a first variable domain with the following consensus sequence: Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-Arg-Ala-Ser-His-X1-Ile-Gln-Arg-Tyr-Leu-Ser-Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-Ile-Leu-Trp-Gly-Ser-Gln-Leu-Gln-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-Thr-Ile-Ser-Ser-Leu-Gln-Pro-Glu-Asp- Phe-Ala-Thr-Tyr-Tyr-Cys-Gly-Gln-Trp-Trp-Ala-Pro-Pro-Gln-Thr-Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-Arg (SEQ ID NO: 10), wherein X1 is His or Asp.
Also provided is an antibody polypeptide selected from the lineage group of BMS2h-116, comprising a first variable domain with the following consensus sequence: Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-X1-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-Arg-Ala-Ser-Gln-Pro-Ile-Gly-Pro-Asp-Leu-Leu-Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-Ile-Tyr-Gln-Thr-Ser-Ile-Leu-Arg-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Glu- Thr-Asp-Phe-Thr-Leu-Thr-Ile-Ser-Asn-Leu-Gln-Pro-Glu-Asp-Y1-Ala-Z1-Tyr-Tyr-Cys-Gln-Gln-Tyr-Trp-Ala-Phe-Pro-Val-Thr-Phe-Gly-A1-Gly-Thr-Lys-Val-Val-Ile-Lys-Arg (SEQ ID NO: 11), wherein X1 is Ser or Tyr; Y1 is Leu or Phe; Z1 is Thr or Lys; and A1 is Lys, Arg, or Gln.
Also provided is an antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein the antibody polypeptide is a domain antibody (dAb). The antibody polypeptide can be a fusion polypeptide comprising the first variable domain and an Fc domain. Alternatively, the fusion polypeptide can comprise an IgG4 Fc domain. The fusion polypeptide also can comprise an IgG1 Fc domain. The fusion polypeptide can also comprise an IgG1 Fc domain. Alternatively, the fusion polypeptide can comprise a CT-Long domain. The fusion polypeptide can also comprise a CT-short domain. Alternatively, the fusion polypeptide can comprise a N297Q Long Fc domain. The fusion polypeptide can alternatively comprise a N297Q Short Fc domain.
Also provided is an antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein the antibody polypeptide further comprises a second variable domain that specifically binds a second antigen, wherein the second antigen is an antigen other than human CD40L. The second antigen can be a cluster of differentiation (CD) molecule or a Major Histocompatibility Complex (MHC) Class II molecule. Alternatively, the second antigen can be serum albumin (SA).
Also provided is a nucleic acid encoding any of the antibody polypeptides provided herein. Further contemplated is a vector comprising the nucleic acid. An isolated host cell can comprise such vector.
A pharmaceutical composition is provided comprising a therapeutically-effective amount of the presently provided antibody polypeptide and a pharmaceutically acceptable carrier. The pharmaceutical composition can further comprise an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.
A method of treating an immune disease in a patient in need of such treatment is provided comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition described herein. An exemplary method administers the pharmaceutical composition in combination with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent. The immune disease can be an autoimmune disease or a graft-related disease. Alternatively, the immune disease is a graft-related disease. Furthermore, the graft-related disease can comprise solid organ, tissue and/or cell transplant rejection. Alternatively, the graft-related disease is graft versus host disease (GVHD). The graft-related disease can further be an acute transplant rejection. Alternatively, the graft-related disease can be a chronic transplant rejection.
Also provided is the method of treating a graft-related disease, wherein the pharmaceutical composition is co-administered with a CTLA4 mutant molecule. The CTLA4 mutant molecule can be L104EA29Y-Ig (belatacept).
A method of treating an immune disease in a patient in need of such treatment is also provided comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition provided herein, wherein the immune disease is selected from the group consisting of selected from the group consisting of Addison's disease, allergies, ankylo sing spondylitis, asthma, atherosclerosis, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes, including Type 1 and/or Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products, systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, transplantation of tissues and organs, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, alcohol addiction, and drug addiction. Alternatively, the immune disease can be myasthenia gravis, idiopathic thrombocytopenic purpura, or systemic sclerosis.
Also provided is a use of an isolated antibody polypeptide disclosed herein for the preparation of a medicament for the treatment of a patient, wherein the patient has or is at risk of having an immune disease. Further provided is a use of an isolated antibody polypeptide disclosed herein for preparation of a medicament for alleviating at least one symptom of an immune disease in a patient in need thereof.
Further provided herein is an isolated antibody polypeptide comprising a first variable domain, wherein said antibody polypeptide specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO: 1, wherein the antibody polypeptide competes with the binding of BMS2h-572-633, and wherein the antibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM. In one aspect, the first variable domain comprises the amino acid sequence of one of the antibody polypeptides selected from the lineage group consisting of BMS2h-572, BMS2h-719, BMS2h-503, and BMS2h-116. In another aspect, the first variable domain comprises an amino acid sequence at least 95% identical to BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313, or BMS2h-116-1320. In yet another aspect, the first variable domain comprises the amino acid sequence of BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313, or BMS2h-116-1320.



BRIEF DESCRIPTION OF THE FIGURES
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
FIG. 1A depicts the domain antibody that comprises a VH variable domain BMS2h-572-633 fused to a modified Fc tail from Abatacept IgG1.
FIG. 1B shows the amino acid sequence (SEQ ID NO: 1355) of the variable domain BMS2h-572-633 (in blue). The Fc fusion protein is a dimer of molecular weight 77,984 Daltons, with each polypeptide chain consisting of 354 amino acids. The variable domain is fused by a linker (green) to the mutated Fc construct of human IgG1, wherein three cysteine residues (shown in purple) are substituted with serine, and one proline (shown in red) is substituted with a serine residue.
FIG. 2 depicts a working model for the CD40-40L pathway. The top panel demonstrates initial stages of an encounter between a T cell and an APC. The initial encounter driven by T cell receptor (TCR) engagement of pMHC complex (signal 1) coupled with an early CD28-CD80 interaction (signal 2) is sufficient for the cell surface expression of trimeric CD40L (bottom panel). Engagement of CD40 by CD40L results in numerous biological responses outlined in the grey box.
FIG. 3 provides sequences (SEQ ID NOS 1356-1361, respectively, in order of appearance) of various Fc domains. Linker regions are shown in boxes.
FIG. 4 shows examples of various Fc-formatted domain antibodies (SEQ ID NOS 1362-1365, respectively, in order of appearance). Linker regions are indicated by boxes.
FIG. 5 depicts SPR sensorgram data for the binding of 12.5-0.39 nM BMS-986004 (2:1 dilution series) to biot-IZ-hCD40L captured on a streptavidin SPR sensor chip at 25° C. Colored lines show the double-referenced sensorgram data, and black lines show the 1:1 Langmuir fit to the data, with an avidity-influenced apparent Kd value of 0.11 nM.
FIG. 6 shows ITC data for titrations of 19 μM IZ-hCD40L into 2 μM BMS-986004 (black) or 18 μM BMS-986004 into 2 μM IZ-hCD40L (blue). The molar ratio (apparent stoichiometry) is defined per mole of IZ-hCD40L trimer and per mole of bivalent BMS-986004 Fc-dimer. Molar ratio values obtained as the equivalence points on the abscissa suggest more than one mole of BMS-986004 can bind per mole of IZ-hCD40L trimer; however, an exact structural model for the complex cannot be determined from the ITC data alone. Squares represent the integrated heat of binding data and solid lines represent the best fit to a “2 sets of sites model.”
FIG. 7 shows in vivo efficacy of mouse CD40L surrogate dAb-Fc (KLH-induced antibody response.
FIG. 8 demonstrates that mouse dAb BMS-2m-126-24-Fc and antibody MR-1 inhibit TNBS-induced colitis in mice.
FIG. 9 shows that BMS-2m-126-24-Fc and CTLA4-Ig work synergistically to prolong the survival of cardiac allografts.
FIG. 10 provides a hypothetic model for anti-CD40 monoclonal antibody-mediated platelet aggregation.
FIG. 11A shows plasma concentration vs. time profile of BMS-986004 after IV dosing of 11 mg/kg in monkeys.
FIG. 11B demonstrates plasma concentration vs. time profiles of BMS-986003 after IV dosing of 2 mg/kg in monkeys.
FIG. 12 presents plasma concentrations vs. time profiles of BMS-986003 (after SC dosing at 0.2, 2 and 20 mg/kg in monkeys) and of 5c8 IgG1 (after IV dosing at 20 mg/kg in monkeys).
FIG. 13 shows plasma concentrations vs. time profiles of BMS-2m-126-24-CT after 1 mg/kg IV and SC dosing, and 10 mg/kg SC dosing to mice.
FIG. 14 demonstrates PK/PD modeling of BMS-986003 and 5c8-IgG1 plasma exposures and anti-KLH antibody response (IgG Titers).
FIG. 15 shows PK/PD modeling of BMS-986004 plasma exposures and ex vivo RO on peripheral blood mononuclear cells (PBMC).
FIG. 16 demonstrates that IV.3 blocks 5c8/sCD40L IC-mediated activation of platelets in human blood.
FIG. 17 shows the effect of Fc variants on platelet activation in human blood.
FIG. 18 demonstrates activation of platelets with 5c8-CT/sCD40L IC in blood from human donors genotyped for FcgRIIa polymorphism.
FIG. 19 diagrams platelet activation by various antibodies in blood from human donors.
FIG. 20 shows levels of platelet activation by various antibodies, including BMS-986003, in hFcgRIIa-expressing transgenic mice.
FIGS. 21, 22, 23, and 24 show is ClustalW2 alignments of representative domain antibody polypeptides from lineages BMS2h-572, BMS2h-719, BMS2h-503, and BMS2h-116, respectively. FIG. 21 discloses SEQ ID NOS 243, 251, 257, 262 and 274-276, respectively, in order of appearance, FIG. 22 discloses SEQ ID NOS 352, 354-355 and 357-361, respectively, in order of appearance, FIG. 23 discloses SEQ ID NOS 1087-1088, respectively, in order of appearance, and FIG. 24 discloses SEQ ID NOS 970-971 and 974, respectively, in order of appearance.
FIG. 25 shows SPR sensorgram data for binding experiments using monovalent dAbs BMS2h-503-1, BMS2h-572-6, BMS2h-719-17, and monovalent Fab fragment of 5c8, where the indicated molecules compete with each other for binding to CD40L (biotinylated IZ-hCD40L).
FIG. 26 shows SPR sensorgram data for experiments testing the binding of BMS2h-572-619-CT-long, BMS2h-572-633-CT-long, BMS2h-572-6-CT-long, BMS2h-719-202-CT-long, BMS2h-572-608-CT-long, BMS2h-572-634-CT-long, BMS2h-572-614-CT-long, BMS2h-572-635-CT-long, and 5c8-CT-long molecules to either CD40L monomer (upper 3 panels) or CD40L trimer (lower 3 panels).



DETAILED DESCRIPTION
Antibody polypeptides that specifically bind to human CD40L are provided. The antibody polypeptides do not activate platelets, and the antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be selected using a primary screen that utilizes cell binding assays, followed by one or more rounds of error-prone or degenerate oligonucleotide-directed affinity maturation. As a result, a genus of antibody polypeptides that specifically bind CD40L are provided.
A “lineage” is a set of related antibody polypeptides that were prepared from a common precursor by error-prone or degenerate oligonucleotide-directed affinity maturation, as disclosed in the examples below, and that are expected to bind CD40L. The nomenclature of the antibody polypeptides is used to designate the various lineages. The nomenclature “BMS2h-572,” for example, refers to antibody polypeptides of lineage 572, which were raised against human CD40L. “Lineage BMS2h-572” antibody polypeptides include BMS2h-572-1 through BMS2h-572-19, BMS2h-572-21 through BMS2h-572-24, BMS2h-572-601 through BMS2h-572-627, and BMS2h-572-630 through BMS2h-572-635.
Accordingly, in one aspect, an antibody polypeptide comprises a variable domain that specifically binds human CD40L, where the antibody polypeptide competes with the binding of any one of the domain antibodies (dAbs) listed in TABLE 1 or TABLE 3. For example, the antibody polypeptide may compete with a dAb selected from the 2h lineage. The dAb also may be selected from a lineage selected from the group consisting of BMS2h-116, BMS2h-503, BMS2h-572, and BMS2h-719, such as the dAb BMS2h-572-633, BMS2h-572-608, or BMS2h-572-614, for instance. In another aspect, an antibody polypeptide specifically binds human CD40L as any one of the dAbs listed in TABLE 1 and TABLE 3. For example, the antibody polypeptide may comprise a variable domain that specifically binds human CD40L as the dAb BMS2h-572-633, BMS2h-572-608, or BMS2h-572-614, for instance.
The antibody polypeptides may be a domain antibody containing a single variable domain. The antibody polypeptides also may comprise additional domains, such as an Fc domain. For instance, the antibody polypeptide may comprise a second variable domain that specifically binds human serum albumin (HSA). Such dual specific antibody polypeptides may have an increased half-life, for example.
As used herein, “specific binding” refers to the binding of an antigen by an antibody polypeptide with a dissociation constant (Kd) of about 1 μM or lower as measured, for example, by surface plasmon resonance (SPR). Suitable assay systems include the BIAcoreTM surface plasmon resonance system and BIAcoreTM kinetic evaluation software (e.g., version 2.1). The affinity or Kd for a specific binding interaction may be about 1 μM or lower, about 500 nM or lower or about 300 nM or lower.
The term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. Generally, about encompasses a range of values that are plus/minus 10% of a referenced value.
In accordance with this detailed description, the following abbreviations and definitions apply. It must be noted that as used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” includes a plurality of such antibodies and reference to “the dosage” includes reference to one or more dosages and equivalents thereof known to those skilled in the art, and so forth.
1. CD40L and CD40L Activities
Antibody polypeptides are provided that bind human CD40L. CD40L is also known as CD154, gp39, TNF-related activation protein (TRAP), 5c8 antigen, or T-BAM. Relevant structural information for human CD40L can be found, for example, at UniProt Accession Number P29965. “Human CD40L” refers to the CD40L comprising the following amino acid sequence:







(SEQ ID NO: 1)









        10         20         30         40



MIETYNQTSP RSAATGLPIS MKIFMYLLTV FLITQMIGSA



 



        50         60         70         80



LFAVYLHRRL DKIEDERNLH EDFVFMKTIQ RCNTGERSLS



 



        90        100        110        120



LLNCEEIKSQ FEGFVKDIML NKEETKKENS FEMQKGDQNP



 



       130        140        150        160



QIAAHVISEA SSKTTSVLQW AEKGYYTMSN NLVTLENGKQ



 



       170        180        190        200



LTVKRQGLYY IYAQVTFCSN REASSQAPFI ASLCLKSPGR



 



       210        220        230        240



FERILLRAAN THSSAKPCGQ QSIHLGGVFE LQPGASVFVN



 



       250        260



VTDPSQVSHG TGFTSFGLLK L






CD40L has also been sequenced in Sus scrofa, Mus musculus, Canis familiaris, Bos ffini, Macaca mulatta, Aotus tivirgatus, Callithrix jacchus, Cercocebus torquatus atys, Macaca nemestrina, Rattus norvegicus, Gallus gallus, Felis catus, and Sus scrofa. 
Binding of the present antibody polypeptides to CD40L antagonizes CD40L activity. “CD40L activities” include, but are not limited to, costimulation and activation an APC in association with T cell receptor stimulation by MHC molecules on the APC, secretion of all immunoglobulin isotypes in the presence of cytokines, stimulation of B cell proliferation, cytokine production, antibody class switching and affinity maturation. For example, patients with X-linked hyper-IgM syndrome express functional CD40 on their B cells, but their activated T cells have a defective CD40L protein, resulting in its inability to activate B cells and induce immunoglobulin isotype switching. Aruffo et al., Cell 72:291-300 (1993).
CD40L activities can be mediated by interaction with other molecules. “CD40 activities” include the functional interaction between CD40L and the following molecules: CD40 (CD40L receptor), α5β1 integrin, and αIIbβ3. For example, CD40L binds its receptor, CD40, which is expressed on a variety of APCs, such as B cells, macrophages, and dendritic cells, as well as on stromal cells, vascular endothelial cells, and platelets.
As used herein, the terms “activate,” “activates,” and “activated” refer to an increase in a given measurable CD40L activity by at least 10% relative to a reference, for example, at least 10%, 25%, 50%, 75%, or even 100%, or more. A CD40L activity is “antagonized” if the activity is reduced by at least 10%, and in an exemplary embodiment, at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, or even 100% (i.e., no detectable activity), relative to the absence of the antagonist. For example, an antibody polypeptide may antagonize some or all CD40L activity. In one embodiment, the antibody polypeptide does not activate B cell proliferation. In another embodiment, the antibody polypeptide does not activate cytokine secretion by T cells or dendritic cells (DCs), where the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-6, IL-10, IL-12, IL-13, IL-17, IL-23, TNF-α, and IFN-γ.
2. Antibody Polypeptides
The antibody polypeptides comprise a variable domain. In one embodiment, the antibody polypeptides are in the form of a dAb that contains a single variable domain. Antibody polypeptides may be full-length anti-CD40L immunoglobulin molecules comprising two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. In this embodiment, the amino terminal portion of each chain includes a variable domain (VL or VH) of about 100-120 amino acids. The complementarity determining regions (CDRs) contained therein are primarily responsible for antigen recognition, although framework residues can play a role in epitope binding. The carboxy-terminal “half” of each heavy chain defines a constant region (Fc) primarily responsible for effector function.
Antibody polypeptides also may be “fragments” comprising a portion of the full-length anti-CD40L immunoglobulin molecule that comprises a variable domain that specifically binds CD40L. Thus, the term “antibody polypeptides” includes an antigen-binding heavy chain, light chain, heavy chain-light chain dimer, Fab fragment, F(ab′)2 fragment, Fv fragment, single chain Fv (scFv), and dAb, for example. The term “antibody polypeptides” thus includes polypeptides made by recombinant engineering and expression, as well as monoclonal antibodies produced by natural recombination and secretion by hybridoma cell clones.
Light chains are classified as kappa (κ) or lambda (λ), and are characterized by a particular constant region, CL, as known in the art. Heavy chains are classified as γ, μ, α, δ, or ε, and define the isotype of an antibody as IgG, IgM, IgA, IgD, or IgE, respectively. The heavy chain constant region is comprised of three domains (CH1, CH2, and CH3) for IgG, IgD, and IgA; and four domains (CH1, CH2, CH3, and CH4) for IgM and IgE. Anti-CD40L antibodies may have a heavy chain constant region selected from any of the immunoglobulin classes (IgA, IgD, IgG, IgM, and IgE).
Each light chain variable domain (VL) and heavy chain variable domain (VH) is composed of three CDRs and four framework regions (FRs), arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The three CDRs of the light chain are referred to as “LCDR1, LCDR2, and LCDR3” and the three CDRs of the heavy chain are referred to as “HCDR1, HCDR2, and HCDR3.”
As used herein, the term “Fc domain” refers to the constant region antibody sequences comprising CH2 and CH3 constant domains as delimited according to Kabat et al., Sequences of Immunological Interest, 5th ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). The Fc domain may be derived from an IgG1 or an IgG4 Fc region, for example.
A variable domain may be fused to an Fc domain. Examples of various Fc-formatted domain antibodies and their potency are provided in TABLE 6. FIG. 3 provides sequences of various Fc domains provided herein. Linker regions are shown in boxes. As used in TABLE 6, “Fc” indicates that the dAb is fused to a human IgG1 short Fc. “CT Long Fc,” also called CT-L2, refers to the Fc from CTLA4. The underlined S are cysteine-to-serine point mutations made to eliminate the disulfides in the Fc hinge. “CT Short,” also called CT-S1, is shorter than CT Long by 7 amino acids. “N297Q Long Fc,” also referred to as N297Q-L4, is the Fc domain of human IgG1 with a N297Q mutation made to eliminate the N-linked carbohydrate in the Fc. “N297Q Short Fc,” also called N297Q-S3, is short than N297Q Long Fc by 7 amino acids, and is a human IgG1 with a N297Q point mutation made to eliminate the N-linked carbohydrate in the Fc domain. “CT-Fc SP5” is the CT Long Fc, where SP5 refers to the octeonectin signal peptide used for secretion from the mammalian expression host. Cleavage site is indicated by “^”. FIG. 4 further provides examples of various Fc domain formats.
When a variable domain is fused to an Fc domain, the carboxyl terminus of the variable domain (either a VL or VH domain, including dAbs) may be linked or fused to the amino terminus of the Fc CH2 domain. Alternatively, the carboxyl terminus of the variable domain may be linked or fused to the amino terminus of a CH1 domain, which itself is fused to the Fc CH2 domain. The protein may comprise the hinge region between the CH1 and CH2 domains in whole or in part.
The CDRs contain most of the residues that form specific interactions with the antigen. In one embodiment, the variable domain of an antibody polypeptide comprises CDR1, CDR2, and CDR3 regions that have the same amino acid sequence as the CDR1, CDR2, and CDR3 regions of one of the dAbs listed in TABLE 1 or TABLE 3 or that each differ from the CDR1, CDR2, and CDR3 regions by one, two, or three amino acids. For example, the antibody polypeptide may comprise CDR1, CDR2, and CDR3 regions that have the same amino acid sequence as the CDR1, CDR2, and CDR3 regions of BMS2h-572-633, BMS2h-572-608, or BMS2h-572-614, for example.
A “domain antibody” (dAb) comprises a single variable (VL or VH) domain that is capable of specifically and monovalently binding an antigen, such as CD40L. For example, a dAb may have a VHH structure, characteristic of a camelid dAb. A “VH domain” as used herein is meant to include a VHH structure. In another embodiment, the VH domains (including all features and combination of features presented as embodiments herein) are other than VHH domains. dAbs may form homo- or heterodimers in solution. While not limited by any particular theory, it is believed that the dAbs disclosed herein do not cause platelet aggregation, because the antibodies containing mutated Fc constructs do not bind FcγRIIa (also known as CD32a) on the platelet surface and do not activate platelets.
As used herein, the term “variable domain” refers to immunoglobulin variable domains defined by Kabat et al., Sequences of Immunological Interest, 5th ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). The numbering and positioning of CDR amino acid residues within the variable domains is in accordance with the well-known Kabat numbering convention.
The term “human,” when applied to antibody polypeptides, means that the antibody polypeptide has a sequence, e.g., framework regions and/or CH domains, derived from a human immunoglobulin. A sequence is “derived from” a human immunoglobulin coding sequence when the sequence is either: (a) isolated from a human individual or from a cell or cell line from a human individual; (b) isolated from a library of cloned human antibody gene sequences or of human antibody variable domain sequences; or (c) diversified by mutation and selection from one or more of the polypeptides above. An “isolated” compound as used herein means that the compound is removed from at least one component with which the compound is naturally associated with in nature.
Antibody polypeptides can be administered to human patients while largely avoiding the anti-antibody immune response often provoked by the administration of antibodies from other species, e.g., mouse. For example, murine antibodies can be “humanized” by grafting murine CDRs onto a human variable domain FR, according to procedures well known in the art. Human antibodies as disclosed herein, however, can be produced without the need for genetic manipulation of a murine antibody sequence.
Variable domains may comprise one or more FR with the same amino acid sequence as a corresponding framework region encoded by a human germline antibody gene segment. For example, a domain antibody may comprise the VH germline gene segments DP47, DP45, or DP38, the Vκ germline gene segment DPK9, the JH segment JH4b, or the Jκ segment Jκ1.
Changes may be made to antibody polypeptide sequences while retaining the ability to bind CD40L specifically. Specifically, the antibody polypeptides (e.g., a dAb) may comprise a variant variable domain that retains the function of specifically binding CD40L as the dAb BMS2h-572-633. In one embodiment, the variant variable domain may compete with BMS2h-572-633 for specific binding to CD40L. Error-prone affinity maturation, as disclosed in the examples below, provides one exemplary method for making and identifying antibody polypeptides with variant sequences that specifically bind CD40L.
For example, a variant variable domain may differ from one of the variable domains listed in TABLE 1 and TABLE 3 by up to 10 amino acids or any integral value between, where the variant variable domain specifically binds CD40L. Alternatively, the variant variable domain may have at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) relative to a sequence listed in the present Sequence Listing. Non-identical amino acid residues or amino acids that differ between two sequences may represent amino acid substitutions, additions, or deletions. Residues that differ between two sequences appear as non-identical positions, when the two sequences are aligned by any appropriate amino acid sequence alignment algorithm, such as BLAST.
In one embodiment, amino acid substitutions may be made to individual FR regions, such that a FR comprises 1, 2, 3, 4, or 5 amino acid differences relative to the amino acid sequence of the corresponding FR encoded by a human germline antibody gene segment. In another embodiment, the variant variable domain may contain one or two amino acid substitutions in a CDR. In other embodiments, amino acid substitutions to FR and CDR regions may be combined. Representative variable domains that specifically bind CD40L are listed in TABLE 1 and TABLE 3.
The information regarding the boundaries of the VL or VH domains of heavy and light chain genes may be used to design PCR primers to amplify the variable domain from a cloned heavy or light chain coding sequence encoding an antibody polypeptide known to bind CD40L. The amplified variable domain may be inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al. (1991) Nucleic Acids Res. 19:4133-4137) and expressed, either alone or as a fusion with another polypeptide sequence, using techniques well known in the art. Based on the disclosed amino acid and polynucleotide sequences, the fusion protein can be produced and purified using only ordinary skill in any suitable mammalian host cell line, such as CHO, 293, COS, NSO, and the like, followed by purification using one or a combination of methods, including protein A affinity chromatography, ion exchange, reverse phase techniques, or the like.
In one aspect, the antibody polypeptide is a “dual specific” antibody polypeptide comprising a first variable domain that specifically binds human CD40L. Dual specific antibody polypeptides comprise a second variable domain that specifically binds a second antigen that is other than human CD40L.
In another embodiment, the second antigen may be a cell surface molecule of an immune effector cell or a soluble molecule such as a cytokine, for example. Binding of the dual specificity antibody polypeptide could be used to antagonize CD40L and antagonize a biological activity of the second antigen. Cell surface molecules of immune effector cells include the cluster of differentiation (CD) molecules. Representative CD markers are listed on the Internet at hypertext transfer protocol http://en.wikipedia.org/wiki/List_of human_clusters_of_differentiation (last modified on Aug. 8, 2012). Cell surface molecules of immune effector cells also include Major Histocompatibility Complex (MHC) Class II molecules. Antibodies against these cell surface molecules are known in the art and can be used a source of a variable domain to construct a dual specific antibody polypeptide.
In one embodiment, antibody polypeptides of a dual specific ligand may be linked by an “amino acid linker” or “linker.” For example, a dAb may be fused to the N-terminus of an amino acid linker, and another dAb may be fused to the C-terminus of the linker. Although amino acid linkers can be any length and consist of any combination of amino acids, the linker length may be relatively short (e.g., five or fewer amino acids) to reduce interactions between the linked domains. The amino acid composition of the linker also may be adjusted to reduce the number of amino acids with bulky side chains or amino acids likely to introduce secondary structure. Suitable amino acid linkers include, but are not limited to, those up to 3, 4, 5, 6, 7, 10, 15, 20, or 25 amino acids in length. Representative amino acid linker sequences include (GGGGS)n (SEQ ID NO: 12), where n may be any integer between 1 and 5. Other suitable linker sequences may be selected from the group consisting of AS, AST, TVAAPS (SEQ ID NO: 13), TVA, and ASTSGPS (SEQ ID NO: 14).
The binding of the second antigen can increase the in vivo half-life of the antibody polypeptide. For example, the second variable domain of the dual specific antibody polypeptide may specifically bind serum albumin (SA), e.g., human serum albumin (HSA). The antibody polypeptide formatted to bind I can have an increased in vivo t-α (“alpha half-life”) or t-β (“beta half-life”) half-life relative to the same unformatted antibody polypeptide. The t-α and t-β half-lives measure how quickly a substance is distributed in and eliminated from the body. The linkage to I may be accomplished by fusion of the antibody polypeptide with a second variable domain capable of specifically binding I, for example. Anti-human serum albumin antibodies are well-known in the art. See, e.g., Abcam®, Human Serum Albumin antibodies ab10241, ab2406, and ab8940, available on the Internet at hypertext transfer protocol www.abcam.com/index.html, or GenWay, ALB antibody, available on the Internet at hypertext transfer protocol www.genwaybio.com. Variable domains that specifically bind I can be obtained from any of these antibodies, and then fused to an antibody polypeptide of the disclosure using recombinant techniques that are well known in the art.
Alternatively, the linking of the antibody polypeptide to I can be accomplished by directly fusing the antibody polypeptide sequence to an I coding sequence using techniques well known to the skilled artisan. The I coding sequences can be obtained by PCR using primers derived from the cDNA sequence available at GenBank Accession No. NM000477, for example.
In one embodiment, the tα-half-life of the I-linked domain antibody composition is increased by 10% or more. In another embodiment, the tα-half-life of the I-linked domain antibody composition is in the range of 0.25 hours to 6 hours. In another embodiment, the tβ-half-life of the I-linked domain antibody composition is increased by 10% or more. In another embodiment, the tβ-half-life of the I-linked domain antibody composition is in the range of 12 to 48 hours.
In another embodiment, an antibody polypeptide may be formatted to increase its in vivo half-life by PEGylation. In one embodiment, the PEG is covalently linked. In another embodiment, the PEG is linked to the antibody polypeptide at a cysteine or lysine residue. In yet another embodiment, the PEG-linked antibody polypeptide has a hydrodynamic size of at least 24 kD. In yet another embodiment, the total PEG size is from 20 to 60 kD, inclusive. In yet another embodiment, the PEG-linked domain antibody has a hydrodynamic size of at least 200 kD.
PEGylation can be achieved using several PEG attachment moieties including, but not limited to N-hydroxylsuccinimide active ester, succinimidyl propionate, maleimide, vinyl sulfone, or thiol. A PEG polymer can be linked to an antibody polypeptide at either a predetermined position, or can be randomly linked to the domain antibody molecule. PEGylation can also be mediated through a peptide linker attached to a domain antibody. That is, the PEG moiety can be attached to a peptide linker fused to an antibody polypeptide, where the linker provides the site (e.g., a free cysteine or lysine) for PEG attachment. Methods of PEGylating antibodies are well known in the art, as disclosed in Chapman, et al., “PEGylated antibodies and antibody fragments for improved therapy: a review,” Adv. Drug Deliv. Rev. 54(4):531-45 (2002), for example.
Antibody polypeptides also may be designed to form a dimer, trimer, tetramer, or other multimer. Antibody polypeptides, e.g., dAbs, can be linked to form a multimer by several methods known in the art, including, but not limited to, expression of monomers as a fusion protein, linkage of two or more monomers via a peptide linker between monomers, or by chemically joining monomers after translation, either to each other directly, or through a linker by disulfide bonds, or by linkage to a di-, tri- or multivalent linking moiety (e.g., a multi-arm PEG). In one embodiment, the multimer can bind a single molecule of CD40.
3. Pharmaceutical Compositions and Methods of Treatment
A pharmaceutical composition comprises a therapeutically-effective amount of one or more antibody polypeptides and optionally a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, for example, water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives, or buffers that enhance the shelf-life or effectiveness of the fusion protein. The compositions can be formulated to provide quick, sustained, or delayed release of the active ingredient(s) after administration. Suitable pharmaceutical compositions and processes for preparing them are well known in the art. See, e.g., Remington, THE SCIENCE AND PRACTICE OF PHARMACY, A. Gennaro, et al., eds., 21st ed., Mack Publishing Co. (2005).
The pharmaceutical composition further may comprise an immunosuppressive/immunomodulatory and/or anti-inflammatory agent. A method of treating an immune disease in a patient in need of such treatment may comprise administering to the patient a therapeutically effective amount of the pharmaceutical composition. Antagonizing CD40L-mediated T cell activation could inhibit undesired T cell responses occurring during autoimmunity, transplant rejection, or allergic responses, for example. Inhibiting CD40L-mediated T cell activation could moderate the progression and/or severity of these diseases.
As used herein, a “patient” means an animal, e.g. mammal, including humans. The patient may be diagnosed with an immune disease. “Treatment” or “treat” or “treating” refers to the process involving alleviating the progression or severity of a symptom, disorder, condition, or disease. An “immune disease” refers to any disease associated with the development of an immune reaction in an individual, including a cellular and/or a humoral immune reaction. Examples of immune diseases include, but are not limited to graft-related disease, inflammation, allergy, and autoimmune disease. The autoimmune disease may be selected from the group consisting of systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, and ulcerative colitis.
Diseases that can be treated by administering the pharmaceutical composition may be selected from the group consisting of Addison's disease, allergies, ankylosing spondylitis, asthma, atherosclerosis, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes, including Type 1 and/or Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products (e.g., Factor VII in hemophiliacs), systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, and vasculitis. Autoimmune-mediated conditions include, but are not limited to, conditions in which the tissue affected is the primary target, and in some cases, the secondary target. Such conditions include, but are not limited to, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, transplantation of tissues and organs, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus' phenomenon, anaphylaxis, alcohol addiction, and drug addiction.
Preferred indications for administration of the present pharmaceutical compositions are, for example, immune thrombocytopenic purpura, systemic sclerosis, myasthenia gravis, allograft rejection, and graft-versus-host disease.
The pharmaceutical composition may be administered alone or in combination therapy, (i.e., simultaneously or sequentially) with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent. Different immune diseases can require use of specific auxiliary compounds useful for treating immune diseases, which can be determined on a patient-to-patient basis. For example, the pharmaceutical composition may be administered in combination with one or more suitable adjuvants, e.g., cytokines (IL-10 and IL-13, for example) or other immune stimulators, e.g., chemokines, tumor-associated antigens, and peptides. Suitable adjuvants are known in the art.
For example, the disclosed pharmaceutical composition may be co-administered, concomitantly or sequentially, with a cytotoxic T-lymphocyte antigen 4 (CTLA4) mutant molecule, such as L104EA29Y-Ig (belatacept). CTLA4 binds to CD80 (B7-1) and CD86 (B7-2) with higher avidity than CD28, and it is transiently expressed on T cells following their activation, where it interrupts the interaction between CD28 and CD80/86. Oosterwegel et al., Curr. Opin. Immunol. 11: 294-300 (1999). This creates a negative feedback signal for T cell activation.
CTLA4 mutant molecules, including L104EA29Y-Ig, have increased binding avidity to CD80/86 compared to wild-type CTLA4. Intervention of the CD28-CD80/86 pathway by L104EA29Y-Ig has been successfully pursued, for example, to treat graft-related diseases in non-human primate transplant models, alone or in combination with other immunosuppressive agents. Larsen et al., Amer. J. Transplant. 5: 443 (2005). U.S. Patent Application number 2010/0166774 describes the structure of L104EA29Y-Ig, methods of producing it, and a formulation comprising a CTLA4 molecule; and the application is herein incorporated by reference. U.S. Pat. Nos. 7,094,874 and 7,482,327 further disclose administration (including co-administration with one or more other drugs) and dosage schedule of L104EA29Y-Ig, and the disclosures of these patents are herein incorporated by reference.
Any suitable method or route can be used to administer the antibody polypeptide or the pharmaceutical composition. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration. A therapeutically effective dose of administered antibody polypeptide(s) depends on numerous factors, including, for example, the type and severity of the immune disease being treated, the use of combination therapy, the route of administration of the antibody polypeptide(s) or pharmaceutical composition, and the weight of the patient. A non-limiting range for a therapeutically effective amount of a domain antibody is 0.1-20 mg/kg, and in an aspect, 1-10 mg/kg, relative to the body weight of the patient. The dose of antibody polypeptide(s) can be further guided by the amount of antibody polypeptide(s) required for CD40 antagonism in in vitro and/or in vivo models of disease states. Representative models are described below and in the examples.
4. In Vitro and In Vivo Models
The ability of antibody polypeptides of the disclosure to antagonize CD40L can be tested in one of several available in vitro or in vivo model systems. Appropriate human, animal, and cell model systems are described below. Further cell assay systems are described in the examples.
4.1. Immune Thrombocytopenic Purpura (ITP) In Vivo Model:
The potential role of CD40-CD40L in the pathogenesis of ITP is reported by Patel et al., British J. Haematology 141: 545-548 (2008). Antiplatelet autoantibodies in patients with ITP bind to circulating platelets and accelerate their destruction. The primary mechanism by which anti-CD40L antibodies are thought to increase the platelet count in ITP is by blocking T-cell based activation of autoreactive B cells that produce anti-platelet antibodies. Anti-CD40L antibodies may also block expression of CD40L on platelets, thus preventing autopresentation of platelet glycoprotein antigens to macrophages. Furthermore, anti-CD40L mAbs inhibit direct interactions between platelet CD40L and other cells, such as plasmacytoid dendritic cells (DCs), which have recently been implicated in driving the type 1 interferon (IFN) response in human lupus patients. Duffau et al., Sci. Transl. Med. 2: 47 (2010).
Patel et al. demonstrated efficacy of two humanized anti-CD40L monoclonal antibodies, hu5c8 and IDEC-131, in 46 human patients with chronic ITP refractory to conventional therapies. The patients had an overall 24% response rate, characterized by increased platelet counts. This demonstrated the potential role of CD40-CD40L in the pathogenesis of ITP.
4.2. Lupus In Vivo and In Vitro Models:
Glomerular and tubular CD40 expression is markedly upregulated in proliferative nephritis. Several studies have reported hyperexpression of CD40L by T cells and elevated soluble sCD40L concentrations in human lupus. Kimura et al., Therapeutic Apheriss and Dialysis 9: 64-68 (2005); Vakkalanka et al., Arthritis & Rheumatism 42: 871-881 (1999).
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and by B cell hyperactivity. Grammer et al., J. Clin. Invest. 112: 1506-1520 (2003) reports the results of treatment of patients with SLE with humanized anti-CD40L mAb 5c8 (BG9588). See also Huang et al., Arthritis & Reumatism 46: 1554-1562 (2002). Grammer et al. report that CD19+ peripheral B cells were examined before and after treatment with the anti-CD40L mAb. Before treatment, SLE patients manifested activated B cells that expressed CD40L, CD69, CD38, CD5, and CD27. The activated B cells disappeared from the periphery during and post-treatment. Before treatment, active SLE patients had circulating CD38bright Ig-secreting cells that were not found in normal individuals. Disappearance of these plasma cells during treatment was associated with decreases in anti-double stranded DNA (anti-dsDNA) Ab levels, proteinuria, and SLE disease activity index. Consistent with this finding, peripheral B cells cultured in vitro spontaneously proliferated and secreted Ig in a manner that was inhibited by anti-CD40L mAb. The CD38+/++IgD+, CD38+++, and CD38+IgD− B cell subsets present in the peripheral blood of SLE patients also disappeared following treatment with the anti-CD40L mAb. Together, these results suggest that spontaneous CD40L-CD40 interactions in active SLE patients drive B cell activation, proliferation, and differentiation to autoantibody-secreting plasma cells that mediate proteinuria and disease activity.
Proliferative lupus glomerulonephritis is a protracted autoimmune disease with a waxing and waning course, characterized by increased level of anti-dsDNA antibodies, decreased serum C3 concentrations, and hematuria. Boumpas et al, Arthritis & Rheumatism 48: 719-727 (2003) report results of a phase II, multicenter, open-label study evaluating the toxicity and efficacy of BG9688, a humanized anti-CD40L monoclonal antibody, in patients with proliferative lupus glomerulonephritis. Although the study had to be terminated prematurely because of thromboembolic events occurring in patients in several BG9588 protocols, a short course of the anti-CD40L antibody treatment in patients with proliferative lupus nephritis reduced anti-dsDNA antibodies, increased C3 concentrations, and decreased hematuria, suggesting that the drug has immunomodulatory function.
4.3. Inflammatory Bowel Disease (IBD) In Vivo Models:
Crohn's disease (CD) and ulcerative colitis (UC) are IBDs that are characterized by leukocytic infiltrates in inflamed intestinal mucosa, which consists primarily of activated CD25+ cells, B cells, and macrophages. Ludwiczek et al., Int. J. Colorectal Dis. 18: 142-147 (2003) report that in CD patients, plasma levels of sCD40L were significantly higher than in healthy individuals. Moreover, CD patients with fistulas and/or abscesses had significantly higher levels of sCD40L than patients with uncomplicated CD. It has also been reported that the CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in IBD. Borcherding et al., Am. J. Pathol. 176: 1816-1827 (2010). Patients with CD also have an increased risk of systemic thromboembolism, and the hyperactive state of platelets from such patients likely results from the enhanced release of sCD40L as a consequence of their higher endogenous content of CD40L. Menchen et al., Gut 58: 920-928 (2009); see also Danese et al., Gut 52: 1435-1441 (2003).
Kasran et al., Aliment. Pharmacol. Ther. 22: 111-122 (2005) investigated the use of a chimeric anti-human CD40 mAb ch5D12 to treat Crohn's disease. The mAb was administered to 18 patients with moderate to severe CD in a single dose, open-label dose escalation phase I/Iia study. Of the 18 patients, 13 (or 72%) experienced a favorable response to the antibody infusion, and 4 patients (or 22%) experienced a remission. Treatment with the anti-CD40 mAb reduced microscopic disease activity and intensity of the lamina propria cell infiltrate, and the mAb was well tolerated.
4.4. Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Psoriatic Arthritis (PsA) In Vivo Models:
Rheumatoid arthritis is a systemic autoimmune disease with intra-articular inflammation as a dominant feature that affects up to 1% of the population. The disease can be subdivided clinically by the presence or absence of autoantibodies (antibodies to cyclic citrullinated peptide (CCP) or rheumatoid factor (RF), both of which are highly correlated to each other. Raychaudhuri et al., Nature Genetics 40: 1216-1223 (2008) reported that they conducted a meta-analysis of two published genome-wide association (GWA) studies totaling 3,393 cases and 12,462 controls, in order to identify RA risk loci in European populations. They genotyped 31 top-ranked short nucleotide polymorphisms (SNPs) not previously associated with RA in an independent replication of 3,929 autoantibody-positive RA cases and 5,807 matched controls from eight separate collections. They identified a common variant at the CD40 gene locus, which implied a central role for the CD40 signaling pathway in RA pathogenesis. The strong association of the CD40 gene with susceptibility to RA was robustly replicated in another study in a large UK cohort of 3,962 patients with RA. Orozso et al., Ann. Rheum. Dis. 69: 813-816 (2010).
A major role of CD40L has also been found in the pathogenesis of juvenile idiopathic arthritis (JIA). Prahalad et al., Pediatric Rheumatology 6: 1-8 (2008). JIA is a heterogeneous group of arthropathies of unknown etiology. It was found that sCD40L was significantly elevated in the serum of children with JIA, along with some cytokines. Logistic regression analysis suggested that sCD40L, as well as IL-6 and TNFα, were positively associated with JIA.
sCD40L was elevated in all JIA subtypes, with highest levels among more severe subtypes. These results implicated sCD40L as a potential biomarker for treatment and monitoring of patients with JIA.
It has also been demonstrated that activated T cells from patients with psoriatic arthritis (PsA), and particularly those with active disease, have a significantly increased expression of CD40L. Daoussis et al., Rheumatology 46: 227-231 (2007). These results indicate a role of the CD40-CD40L pathway in the pathogenesis of PsA and that a therapy selectively targeting CD40L could benefit PsA patients.
4.5. Systemic Sclerosis In Vivo Models:
Systemic sclerosis (SSc) is an autoimmune connective tissue disorder characterized by fibrous and vascular changes in the skin and internal visceral organs. In a study involving 52 Japanese patients with SSc, serum sCD40L levels were elevated when compared with healthy controls. Komura et al., J. Reumatol. 31: 514-519 (2004). Moreover, levels of sCD40L in patients with SSc were higher than in patients with systemic lupus erythematosus (SLE) who had elevated sCD40L levels compared to controls, and sCD40L levels correlated positively with C reactive peptide levels in SSc patients. It has also been reported that blockade of CD40L with anti-CD40L antibody in cultured T and B cells from SSc patients inhibited anti-topoisomerase I antibody production. Kuwana et al., J. Immunol. 155: 2703-2714 (1995). These results suggest that inhibition of CD40-CD40L interactions may be potential therapeutic targets in therapy of SSc as well as SLE.
4.6. Atherosclerosis In Vivo Models:
Several studies have suggested a role of CD40-CD40L signaling pathway during atherogenesis. Mach et al. demonstrated that in mice, treatment with monoclonal anti-CD40L antibody limited atherosclerosis in mice lacking receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks. Nature 394: 200-203 (1998). The antibody reduced the size of aortic atherosclerotic lesions by 59% and their lipid content by 79%. Additionally, atheroma of mice treated with anti-CD40L antibody contained significantly fewer macrophages and T lymphocytes, and exhibited decreased expression of vascular cell adhesion molecule-1.
Anti-CD40L antibody treatment of low-density lipoprotein receptor-deficient mice during the second half of a 26-week regimen of a high-cholesterol diet did not regress, but did significantly reduce further progression of established atherosclerotic lesions within the aortic arch and particularly the thoracic and abdominal aorta, as compared to control treatment. Schonbeck et al., Proc. Natl. Acad. Sci. 97: 7458-7463 (2000). Furthermore, anti-CD40L treatment changed the composition of atheroma in manners thought to favor plaque stability, e.g., reduced relative content of macrophages and lipid, as well as increased relative content of smooth muscle cells and collagen. These studies lend support to the importance of the CD40-CD40L signaling pathway in atherosclerosis and its complications, such as coronary artery disease.
4.7. Allograft Rejection In Vivo Models:
Targeting the CD40-CD40L pathway has long been of much interest for prevention of rejection of solid organ transplants (SOT), particularly in light of the promising data from numerous published transplant studies in non-human primates. It has been demonstrated that reduced CD40L expression on ex vivo activated CD4+ T lymphocytes correlates with excellent renal allograft function. Lederer et al., Int. Arch. Allergy Immunol. 133: 276-284 (2004). Furthermore, several studies have demonstrated that anti-CD40L mAbs can both prevent and reverse acute allograft rejection in primates. For example, Kirk et al., Proc. Natl. Acad. Sci. USA 94: 8789-8794 (1997) reported that, in rhesus monkeys transplanted with renal allografts, anti-CD40L mAb 5C8 alone or in combination with CTLA4-Ig significantly prolonged rejection-free survival. The CD40L-specific mAb hu5c8 alone also allowed for allogeneic islet engraftment and long-term insulin independence in rhesus monkeys that were transplanted an adequate number of viable pancreatic islets. Kenyon et al., Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999). Preston et al., Amer. J. Transplantation 5: 1032-1041 (2005) performed renal transplants in MHC-mismatched rhesus monkeys and treated the recipients with combinations of CD40L-specific mAb IDEC-131, and/or sirolimus, and/or pre-transplant donor-specific transfusion. IDEC-131 was highly effective in preventing renal allograft rejection in primates. In cynomolgus monkeys that underwent renal allotransplantation, treatment with anti-CD40L mAb ABI793 effectively prevented graft rejection. Schuler et al., Transplantation 77: 717-726 (2004). In addition to preventing allograft rejection, CD40L-specific mAbs induced donor specific tolerance in primate transplant models. Preston et al., Amer. J. Transplantation 5: 1032-1041 (2005); Kenyon et al., Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999).
In pediatric human patients that were undergoing acute graft rejection after liver or small-bowel transplantation, a correlation was observed between the expression of CD40L on CD8+ T cells and the risk of transplant rejection. Ashokkumar et al., Amer. J. Transplantation 9: 179-191 (2009) and Ashokkumar et al., Surgery 146: 166-173 (2009). Similarly, in adult patients that were undergoing allograft rejection following liver or renal transplantation, histological analysis demonstrated an association between CD40L expression and acute or chronic rejection. Bartlett et al., Amer. J. Transplantation 3: 1363-1368 (2003) and Biancone et al., Nephrol. Diall. Translpant. 13: 716-722 (1998).
Several studies support targeting CD40L over CD40 to achieve better efficacy in transplantation. For example, graft survival is longer and more durable when CD40L is selectively blocked, compared to CD40. Gilson et al., J. Immunol. 183: 1625-35 (2009). Furthermore, recent data suggest that CD40L blockade may enhance induction of Tregs and/or suppressor cells to promote graft survival. Garcia et al., J. Clin. Inv. 120: 2486-96 (2010). Also, blockade of CD40L, but not CD40, has demonstrated induction of long-lived immunological tolerance resulting in indefinite graft survival, particularly when combined with blockade of the B7 pathway. Kenyon et al., Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999); Kawai et al., Amer. J. Transplantation 4: 1391-1398 (2004); Preston et al., Amer. J. Transplantation 5: 1032-1041 (2005); Adams et al., J. Immunol. 174: 542-50 (2005). The synergy of blocking CD40-40L and B7-CD28 pathways in enhancing graft survival is especially important, because it presents the presently disclosed domain antibodies as a natural choice for combination with belatacept (CTLA4-Ig) for SOT.
4.8. Graft-Versus-Host Disease In Vivo Model:
Chronic and acute graft-versus-host disease (cGVHD and aGVHD) are complications that can occur after a stem cell or bone marrow transplant in which the transplanted donor cells attack the transplant recipient's body. Acute GVHD in humans takes place withing about 60 days post-transplantation and results in damage to the skin, liver, and gut by the action of cytolytic lymphocytes. Chronic GVHD occurs later and is a systemic autoimmune disease that affects primarily the skin, resulting in the polyclonal activation of B cells and the hyperproduction of Ig and autoantibodies.
CD40L-CD40 interactions appear to be critical in the development of both cGVHD and aGVHD. Durie et al., J. Clin. Invest. 94: 1333-1338 (1994). In a mouse in vivo model, anti-CD40L antibodies blocked the following cGVHD-associated phenomena: splenomegaly, in vitro polyclonal Ig production, elevated levels of serum IgE and serum anti-DNA autoantibodies, and the generation of anti-host cytotoxic T cells. Antibody production remained inhibited for extended periods of time after the end of anti-CD40L antibody administration. In mice with aGVHD, which is associated with the induction of a profound antiallogenic cytotoxic T cell (CTL) response, treatment with anti-CD40L prevented the generation of H-2b-derived CTL. The results of the study suggest that CD40L-CD40 interactions are critical in GVHD and that CD40L may be a valuable ligand for targeting immunotherapeutic agents to control GVHD.
4.9. Myasthenia Gravis In Vivo Model:
Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG), are T-cell dependent autoimmune disorders caused by autoantibodies against the nicotinic acetylcholine receptors (AChR) at the neuromuscular junction of skeletal muscle. The role of CD40-CD40L in EAMG was shown in CD40L (CD40L−/−) knockout mice. Shi et al, Eur. J. Immunol. 28: 3587-3593 (1998). The CD40L knockout mice were completely resistant to EAMG induction and had diminished Th1 and Th2 responses as well as severely impaired T-cell dependent AChR-reactive B cell responses.
It has also been demonstrated that blockade of CD40L-CD40 signaling by anti-CD40L antibodies is capable of suppressing EAMG. Im et al., J. Immunol. 166: 6893-6898 (2001). Antibodies given to rats at the chronic stage of EAMG suppress the clinical progression of the autoimmune response and lead to a decrease in the AChR-specific humoral response and delayed-type hypersensitivity. The effect of anti-CD40L treatment during the chronic phase of EAMG is of particular relevance to human MG, which is a chronic disease. It suggests that antagonizing CD40L can be used for immunotherapy of MG and other antibody-mediated autoimmune diseases.
5. Thromboembolism
CD40-CD40L interactions on T and antigen presenting cells are important for adaptive immune responses, such as B-cell proliferation, immunoglobulin (Ig) production, upregulation of co-stimulatory activity (CD80, CD86), cytokine production, and Ig class-switching. The receptor and ligand are also expressed on platelets (off-target cell population), where CD40 is constitutively found on platelets, while CD40L is expressed on activated platelets and cleaved to sCD40L (>90% of circulating sCD40L is derived from platelets). Feroni et al., Curr. Med. Chem. 14: 2170-2180 (2007). At least three anti-CD40L monoclonal antibodies (mAb) caused TE in the clinic and/or nonclinical studies conducted in non-human primates (NHP). hu5c8 (BG9588) caused TE in multiple clinical trials (lupus and renal transplantation). Boumpas et al., Arthritis & Rheumatism 48: 719-727 (2003). IDEC131 caused TE in one patient in a Crohn's disease trial, leading to termination of ongoing trials at the time. Sidiropoulus & Boumpas, Lupus 13: 391-397 (2004). Both hu5c8 and ABI1793 (which binds CD40 at a different epitope from 5c8) caused TE/thrombosis in renal transplantation studies in cynomolgus or rhesus monkeys. Schuler et al., Transplantation 77: 717-726 (2004); Kanmaz et al., Transplantation 77: 914-920 (2004); Koyama et al., Transplantation 77: 460-461 (2004). In a non-published disclosure, Biogen reported a thrombosis incidence of 1⁄4 and 6/12 in rhesus monkeys given 5 and 20 mg/kg weekly, respectively, for 6-months, but not in cynomolgus monkeys given 50 mg/kg at the same frequency and duration. The basis for the species difference is not clear.
One of the hypotheses is that the TE associated with administration of these antibodies is mediated by anti-CD40Lmab-CD40L immune complex (IC)-mediated cross linking of platelets, facilitated by IC binding to FcgRIIa, an IgG Fc receptor, causing activation and aggregation (FIG. 10). Blocking the interaction of Fc moiety of IgG with FcgRIIa is, therefore, expected to mitigate platelet cross linking and thrombosis. Approaches and methods developed to evaluate the risk for TE/thrombosis are described in Examples below.
EXAMPLES
TABLE 1 lists representative anti-human CD40L VH domain amino acid sequences useful for the disclosed antibody polypeptides. TABLE 2 discloses representative nucleic acids that encode the VH domain sequences listed in TABLE 1. TABLE 3 lists representative anti-human CD40L VK domain amino acid sequences useful for the antibody polypeptides of the present disclosure. TABLE 4 in turn discloses representative nucleic acids that encode the VK domain sequences listed in TABLE 3. As well known in the art, multiple codons can encode the same amino acid. Nucleic acids encoding a protein sequence thus include nucleic acids having codon degeneracy. The antibody polypeptides disclosed in TABLE 1 and TABLE 3 specifically bind CD40L. They were made using the reiterative initial/primary screening and affinity methodologies described in the examples that follow.







TABLE 1





Anti-human CD40L VH Domain Amino Acid Sequences
















BMS2h-10 (SEQ ID NO: 15)



EVQLLESGGG LVQPGGSLRL SCAASGFTFI AYDMSWVRQA PGKGLEWVSW IDEWGLQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKT PEE------- FDYWGQGTLV TVSS


 


BMS2h-11 (SEQ ID NO: 16)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYEMSWVRQA PGKGLEWVSG IDGEGSDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RS-------- FDYWGQGTLV TVSS


 


BMS2h-111 (SEQ ID NO: 17)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYPMTWVRQA PGKGLEWVST IHGSGSATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP YTSRHNSLGH FDYWGQGTLV TVSS


 


BMS2h-112 (SEQ ID NO: 18)


EVQLLESGGG LVQPGGSLRL SCAASGFTFM DYPMGWVRQA PGKGLEWVSS IGPVGMSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG GTSGRHNTK- FDYWGQGTLV TVSS


 


BMS2h-113 (SEQ ID NO: 19)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT EYPMSWVRQA PGKGLEWVSV ISPLGFTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWT GGSGILNSS- FDYWGQGTLV TVSS


 


BMS2h-114 (SEQ ID NO: 20)


EVQLLESGGG LVQPGGSLRL SCAASGFRVS NYDLTWVRQA PGKGLEWVST ISATNGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAAVT WWLLRHNDN- LGFWGQGTLV TVSS


 


BMS2h-115 (SEQ ID NO: 21)


EVQLLESGGG LVQPGGSLRL SCAASGFSIS YKNMAWVRQA PGKGLEWVSA IKAANGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCATGS QKKRTYT--- FDFWGQGTLV TVSS


 


BMS2h-12 (SEQ ID NO: 22)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR LYEMAWVRQA PGKGLEWVSG IDILGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDL SWQG------ FDYWGQGTLV TVSS


 


BMS2h-120 (SEQ ID NO: 23)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR SYTMGWVRQA PGKGLEWVSS INPMGYQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHG VGKGTKPHN FDYWGQGTLV TVSS


 


BMS2h-121 (SEQ ID NO: 24)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE LYRMSWVRQA PGKGLEWVSE ISGSGFPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSL HDKTQHHQE FDYWGQGTLV TVSS


 


BMS2h-123 (SEQ ID NO: 25)


EVQLLESGGG LVQPGGSLRL SCAASGFTFI EYPMSWVRQA PGKGLEWVSL ISPSGVFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD ESST FDYWGQGTLV TVSS


 


BMS2h-124 (SEQ ID NO: 26)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYDMDWVRQA PGKGLEWVST IGSSGYPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAERM PGYFPGFARQ FDYWGQGTLV TVSS


 


BMS2h-125 (SEQ ID NO: 27)


EVQLLESGGG LVQPGGSLRL SCAASGFTFW RYAMGWVRQA PGKGLEWVST INDEGRETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKR VSSSVNAPYE FDYWGQGTLV TVSS


 


BMS2h-126 (SEQ ID NO: 28)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA NYSMSWVRQA PGKGLEWVSS IDRLGTHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVL ADLIAGHAE FDYWGQGTLV TVSS


 


BMS2h-127 (SEQ ID NO: 29)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP SYDMAWVRQA PGKGLEWVSG ISRSGSMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGV DAHVYYMEPF FDYWGQGTLV TVSS


 


BMS2h-128 (SEQ ID NO: 30)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYQMAWVRQA PGKGLEWVST ISSDGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TV FDYWGQGTLV TVSS


 


BMS2h-129 (SEQ ID NO: 31)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP KYEMAWVRQA PGKGLEWVSS IDGDGKSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD QF FDYWGQGTLV TVSS


 


BMS2h-13 (SEQ ID NO: 32)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS YYSMYWVRQA PGKGLEWVSS ISPFGWGTYY


ADSVKGRFTI SRDNSKDTLY LQMNSLRAED TAVYYCAKYG ETSGPISEN FDYWGQGTLV TVSS


 


BMS2h-130 (SEQ ID NO: 33)


EVQLLESGGG LVQPGGSLRL SCTASGFTFA GYQMSWVRQA PGKGLEWVSS ITNEGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KY FDYWGQGTLV TVSS


 


BMS2h-131 (SEQ ID NO: 34)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG EYEMVWVRQA PGKGLEWVSS ITSDGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG IRFDYWGQGTLV TVSS


 


BMS2h-132 (SEQ ID NO: 35)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYDMAWVRQA PGKGLEWVSG IVDDGLMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD VAFDYWGQGTLVTVSN


 


BMS2h-133 (SEQ ID NO: 36)


EVQLLESGGG LVQPGGSLRL SCAASGFTFI GYAMAWVRQA PGKGLEWVSS IGPLGATTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLP AGTSSHSVDFDYWGQGTLV TVSS


 


BMS2h-134 (SEQ ID NO: 37)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYEMTWVRQA PGKGLEWVSS ITSDGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS VQ FDYWGQGTLV TVSS


 


BMS2h-135 (SEQ ID NO: 38)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR RYVMGWVRQA PGKGLEWVSW IEADGRTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL TDQHVIE FDYWGQGTLV TVSS


 


BMS2h-136 (SEQ ID NO: 39)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD GYRMGWVRQA PGKGLEWVSS IAPDGNYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFW GMQFDYWGQGTLV TVSS


 


BMS2h-137 (SEQ ID NO: 40)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYPMGWVRQA PGKGLEWVSS IGPIGFTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEMK SPYKPQ---- FDYWGQGTLV TVSS


 


BMS2h-138 (SEQ ID NO: 41)


EVQLLESGGG LVQPGGSLRL SCAASGFTFL AYWMVWVRQA PGKGLEWVSS ISPSGTHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRVED TAVYYCAKYT EPGLGS---- FDYWGQGTLV TVSS


 


BMS2h-139 (SEQ ID NO: 42)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYEMGWVRQA PGKGLEWVSV ISEVGSLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPH DSSIG----- FDYWGQGTLV TVSS


 


BMS2h-14 (SEQ ID NO: 43)


EVQLLESGGG LVQPGGSLRL SCAASGFTFW SYDMTWVRQA PGKGLEWVSS IMASGDDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWD RD-------- FDYWGQGTLV TVSS


 


BMS2h-15 (SEQ ID NO: 44)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYVMSWVRQA PGKGLEWVST ISPIGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEFP LIILPD---- FDYWGQGTLV TVSS


 


BMS2h-16 (SEQ ID NO: 45)


EVQLLESGGG LVQPGGSLRL SCAASGFTFM EYAMIWVRQA PGKGLEWVSI ISPLGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYQ DSSDSQYTN- FDYWGQGTLV TVSS


 


BMS2h-17 (SEQ ID NO: 46)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE DYGMGWARQA PGKGLEWVSS IGPLGLWTYY


ADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSP LEGLITN--- FDYWGQGTLV TVSS


 


BMS2h-176 (SEQ ID NO: 47)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD AYEMGWVRQA PGKGLEWVSI IDWDGNSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG DNVGI----- FDYWGQGTLV TVSS


 


BMS2h-177 (SEQ ID NO: 48)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYYMVWVRQA PGKGLEWVSA IDEWGFATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHW EFTSDTSR-FDYWGQGTLV TVSS


 


BMS2h-178 (SEQ ID NO: 49)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE DFDMAWVRQA PGKGLEWVSS INDQGSLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD QF-------- FDYWGQGTLV TVSS


 


BMS2h-179 (SEQ ID NO: 50)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYDMMWVRQA PGKGLEWVSR ISPQGQRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR GQSRIPMR-FDYWGQGTLV TVSS


 


BMS2h-18 (SEQ ID NO: 51)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYDMTWVRQA PGKGLEWVSY ISSDGYSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPH GSPRE----- FDYWGQGTLV TVSS


 


BMS2h-180 (SEQ ID NO: 52)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYEMGWVRQA PGKGLEWVST ITSLGESTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RI-------- FDYWGQGTLV TVSS


 


BMS2h-181 (SEQ ID NO: 53)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA FYPMMWVRQA PGKGLEWVSW IDATGTRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGN YGSSYTMGV- FDYWGQGTLV TVSS


 


BMS2h-182 (SEQ ID NO: 54)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD EYPMYWVRQA PGKGLEWVSS IGPSGPNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSP YFDVIPSY-FDYWGQGTLV TVSS


 


BMS2h-183 (SEQ ID NO: 55)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYGMGWVRQA PGKGLEWVSS IQSSGLRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRA NSRRG----- FDYWGQGTLV TVSS


 


BMS2h-184 (SEQ ID NO: 56)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQA PGKGLEWVSS ITSHGGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KD-------- FDYWGQGTLV TVSS


 


BMS2h-185 (SEQ ID NO: 57)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA HYPMSWVRQA PGKGLEWVSS IGRLGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRA TPVPIKGL-FDYWGQGTLV TVSS


 


BMS2h-186 (SEQ ID NO: 58)


EVQLLESGGG LVQPGGSLRL SCAASGLTFG RYEMAWVRQA PGKGLEWVSS IDSDGWVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQPD SL-------- FDYWGQGTLV TVSS


 


BMS2h-187 (SEQ ID NO: 59)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYSMVWVRQA PGKGLEWVSG INRGGTRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW RRG------- FDYWGQGTLV TVSS


 


BMS2h-188 (SEQ ID NO: 60)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT RYRMSWVRQA PGKGLEWVSG ISRDGYRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGM TAS------- FDYWGQGTLV TVSS


 


BMS2h-189 (SEQ ID NO: 61)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ MYPMGWVRQA PGKGLEWVSM IEPAGDLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYQ EQPW------ FDYWGQGTLV TVSS


 


BMS2h-19 (SEQ ID NO: 62)


EVQLLESGGG LVQPGGSLRL SCAASGFPFP QYQMAWVRQA PGKGLEWVSM ITSDGLDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPE PL-------- FDYWGQGTLV TVSS


 


BMS2h-190 (SEQ ID NO: 63)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS MYDMHWVRQA PGKGLEWVST ILSDGTDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG AM-------- FDYWGQGTLV TVSS


 


BMS2h-191 (SEQ ID NO: 64)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK LYPMTWVRQA PGKGLEWVSS IDAGGHETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDW WDYL------ FDYWGQGTLV TVSS


 


BMS2h-192 (SEQ ID NO: 65)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS RYPMSWVRQA PGKGLEWVSS INRSGMRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGH QAP------- FDYWGQGTLV TVSS


 


BMS2h-193 (SEQ ID NO: 66)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT GYAMSWVRQA PGKGLEWVST INANGIRTYY


ADSVKGRFTI SRDNSKNTLY LQMNGLRAED TAVYYCAKGG VWRWGTGHK- FDYWGQGTLV TVSS


 


BMS2h-194 (SEQ ID NO: 67)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK QYDMRWVRQA PGKGLEWVST ISQNGTKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSR TGRY------ FDYWGQGTLV TVSS


 


BMS2h-195 (SEQ ID NO: 68)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG TYDMGWVRQA PGKGLEWVSR INWQGDRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG FGHYVDGLG- FDYWGQGTLV TVSS


 


BMS2h-196 (SEQ ID NO: 69)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS GYEMAWVRQA PGKGLEWVSS ITDMGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TA-------- FDYWGPGTLV TVSS


 


BMS2h-197 (SEQ ID NO: 70)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA KYKMWWVRQA PGKGLEWVSS ITPKGHSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRP MTP------- FDYWGQGTLV TVSS


 


BMS2h-198 (SEQ ID NO: 71)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYNMSWVRQA PGKGLEWVSS IRPRGGKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWR REGYTGSK-FDYWGQGTLV TVSS


 


BMS2h-199 (SEQ ID NO: 72)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYGMTWVRQA PGKGLEWVSS IWPRGQKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGN SRYV------ FDYWGQGTLV TVSS


 


BMS2h-2 (SEQ ID NO: 73)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQA PGKGLEWVST ITSDGISTYY


ADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCAKSG RF-------- FDYWGQGTLV TVSS


 


BMS2h-20 (SEQ ID NO: 74)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS GYQMAWVRQA PGKGLEWVSG ISSEGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG RR-------- FDYWGQGTLV TVSS


 


BMS2h-200 (SEQ ID NO: 75)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT NYSMGWVRQA PGKGLEWVST IRPNGTKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRS SAHLQR---- FDYWGQGTLV TVSS


 


BMS2h-201 (SEQ ID NO: 76)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYSMGWVRQA PGKGLEWVSS IGRHGGRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKG STYPR----- FDYWGQGTLV TVSS


 


BMS2h-202 (SEQ ID NO: 77)


EVQLLESGGG LVQPGGSLRL SCTASGFTFS HYEMGWVRQA PGKGLEWVSS IEPFGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVY PQGS------ FDYWGQGTLV TVSS


 


BMS2h-203 (SEQ ID NO: 78)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYTMGWVRQA PGKGLEWVSS IRPDGKITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEVY SSCAMCTPLL FDYWGQGTLV TVSS


 


BMS2h-204 (SEQ ID NO: 79)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYSMAWVRQA PGKGLEWVSD IGPRGFSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG RGQRDTSQP- FDYWGQGTLV TVSS


 


BMS2h-205 (SEQ ID NO: 80)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYQMAWVRQA PGKGLEWVSG ITSGGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RG-------- FDYWGQGTLV TVSS


 


BMS2h-206 (SEQ ID NO: 81)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYEMTWVRQA PGKGLEWVSG ISSDGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VL-------- FDYWGQGTLV TVSS


 


BMS2h-207 (SEQ ID NO: 82)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD KYLMSWVRQA PGKGLEWVSG IEPLGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEA SGD------- FDYWGQGTLV TVSS


 


BMS2h-208 (SEQ ID NO: 83)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT EYEMSWVRQA PGKGLEWVSS IDNVGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KL-------- FDYWGQGTLV TVSS


 


BMS2h-209 (SEQ ID NO: 84)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYEMWWVRQA PGKGLEWVSA ISRQGFATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDL ERDD------ FDYWGQGTLV TVSS


 


BMS2h-21 (SEQ ID NO: 85)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA NYEMGWARQA PGKGLEWVSV ISEWGYSTYY


ADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLV GGTQYE---- FDYWGQGTLV TVSS


 


BMS2h-22 (SEQ ID NO: 86)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH NYEMSWVRQA PGKGLEWVSS ISSGGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VK-------- FDYWGQGTLV TVSS


 


BMS2h-23 (SEQ ID NO: 87)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG LYEMTWVRQA PGKGLEWVSS ITGDGISTYY


ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKAG RK-------- FDYWGQGTLV TVSS


 


BMS2h-24 (SEQ ID NO: 88)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYQMAWVRQA PGKGLEWVSS ITSEGGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KN-------- FDYWGQGTLV TVSS


 


BMS2h-24-1 (SEQ ID NO: 89)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYQMAWVRQA PGKGLEWVSS ITSEGGSTYY


ADSVKGRFTI SRDNSKNTVY LQMNSLRAED TAVYYCAKPG KN-------- FDYWGQGTLV TVSS


 


BMS2h-25 (SEQ ID NO: 90)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYEMTWVRQA PGKGLEWVST ITSQGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RS-------- FDYWGQGTLV TVSS


 


BMS2h-26 (SEQ ID NO: 91)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR SYEMTWVRQA PGKGLEWVSS ITSDGGTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KT-------- FDYWGQGTLV TVSS


 


BMS2h-27 (SEQ ID NO: 92)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN LYEMTWVRQA PGKGLEWVSS ITSDGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD SP-------- FDYWGQGTLV TVSS


 


BMS2h-28 (SEQ ID NO: 93)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HYDMAWVRQA PGKGLEWVST ISDNGNGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RD-------- FDYWGQGTLV TVSS


 


BMS2h-29 (SEQ ID NO: 94)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG RYQMAWVRQA PGKGLEWVSS ISSDGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RA-------- FDYWGQGTLV TVSS


 


BMS2h-30 (SEQ ID NO: 95)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA RYQMAWVRQA PGKGLEWVST ISDDGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLD KL-------- FDYWGQGTLV TVSS


 


BMS2h-300 (SEQ ID NO: 96)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NDEMTWVRQA PGKGLEWVSA IDTTGGQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KE-------- FDYWGQGTLV TVSS


 


BMS2h-301 (SEQ ID NO: 97)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG ESEMSWVRQA PGKGLEWVSS ILDEGSGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KD-------- FDYWGQGTLV TVSS


 


BMS2h-302 (SEQ ID NO: 98)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSA ITDDGDDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN AGA------- FDYWGQGTLV TVSS


 


BMS2h-303 (SEQ ID NO: 99)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE VYDMAWVRQA PGKGLEWVSG IVNDGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KD-------- FDYWGQGTLV TVSS


 


BMS2h-304 (SEQ ID NO: 100)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NTEMTWVRQA PGKGLEWVSS IADDGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG QA-------- FDYWGQGTLV TVSS


 


BMS2h-31 (SEQ ID NO: 101)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYQMAWVRQA PGKGLEWVST ISDDGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD LY-------- FDYWGQGTLV TVSS


 


BMS2h-32 (SEQ ID NO: 102)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE VYQMGWVRQA PGKGLEWVSF IVPGGDLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETW PE-------- FDYWGQGTLV TVSS


 


BMS2h-4 (SEQ ID NO: 103)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYEMTWVRQA PGKGLEWVSS ITSDGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN PP-------- FDYWGQGTLV TVSS


 


BMS2h-40 (SEQ ID NO: 104)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK AYDMGWVRQA PGKGLEWVSQ IGRDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPR RYAIF----- TFDRGQGTLV TVSS


 


BMS2h-400 (SEQ ID NO: 105)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK QYPMVWVRQA PGKGLEWVST ISTNGVRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWT DIISSSE--- FDYWGQGTLV TVSS


 


BMS2h-401 (SEQ ID NO: 106)


EVQLLESGGG LVQPGGSLRL SCAASGFTFF NYDMSWVRQA PGKGLEWVSA ISGSGGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVF VWSADIDFD- FDYWGQGTLV TVSS


 


BMS2h-402 (SEQ ID NO: 107)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYDMSWVRQA PGKGLEWVSH IASWGGKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVT VKDGGYLMD- FDYWGQGTLV TVSS


 


BMS2h-403 (SEQ ID NO: 108)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA EYAMAWVRQA PGKGLEWVSS IGRDGAVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWK AAKERGSW-FDYWGQGTLV TVSS


 


BMS2h-404 (SEQ ID NO: 109)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ AYQMQWVRQA PGKGLEWVST ISPNGLFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL SS-------- FDYWGQGTLV TVSS


 


BMS2h-407 (SEQ ID NO: 110)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTN WNGVDL---- FDYWGQGTLV TVSS


 


BMS2h-408 (SEQ ID NO: 111)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP TYMMSWVRQA PGKGLEWVST INTNGRDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD SNMSF----- FDYWGQGTLV TVSS


 


BMS2h-409 (SEQ ID NO: 112)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GYSMTWVRQA PGKGLEWVSS INASGTLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDG NRSEVF---- FDYWGQGTLV TVSS


 


BMS2h-41 (SEQ ID NO: 113)


EVQLLESGGG LVQPGGSLRL SCAASGFTFF EYEMTWVRQA PGKGLEWVSS IANDGSTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RQ-------- FDYWGQGTLV TVSS


 


BMS2h-410 (SEQ ID NO: 114)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ DYLMAWVRQA PGKGLEWVSE INQDGTVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAESS PY-------- FDYWGQGTLV TVSS


 


BMS2h-411 (SEQ ID NO: 115)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYAMSWVRQA PGKGLEWVSS ISRDGHVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS SKGGTFASS- FDYWGQGTLV TVSS


 


BMS2h-412 (SEQ ID NO: 116)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AVPMTWVRQA PGKGLEWVSA ITDDGLRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGH IYGDY----- FDYWGQGTLV TVSS


 


BMS2h-413 (SEQ ID NO: 117)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE LYRMMWVRQA PGKGLEWVSA ISSDGDTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEHW LGTTLSLRD- FDYWGQGTLV TVSS


 


BMS2h-414 (SEQ ID NO: 118)


EVQLLESGGG LVQPGGSLRL SCAASGFTFY RYTMAWVRQA PGKGLEWVSQ ISPRGNITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG VAGAESPEY- FDYWGQGTLV TVSS


 


BMS2h-415 (SEQ ID NO: 119)


EVQLLESGGG LVQPGGSLRL SCAASGFTFL GYYMSWIRQA PGKGLEWVST IGPIGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSQ NIYGP----- FDYWGQGTLV TVSS


 


BMS2h-416 (SEQ ID NO: 120)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE QYDMAWVRQA PGKGLEWVSE ISRDGGRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEEY PY-------- FDYWGQGTLV TVSS


 


BMS2h-417 (SEQ ID NO: 121)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP QYSMVWVRQA PGKGLEWVST ISPLGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMS KLLLSRE--- FDYWGQGTLV TVSS


 


BMS2h-418 (SEQ ID NO: 122)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTN WNGVDL---- FDYWGQGTLV TVSS


 


BMS2h-419 (SEQ ID NO: 123)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT RHGMAWVRQA PGKGLEWVST ITPTGNTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDA HDEGY----- FDYWGQGTLV TVSS


 


BMS2h-42 (SEQ ID NO: 124)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG PYEMTWVRQA PGKGLEWVSS IVGDGLDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RV-------- FDYWGQGTLV TVSS


 


BMS2h-420 (SEQ ID NO: 125)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG STPMMWVRQA PGKGLEWVSE IRDTGLATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCASVS ---------- FDYWGQGTLV TVSS


 


BMS2h-421 (SEQ ID NO: 126)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH LGDMHWVRQA PGKGLEWVSS ISGTGHTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPM NDQG------ FDYWGQGTLV TVSS


 


BMS2h-422 (SEQ ID NO: 127)


EVQLLESGGG LVQPGGSLRL SCAASGFTFM DEDMLWVRQA PGKGLEWVSR INSLGTHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSF MM-------- FDYWGQGTLV TVSS


 


BMS2h-423 (SEQ ID NO: 128)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR NYQMHWVRQA PGKGLEWVSG IDATGRATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARST RS-------- FDYWGQGTLV TVSS


 


BMS2h-424 (SEQ ID NO: 129)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT NADMVWVRQA PGKGLEWVSS ISGSGGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY LTSH------ FDYWGQGTLV TVSS


 


BMS2h-425 (SEQ ID NO: 130)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYSMAWVRQA PGKGLEWVST ITPSGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS QAVTRS---- FDYWGQGTLV TVSS


 


BMS2h-426 (SEQ ID NO: 131)


EVQLLESGGD LVQPGGSLRL SCAASGFTFS DEGMMWVRQA PGKGLEWVSE INQQGSATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTI GM-------- FDYWGQGTLV TVSS


 


BMS2h-427 (SEQ ID NO: 132)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DQPMVWVRQA PGKGLEWVSS IGARGGPTYY


ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCAKWF DIIAWDPFS- FDYWGQGTLV TVSS


 


BMS2h-428 (SEQ ID NO: 133)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN QYPMMWVRQA PGKGLEWVSS ITPSGFLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWN PFITT----- FDYWGQGTLV TVSS


 


BMS2h-429 (SEQ ID NO: 134)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVST ITPNGYYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFD YSLR------ FDYWGQGTLV TVSS


 


BMS2h-43 (SEQ ID NO: 135)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYEMAWVRQA PGKGLEWVSS IGSDGGPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED SAVYYCAKPD RA-------- FDYWGQGTLV TVSS


 


BMS2h-430 (SEQ ID NO: 136)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AEQMTWARQA PGKGLEWVST ITPHGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWR TLVDWPTSES FDYWGQGTLV TVSS


 


BMS2h-44 (SEQ ID NO: 137)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT SYEMGWVRQA PGKGLEWVSS IEPTGITTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPH FTELG----- FDYWGQGTLV TVSS


 


BMS2h-449 (SEQ ID NO: 138)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GEQMAWVRQA PGKGLEWVST ITLPGPYTFY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGN GTF------- FDYWGQGTLV TVSS


 


BMS2h-45 (SEQ ID NO: 139)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYAMAWVRQA PGKGLEWVSK IGAQGLHTYY


AGSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQT TMDYER---- FDYWGQGTLV TVSS


 


BMS2h-450 (SEQ ID NO: 140)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD EVDMSWVRQA PGKGLEWVSA IGNNGLKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSA LSYRPPV--- FDYWGQGTLV TVSS


 


BMS2h-451 (SEQ ID NO: 141)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ DDTMSWVRQA PGKGLEWVST ITLKGPSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSR DGLY------ FDYWGQGTLV TVSS


 


BMS2h-452 (SEQ ID NO: 142)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SSPMAWVRQA PGKGLEWVSS IGRDGSTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS PYRR------ FDYWGQGTLV TVSS


 


BMS2h-453 (SEQ ID NO: 143)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYSMVWVRQA PGKGLEWVST IVSHGGTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGK GYNAQY---- FDYWGQGTLV TVSS


 


BMS2h-454 (SEQ ID NO: 144)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVST ITPNGYYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFD YSLR------ FDYWGQGTLV TVSS


 


BMS2h-455 (SEQ ID NO: 145)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN DYDMIWVRQA PGKGLEWVST ISSHGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD VF-------- FDYWGQGTLV TVSS


 


BMS2h-456 (SEQ ID NO: 146)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVST ITPNGYYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS DS-------- FDYRGQGTLV TVSS


 


BMS2h-457 (SEQ ID NO: 147)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYEMAWVRQA PGKGLEWVSG IQSNGNITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAN SQVEY----- FDYWGQGTLV TVSS


 


BMS2h-458 (SEQ ID NO: 148)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG VEPMSWVRQA PGKGLEWVSN IGRDGSMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG KHGT------ FDYWGQGTLV TVSS


 


BMS2h-459 (SEQ ID NO: 149)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYRMMWVRQA PGKGLEWVSW IDERGSLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRR KGTKQ----- FDYWGQGTLV TVSS


 


BMS2h-46 (SEQ ID NO: 150)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE LYAMAWVRQA PGKGLEWVSG IGAVGETTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEA NNLSDNLV-FDYWGQGTLV TVSS


 


BMS2h-460 (SEQ ID NO: 151)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVST ITPNGYYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS VEW------- FDYWGQGTLV TVSS


 


BMS2h-461 (SEQ ID NO: 152)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN SYTMNWVRQA PGKGLEWVSS INPWGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL VL-------- FDYWGQGTLV TVSS


 


BMS2h-462 (SEQ ID NO: 153)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD GDMMSWVRQA PGKGLEWVSS ITQLGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQN WRTLT----- FDYWGQGTLV TVSS


 


BMS2h-463 (SEQ ID NO: 154)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN AYGMMWVRQA PGKGLEWVSS ILSDGVITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSA RGANF----- FDYWGQGTLV TVSS


 


BMS2h-464 (SEQ ID NO: 155)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HYMMVWVRQA PGKGLEWVSS ITPHGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEFN AIFSEA---- FDYWGQGTLV TVSS


 


BMS2h-465 (SEQ ID NO: 156)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYSMAWVRQA PGKGLEWVST ITPSGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS QAVTRS---- FDYWGQGTLV TVSS


 


BMS2h-466 (SEQ ID NO: 157)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD LYAMAWVRQA PGKGLEWVSM IGRDGRFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLA GSLRGR---- FDYWGQGTLV TVSS


 


BMS2h-467 (SEQ ID NO: 158)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN KASMGWVRQA PGKGLEWVST ITPHGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQR WGVE------ FDYWGQGTLV TVSS


 


BMS2h-468 (SEQ ID NO: 159)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ GYSMGWVRQA PGKGLEWVSS IAGRGGVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL YIYHSL---- FDYWGQGTLV TVSS


 


BMS2h-469 (SEQ ID NO: 160)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP GMEMSWVRQA PGKGLEWVSA ITGTGSTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY HP-------- FDYWGQGTLV TVSS


 


BMS2h-470 (SEQ ID NO: 161)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP MVAMSWVRQA PGKGLEWVSS IARDGNVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAKVS PTG------- FDYWGQGTLV TVSS


 


BMS2h-471 (SEQ ID NO: 162)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQDMSWVRQA PGKGLEWVSG ITDDGESTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD YD-------- FDYWGQGTLV


TVSS


 


BMS2h-472 (SEQ ID NO: 163)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG EYNMMWVRQA PGKGLEWVSQ ITRDGSRTYY


ADSVRGRFTI SRDNSRNTLY LQMNSLRAED SAVYYCAKLS NIG------- FDYWGQGTLV TVSS


 


BMS2h-473 (SEQ ID NO: 164)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYSMIWARQA PGKGLEWVSS ITPYGSYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTD YL-------- FDYWGQGTLV TVSS


 


BMS2h-474 (SEQ ID NO: 165)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD TYSMMWVRQA PGKGLEWVST ITPYGSSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWG LV-------- FDYWGQGTLV TVSS


 


BMS2h-475 (SEQ ID NO: 166)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT TGPMMWVRQA PGKGLEWVSA IGIGGDTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLT PSNQ------ FDYWGQGTLV TVSS


 


BMS2h-476 (SEQ ID NO: 167)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK QYQMMWVRQA PGKGLEWVSS ITPSGFLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWN PFIST----- FDYWGQGTLV TVSS


 


BMS2h-477 (SEQ ID NO: 168)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP NYDMVWVRQA PGKGLEWVSS ISALGNVTYY


ADSVKGRFTI SRDNSKNTLY LQTNSLRAED TAVYYCAKWR SAITGN----


FDYWGQGTLV TVSS


 


BMS2h-478 (SEQ ID NO: 169)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK EYQMSWVRQA PGKGLEWVST ISPSGMNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWR SVVRPWPGV- FDYWGQGTLV TVSS


 


BMS2h-479 (SEQ ID NO: 170)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD DESMAWVRQA PGKGLEWVSS ITPHGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLH LKLYESH--- FDYWGQGTLV TVSS


 


BMS2h-480 (SEQ ID NO: 171)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GGEMGWVRQA PGKGLEWVSM IPMDGSATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG ST-------- FDYWGQGTLV TVSS


 


BMS2h-481 (SEQ ID NO: 172)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD FMPMAWVRQA PGKGLEWVSS IGRDGAYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLA SPAQ------ FDYWGQGTLV TVSS


 


BMS2h-482 (SEQ ID NO: 173)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DEPMLWVRQA PGKGLEWVSS IGGTGTTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGN QGDFINR--- FHYWGQGTLV TVSS


 


BMS2h-483 (SEQ ID NO: 174)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH AYNMAWVRQA PGKGLEWVST ISPRGSYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWP PPSSH----- FDYWGQGTLV TVSS


 


BMS2h-5 (SEQ ID NO: 175)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD GYEMAWVRQA PGKGLEWVSS ITSDGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG LR-------- FDYWGQGTLV TVSS


 


BMS2h-505 (SEQ ID NO: 176)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GYMMYWVHQA PGKGLEWVSS ISPQGHFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAELR ELPRL----- FDYWGQGTLV TVSS


 


BMS2h-506 (SEQ ID NO: 177)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMGWVRQA PGKGLEWVSS IDASGGPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAN GKKFPFTKY- FDYWGQGTLV TVSS


 


BMS2h-507 (SEQ ID NO: 178)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP SVHMAWVRQA PGKGLEWVSG INLTGVDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSA TTRQAHPLY- FDYWGQGTLV TVSS


 


BMS2h-515 (SEQ ID NO: 179)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK EGEMYWVRQA PGKGLEWVST ISTNGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKST RDLG------ FAYWGQGTLV TVSS


 


BMS2h-516 (SEQ ID NO: 180)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYEMAWARQA PGKGLEWVSF ISPRGHFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPA KT-------- FDYWGQGTLV TVSS


 


BMS2h-517 (SEQ ID NO: 181)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD TYEMLWVRQA PGKGLEWVSR ISVDGSITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTR MR-------- FDYWGQGTLV TVSS


 


BMS2h-518 (SEQ ID NO: 182)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSN ISRDGSKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEAQ SGGLRSGLTT FDYWGQGTLV TVSS


 


BMS2h-519 (SEQ ID NO: 183)


EVQLLESGGG LVQPGGSLRL SCADSGFTFS SYAMSWVRQA PGKGLEWVSS IGRDGAYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG PKGIA----- FDYWGQGTLV TVSS


 


BMS2h-520 (SEQ ID NO: 184)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS PHAMAWVRQA PGKGLEWVSG IDGGGSMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSD PP-------- FDYWGQGTLV TVSS


 


BMS2h-521 (SEQ ID NO: 185)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH AGEMHWVRQA PGKGLEWVSS ITLPGDMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN TGYT------ FDYWGQGTLV TVSS


 


BMS2h-522 (SEQ ID NO: 186)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYGMSWVRQA PGKGLEWVSS ISWDGSLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQNT RL-------- FDYWGQGTLV TVSS


 


BMS2h-523 (SEQ ID NO: 187)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH DADMLWVRQA PGKGLEWVSG ILSPGEDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFG LP-------- FDYWGQGTLV TVSS


 


BMS2h-524 (SEQ ID NO: 188)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR TDQMNWVRQA PGKGLEWVSS ISPSGAYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL GA-------- FDYWGQGTLV TVSS


 


BMS2h-525 (SEQ ID NO: 189)


EVQLLESGGG LVQPGGSLRL SCAASGFIFE QYQMVWVRQA PGKGLEWVSW ISPDGTHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFS LRKMEK---- FDYWGQGTLV TVSS


 


BMS2h-526 (SEQ ID NO: 190)


EVQLLESGGG LVQPGGSLRL SCAASGFTFQ DEQMAWVRQA PGKGLEWVSS IASDGMSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQPG KN-------- FDHWGQGTLV TVSS


 


BMS2h-527 (SEQ ID NO: 191)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYAMSWVRQA PGKGLEWVSS ITTGGERTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRW NLYTES---- FDYWGQGTLV TVSS


 


BMS2h-528 (SEQ ID NO: 192)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG GQPMDWVRQA PGKGLEWVSS IAPDGIHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNL GQG------- FDYWGQGTLV TVSS


 


BMS2h-529 (SEQ ID NO: 193)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYQMTWVRQA PGKGLEWVSS ISPSGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWK AL-------- FDYWGQGTLV TVSS


 


BMS2h-530 (SEQ ID NO: 194)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP HSTMYWVRQA PGKGLEWVSL ILPSGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFS DER------- FDYWGQGTLV TVSS


 


BMS2h-531 (SEQ ID NO: 195)


EVQLSESGGG LVQPGGSLRL SCAASGFTFG DGNMDWVRQA PGKGLEWVSG ISSDGVTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR GQG------- FDYWGQGTLV TVSS


 


BMS2h-532 (SEQ ID NO: 196)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYMMWWVRQA PGKGLEWVSS ISPHGVYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL HT-------- FDYWGQGTLV TVSS


 


BMS2h-533 (SEQ ID NO: 197)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYTMAWGRQA PGKGLEWVSF IAGPGNYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG STATYNNGQ- FDYWGQGTLV TVSS


 


BMS2h-534 (SEQ ID NO: 198)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT EYSMVWVRQA PGKGLEWVSS ISGSGRVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL KLVRAPNP-FDYWGQGTLV TVSS


 


BMS2h-535 (SEQ ID NO: 199)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYQMAWVRQA PGKGLEWVSG ISKTGHSTYY


ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKAS HSLGPL---- FDYWGQGTLV TVSS


 


BMS2h-54 (SEQ ID NO: 200)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT AYRMAWVRQA PGKGLEWVSW ISPSGSGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTL TDSPSGHYE- FDYWGQGTLV TVSS


 


BMS2h-55 (SEQ ID NO: 201)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA RYEMGWVRQA PGKGLEWVSR ITAQGLGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYL TDFSSGHQE- FDYWGQGTLV TVSS


 


BMS2h-553 (SEQ ID NO: 202)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYGMSWVRQV PGKGLEWVSG ISHNGMLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYW PSTSWETD-FDYWGQGTLV TVSS


 


BMS2h-554 (SEQ ID NO: 203)


EVQLLESGGG SVQPGGSLRL SCAASGFTFG NEPMAWVRQA PGKGLEWVSS IEMQGKNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR GQG------- FDYWGQGTLV TVSS


 


BMS2h-555 (SEQ ID NO: 204)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSC IDNLGSPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAKTI SHQYDR---- FDYWGQGTLV TVSS


 


BMS2h-556 (SEQ ID NO: 205)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSS IDEGGRWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWT PHKQLS---- FDYWGQGTLV TVSS


 


BMS2h-557 (SEQ ID NO: 206)


EVQLLESGGG LVQPGGSLRL SCAASGFSFA DEYMVWARQA PGKGLEWVSE IDPLGTGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG TA-------- FDYWGQGTLV TVSS


 


BMS2h-558 (SEQ ID NO: 207)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS THDMMWVRQA PGKGLEWVSS ISDDGISTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD MSLIE----- FDYWGQGTLV TVSS


 


BMS2h-559 (SEQ ID NO: 208)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD GTPMVWVRQA PGKGLEWVSG ISGDGRNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPY ALTSSKP--- FDYWGQGTLV TVSS


 


BMS2h-56 (SEQ ID NO: 209)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN DYTMGWVRQA PGKGLEWVSW IHGTGGQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAL ADRSGGVVE- FDYWGQGTLV TVSS


 


BMS2h-560 (SEQ ID NO: 210)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE AETMAWVRQA PGKGLEWVSC ISNDGNTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKES LISPGL---- FDYWGQGTLV TVSS


 


BMS2h-561 (SEQ ID NO: 211)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT GEYMNWVRQA PGKGLEWVST INETGYMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS TRGVP----- FDYWGQGTLV TVSS


 


BMS2h-562 (SEQ ID NO: 212)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR SYDMGWVRQA PGKGLEWVST ISPMGVFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSN QHAHDP---- FDYWGQGTLV TVSS


 


BMS2h-563 (SEQ ID NO: 213)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYDMGWVRQA PGKGLEWVSS ISPMGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAA LTEPM----- FDYWGQGTLV TVSS


 


BMS2h-564 (SEQ ID NO: 214)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYDMGWVRQA PGKGLEWVST ISPLGHFTYY


ADSVKGRSTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAE EA-------- FDYWGQGTLV TVSS


 


BMS2h-565 (SEQ ID NO: 215)


EVQLLESGGG LVQPGGSLRL SCAASGFAFP RYGMTWVRQA PGKGLEWVSN IDQFGMKTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEEY AS-------- FDYWGQGTLV TVSS


 


BMS2h-566 (SEQ ID NO: 216)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD KYDMGWVRQA PGKGLEWVST ISPMGVFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGR GNTSD----- FDYWGQGTLV TVSS


 


BMS2h-567 (SEQ ID NO: 217)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYDMAWVRQA PGKGLEWVST ISGAGHFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSF PRDE------ FDYWGQGTLV TVSS


 


BMS2h-568 (SEQ ID NO: 218)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP KYEMRWVRQA PGKGLEWVSE IGLDGSPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG DPNG------ FDYWGQGTLV TVSS


 


BMS2h-569 (SEQ ID NO: 219)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP TSEMDWVRQA PGKGLEWVSG IGPDGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHA DW-------- FDYWGQGTLV TVSS


 


BMS2h-57 (SEQ ID NO: 220)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS EYDMYWVRQA PGKGLEWVSW IDTDGGDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG LK-------- FDYWGQGTLV TVSS


 


BMS2h-570 (SEQ ID NO: 221)


EVQLLESGGG LVQPGGSLRL SCTASGFTFE NASMQWVRQA PGKGLEWVSS IEGQGNATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSS SWS------- FDYWGQGTLV TVSS


 


BMS2h-571 (SEQ ID NO: 222)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT RNEMGWVRQA PGKGLEWVST ITPTGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTD PGNRY----- FDYWGQGTLV TVSS


 


BMS2h-572 (SEQ ID NO: 223)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-1 (SEQ ID NO: 224)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWFRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-10 (SEQ ID NO: 225)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-11 (SEQ ID NO: 226)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTQV TVSS


 


BMS2h-572-12 (SEQ ID NO: 227)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-13 (SEQ ID NO: 228)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKDRFTI SRDNSKNTLY LLMNSLRAED TAVYYCAKVG KESN------ FDYWGQGTLV TVSS


 


BMS2h-572-14 (SEQ ID NO: 229)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-15 (SEQ ID NO: 230)


EVRLLESGGG LVQPGGSLRL SCAASGFNFN WQLMGWIRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-16 (SEQ ID NO: 231)


EVQLLESGGG LVRPGGSLRL SCVASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-17 (SEQ ID NO: 232)


EVQLLESGGG LVQTGGSLRL SCAASGFTYN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRADD TAVYYCVKVG KESN------ FDYRGHGTLV TVSS


 


BMS2h-572-18 (SEQ ID NO: 233)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRKA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-19 (SEQ ID NO: 234)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-2 (SEQ ID NO: 235)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESK------ FDYLGQGTLV TVSS


 


BMS2h-572-21 (SEQ ID NO: 236)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


AESVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ LDYRGQGTLV TVSS


 


BMS2h-572-22 (SEQ ID NO: 237)


EVQLFESGGG SVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-23 (SEQ ID NO: 238)


EVQLLESGGG LVQPGGSLRL TCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFII SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-24 (SEQ ID NO: 239)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSTNTLY LQMNSLRAED TAVYYCAKVG KESE------ FDYRGQGTLV TVSS


 


BMS2h-572-3 (SEQ ID NO: 240)


EVRLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI TRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ LDYRGQGTLV TVSS


 


BMS2h-572-4 (SEQ ID NO: 241)


EVQLLVSGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-5 (SEQ ID NO: 242)


EVQLLVSGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNMLY LQMNGLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS


 


BMS2h-572-6 (SEQ ID NO: 243)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-601 (SEQ ID NO: 244)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-602 (SEQ ID NO: 245)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WHLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESS------ SDYRGQGTLV TVSS


 


BMS2h-572-603 (SEQ ID NO: 246)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WHLMAWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV


TVSS


 


BMS2h-572-604 (SEQ ID NO: 247)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-605 (SEQ ID NO: 248)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMAWARQA PGKGLEWVSG IEGPGDITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-606 (SEQ ID NO: 249)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WHLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-607 (SEQ ID NO: 250)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-608 (SEQ ID NO: 251)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-609 (SEQ ID NO: 252)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-610 (SEQ ID NO: 253)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-611 (SEQ ID NO: 254)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRRA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-612 (SEQ ID NO: 255)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSN------ SDYRGQGTLV TVSS


 


BMS2h-572-613 (SEQ ID NO: 256)


EVQLLESGGG LAQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-614 (SEQ ID NO: 257)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK------ SDYRGQGTLV TVSS


 


BMS2h-572-615 (SEQ ID NO: 258)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDKN------ SDYRGQGTLV TVSS


 


BMS2h-572-616 (SEQ ID NO: 259)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESK------ SDYRGQGTLV TVSS


 


BMS2h-572-617 (SEQ ID NO: 260)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG RDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-618 (SEQ ID NO: 261)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KYSN------ SDYRGQGTLV TVSS


 


BMS2h-572-619 (SEQ ID NO: 262)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS


 


BMS2h-572-620 (SEQ ID NO: 263)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDDS------ SDYRGQGTLV TVSS


 


BMS2h-572-621 (SEQ ID NO: 264)


EVQLLEFGGG LVQPGGSLRF SCAASGFTFN WQLMGWFRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG RDSN------ SDYRGQGTLV TVSS


 


BMS2h-572-622 (SEQ ID NO: 265)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDST------ SDYRGQGTLV TVSS


 


BMS2h-572-623 (SEQ ID NO: 266)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESS------ SDYRGQGTLV TVSS


 


BMS2h-572-624 (SEQ ID NO: 267)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSA------ SDYRGQGTLV TVSS


 


BMS2h-572-625 (SEQ ID NO: 268)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG NDSY------ SDYRGQGTLV TVSS


 


BMS2h-572-626 (SEQ ID NO: 269)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNGLRAED TAVYYCVKVG KDSS------ SDYRGQGTLV TVSS


 


BMS2h-572-627 (SEQ ID NO: 270)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCVKVG KDSA------ SDYRGQGTLV TVSS


 


BMS2h-572-630 (SEQ ID NO: 271)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK------ SDYRGQGTLV TVSS


 


BMS2h-572-631 (SEQ ID NO: 272)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS


 


BMS2h-572-632 (SEQ ID NO: 273)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-633 (SEQ ID NO: 274)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK------ SDYRGQGTLV TVSS


 


BMS2h-572-634 (SEQ ID NO: 275)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS


 


BMS2h-572-635 (SEQ ID NO: 276)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS


 


BMS2h-572-7 (SEQ ID NO: 277)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED SAVYYCAKVG KESN------ FDYLGQGTLV TVSS


 


BMS2h-572-8 (SEQ ID NO: 278)


EVQLLESGGG LVQPGGSLRL SCVASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-572-9 (SEQ ID NO: 279)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS


 


BMS2h-573 (SEQ ID NO: 280)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS GWEMGWVRQA PGKGLEWVSS IDESGLNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGA PQYQIT---- FDYWGQGTLV TVSS


 


BMS2h-574 (SEQ ID NO: 281)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP NYGMYWVRQA PGKGLEWVSY ISRRGLLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTS HYMNNG---- FDYWGQGTLV TVSS


 


BMS2h-575 (SEQ ID NO: 282)


EVQLLESGGG LVQPGGSLRL SCAASGFTFV DYTMAWVRQA PGKGLEWVSS ISPIGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDP YGMEDGLTW- FDYWGQGTLV TVSS


 


BMS2h-576 (SEQ ID NO: 283)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD AYDMQWVRQA PGKGLEWVST ITSEGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS DL-------- FDYWGQGTLV TVSS


 


BMS2h-577 (SEQ ID NO: 284)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD GYDMGWVRQA PGKGLEWVST ISRGGWFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGT SQSSTGS--- FDYWGQGTLV TVSS


 


BMS2h-578 (SEQ ID NO: 285)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR RYDMLWARQA PGKGLEWVSE ISPTGALTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG ST-------- FDYWGQGTLV TVSS


 


BMS2h-579 (SEQ ID NO: 286)


EVQLLESGGG LVQPGGSLRL SCAASGFTFF PYYMSWVRQA PGKGLEWVSS ISGTGGLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTT QNATL----- FDYWGQGTLV TVSS


 


BMS2h-58 (SEQ ID NO: 287)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE VYTMAWVRQA PGKGLEWVST IDESGRDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VW-------- FDYWGQGTLV TVSS


 


BMS2h-580 (SEQ ID NO: 288)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA FYKMGWVRQA PGKGLEWVST ITPKGHHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVF KGKGWTRPSG FDYWGQGTLV TVSS


 


BMS2h-581 (SEQ ID NO: 289)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN EYSMMWVRQA PGKGLEWVSS IGRRGWLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAV LLDSTK---- FDYWGQGTLV TVSS


 


BMS2h-582 (SEQ ID NO: 290)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD EYPMTWVRQA PGKGLEWVST ISARGPFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGR HWLRNGR--- FDYWGQGTLV TVSS


 


BMS2h-583 (SEQ ID NO: 291)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG MQSMQWVRQA PGKGLEWVSS ITDDGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RV-------- FDYWGQGTLV TVSS


 


BMS2h-584 (SEQ ID NO: 292)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG AADMQWVRQA PGKGLEWVSL ITNDGISTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DR-------- FDYWGQGTLV TVSS


 


BMS2h-586 (SEQ ID NO: 293)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN KYRMQWVRQA PGKGLEWVSS IDSSGELTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEEV PMGNQTF--- FDYWGQGTLV TVSS


 


BMS2h-587 (SEQ ID NO: 294)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYTMGWVRQA PGKGLEWVSS ITSQGAFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAT GTDSS----- FDYWGQGTLV TVSS


 


BMS2h-588 (SEQ ID NO: 295)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE DYEMSWVRQA PGKGLEWVSC IGPGGKPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVD GH-------- FDYWGQGTLV TVSS


 


BMS2h-589 (SEQ ID NO: 296)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS QYDMGWVRQA PGKGLEWVST ISSRGWLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP GGRRR----- FDYWGQGTLV TVSS


 


BMS2h-59 (SEQ ID NO: 297)


EVQLLESGGG LVQPGGSLRL SCAASGFTFL DYAMGWVRQA PGKGLEWVST ISPMGMGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSS AISFTSDISN FDYWGQGTLV TVSS


 


BMS2h-590 (SEQ ID NO: 298)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYPMSWVRQA PGKGLEWVSS ISWSGFQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VARMPTGIA- FDYWGQGTLV TVSS


 


BMS2h-591 (SEQ ID NO: 299)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYEMQWVRQA PGKGLEWVSS IDSAGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF GM-------- FDYWGQGTLV TVSS


 


BMS2h-592 (SEQ ID NO: 300)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS EYPMKWVRQA PGKGLEWVST IDRQGDRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTV RRGLPRPSRY FDYWGQGTLV TVSS


 


BMS2h-593 (SEQ ID NO: 301)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYDMGWVRQA PGKGLEWVSS ISPMGTFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL SVYSGLD--- FDYWGQGTLV TVSS


 


BMS2h-594 (SEQ ID NO: 302)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYDMGWVRQA PGKGLEWVSD IDYIGKTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAS DEVGVNTSK- FDYWGQGTLV TVSS


 


BMS2h-595 (SEQ ID NO: 303)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA RYDMGWVRQA PGKGLEWVST ISPTGVLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGF ED-------- FDYWGQGTLV TVSS


 


BMS2h-596 (SEQ ID NO: 304)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSL ISHTGHATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGH WP-------- FDYRGQGTLI TVSS


 


BMS2h-597 (SEQ ID NO: 305)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE DEWMSWVRQA PGKGLEWVSD ISPGGWTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY RPFDE----- FDYWGQGTLV TVSS


 


BMS2h-598 (SEQ ID NO: 306)


EVQLLESGGG LVQPGGSLRL SCAASGVTFD AIEMSWVRQA PGKGLEWVSS ISRHGEYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEDA WSRH------ FDYWGQGTLV TVSS


 


BMS2h-599 (SEQ ID NO: 307)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD STDMSWVRQA PGKGLEWVSG ILDNGSNTYY


ADSVKGRFTI SRDNSKNMLY LQMNSLRAED TAVYYCAKGA RD-------- FDYWGQGTLV TVSS


 


BMS2h-600 (SEQ ID NO: 308)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG RQSMQWVRQA PGKGLEWVSS IDDDGFSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD PWG------- FDYWGQGTLV TVSS


 


BMS2h-601 (SEQ ID NO: 309)


EVQLLESGGG LVQPGGSLRL SCTASGFTFS DTQMAWVRQA PGKGLEWVSG IDDGGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RH-------- FDYWGQGTLV TVSS


 


BMS2h-602 (SEQ ID NO: 310)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG STTMGWVRQA PGKGLEWVSV ISDDGGFTYY


ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKVD GYGV------ FDYWGQGTLV TVSS


 


BMS2h-603 (SEQ ID NO: 311)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR SGDMNWVRQA PGKGLEWVST ITNDGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSD SD-------- FDYWGQGTLV TVSS


 


BMS2h-61 (SEQ ID NO: 312)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA AYAMTWVRQA PGKGLEWVSY ISPNGTATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEYV GMRWNS---- FDYWGQGTLV TVSS


 


BMS2h-62 (SEQ ID NO: 313)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYEMAWVRQA PGKGLEWVSS ITSLGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RK-------- FDYWGQGTLV TVSS


 


BMS2h-65 (SEQ ID NO: 314)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN EYEMTWVRQA PGKGLEWVST ITSEGSGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN GK-------- FDYWGQGTLV TVSS


 


BMS2h-66 (SEQ ID NO: 315)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMLWVRQA PGKGLEWVST ITSEGHSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TS-------- FDYWGQGTLV TVSS


 


BMS2h-67 (SEQ ID NO: 316)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMSWVRQA PGKGLEWVST IDSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VK-------- FDYWGQGTLV TVSS


 


BMS2h-68 (SEQ ID NO: 317)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK DYEMTWVRQA PGKGLEWVSS ISSTGQSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG NK-------- FDYWGQGTLV TVSS


 


BMS2h-69 (SEQ ID NO: 318)


EVQLLESGGG LVQPGGSLRL SCAASGFTFL DYGMAWVRQA PGKGLEWVSA ISPLGLSTYY


ADSVKSRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEV RVGRGVHPPK FDYWGQGTLV TVSS


 


BMS2h-7 (SEQ ID NO: 319)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN LYEMTWVRQA PGKGLEWVSS ITSDGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG VI-------- FDYWGQGTLV TVSS


 


BMS2h-70 (SEQ ID NO: 320)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE NYAMSWVRQA PGKGLEWVST IAPLGVPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKK VGAWLQSRS- FDYWGQGTLV TVSS


 


BMS2h-701 (SEQ ID NO: 321)


EVQLLESGGG LVQPGGSLRL SCAASGFTFM DYEMHWVRQA PGKGLEWVST IGASGHYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYL DMLLFG---- FDYWGQGTLV TVSS


 


BMS2h-702 (SEQ ID NO: 322)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA EYEMMWARQA PGKGLEWVSR IAGNGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIML SH-------- FDYWGQGTLV TVSS


 


BMS2h-703 (SEQ ID NO: 323)


EVQLLESGGG LVQPGGSLRL SCAASGFTFY NYDMSWVRQA PGKGLEWVSG IDSMGLVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGS NASDWVV--- FDYWGQGTLV TVSS


 


BMS2h-704 (SEQ ID NO: 324)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYHMTWVRQA PGKGLEWVSS IADTGDRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLR GMARVWG--- FDYWGQGTLV TVSS


 


BMS2h-705 (SEQ ID NO: 325)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS YYDMMWVRQA PGKGLEWISS ISDRGLQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFT EIPLDWLEV- FDYWGQGTLV TVSS


 


BMS2h-706 (SEQ ID NO: 326)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG SYKMLWVRQA PGKGLEWVSS ITNSGTETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSM YPDLEIVH-FDYWGQGTLV TVSS


 


BMS2h-707 (SEQ ID NO: 327)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE TYRMSWVRQA PGKGLEWVSA IDQEGSATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNS GTRPGLR--- FDYWGQGTLV TVSS


 


BMS2h-708 (SEQ ID NO: 328)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYDMLWVRQA PGKGLEWVSR IDASGYFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQLL KLSLNPN--- FDYWGQGTLV TVSS


 


BMS2h-709 (SEQ ID NO: 329)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS IHNTGLSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGT QHRFVV---- FDYWGQGTLV TVSS


 


BMS2h-71 (SEQ ID NO: 330)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GYPMSWVRQA PGKGLEWVST ISPLGPDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLL MGEYLNSRT- FDYWGQGTLV TVSS


 


BMS2h-710 (SEQ ID NO: 331)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN TYSMSWVRQA PGKGLEWVSW IDADGWVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQTG HT-------- FDYWGQGTLV TVSS


 


BMS2h-711 (SEQ ID NO: 332)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSR IVDPGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DQ-------- FDYWGQGTLV TVSS


 


BMS2h-712 (SEQ ID NO: 333)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYEMKWVRQA PGKGLEWVST ITPSGGHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAIPL SS-------- FDYWGRGTLV TVSS


 


BMS2h-713 (SEQ ID NO: 334)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYVMIWVRQA PGKGLEWVSL INGAGDMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGG ARSFGVPPN- FDYWGQGTLV TVSS


 


BMS2h-714 (SEQ ID NO: 335)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSR IVDPGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DQ-------- FDYWGQGTLV TVSS


 


BMS2h-715 (SEQ ID NO: 336)


EVQLLESGGG LVQPGGSLRL SCVASGFTFT LYNMSWVRQA PGKGLEWVSV ISSKGDSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQTS SV-------- FDYWGQGTLV TVSS


 


BMS2h-716 (SEQ ID NO: 337)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE AYYMSWVRQA PGKGLEWVSG IVNNGLLTYY


ADSVKGRFTI SRDNSKNMLY LQMNSLRAED TAVYYCAKSA VHPSYRAEL- FDYWGQGTLV TVSS


 


BMS2h-717 (SEQ ID NO: 338)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYEMAWVRQA PGKGLEWVSR IEPDGSNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP DNFTM----- FDYWGQGTLV TVSS


 


BMS2h-718 (SEQ ID NO: 339)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN KYMMGWVRQA PGKGLEWVSS IDSLGHYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEAE FP-------- FDYWGQGTLV TVSS


 


BMS2h-719 (SEQ ID NO: 340)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-1 (SEQ ID NO: 341)


EVQLLESGGG MVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTQV TVSS


 


BMS2h-719-10 (SEQ ID NO: 342)


EVQLLESGGG MVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-11 (SEQ ID NO: 343)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRKA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSENTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-12 (SEQ ID NO: 344)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-13 (SEQ ID NO: 345)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCADPF TE-------- LDYWGHGTLV TVSS


 


BMS2h-719-14 (SEQ ID NO: 346)


EVQLLESGGG LVRPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-15 (SEQ ID NO: 347)


EVQLLESGGG LVQPGGSLRL SCAASGFAFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LHMNSLRAED TAVYYCADPF TE-------- IDYWGQGTLV TVSS


 


BMS2h-719-16 (SEQ ID NO: 348)


EVQLLESGGG LVQPGGSLRL SCAASGFPFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYRAQGTLV TVSS


 


BMS2h-719-17 (SEQ ID NO: 349)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMSWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- IDYWGQGTQV TVSS


 


BMS2h-719-18 (SEQ ID NO: 350)


EVQLLESGGG LVHPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRDED TAVYYCAEPF TE-------- FDYGGQGTLV TVSS


 


BMS2h-719-19 (SEQ ID NO: 351)


EVQLLESGGG WVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-2 (SEQ ID NO: 352)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-20 (SEQ ID NO: 353)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- IDYRGQGTLV TVSS


 


BMS2h-719-202 (SEQ ID NO: 354)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK KYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-203 (SEQ ID NO: 355)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN SYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-21 (SEQ ID NO: 356)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-213 (SEQ ID NO: 357)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- MDYWGHGTLV TVSS


 


BMS2h-719-214 (SEQ ID NO: 358)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-215 (SEQ ID NO: 359)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- LDYWGHGTLV TVSS


 


BMS2h-719-218 (SEQ ID NO: 360)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


AESVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-225 (SEQ ID NO: 361)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN TYEMQWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-226 (SEQ ID NO: 362)


EVQLLESGGG LVQPGGSLRL SCAASGFTFN KYEMMWARQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS


 


BMS2h-719-3 (SEQ ID NO: 363)


EVQLSESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-4 (SEQ ID NO: 364)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQT PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-5 (SEQ ID NO: 365)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LEMNSMRAED TAVYYCAEPF TE-------- FDNWGQGTLV TVSS


 


BMS2h-719-6 (SEQ ID NO: 366)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTQV TVSS


 


BMS2h-719-7 (SEQ ID NO: 367)


EVQLLESGGG LVQPGGSLRL SCAASGFNFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS


 


BMS2h-719-8 (SEQ ID NO: 368)


EVQLLESGGD LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYRGQGTLV TVSS


 


BMS2h-719-9 (SEQ ID NO: 369)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMSWVRQA PGKGLEWVSS ISSDGSFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGRGTLV TVSS


 


BMS2h-72 (SEQ ID NO: 370)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSS ISPLGLWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS AGAETHVYRL FDYWGQGTLV TVSS


 


BMS2h-720 (SEQ ID NO: 371)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYEMMWVRQA PGKGLEWVSS IGVLGHTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLM SLRTFENL-FDYWGQGTLV TVSS


 


BMS2h-722 (SEQ ID NO: 372)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT KYPMAWVRQA PGKGLEWVSG IDANGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGT WRRHFAI--- FDYWGQGTLV TVSS


 


BMS2h-723 (SEQ ID NO: 373)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD LYDMMWVRQA PGKGLEWVSS ISDLGTLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNG FRVTSNDRR- FDYWGQGTLV TVSS


 


BMS2h-724 (SEQ ID NO: 374)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT GGDMWWVRQA PGKGLEWVSM IEGGGVTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAELD LRTGQ----- FDYWGQGTLV TVSS


 


BMS2h-725 (SEQ ID NO: 375)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-1 (SEQ ID NO: 376)


EVQLLESGGG LVQPGGSLHL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCADPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-10 (SEQ ID NO: 377)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-11 (SEQ ID NO: 378)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMSSLRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-12 (SEQ ID NO: 379)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDDSKNTLY LQMNSLRVED TAVYYCAEPS DPTM------ FVYWGQGTLV TVSS


 


BMS2h-725-13 (SEQ ID NO: 380)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTM------ FVYWGQGTLV TVSS


 


BMS2h-725-14 (SEQ ID NO: 381)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTM------ FDYWGQGTLV TVSS


 


BMS2h-725-15 (SEQ ID NO: 382)


EVQLLESGGG MVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSMRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-16 (SEQ ID NO: 383)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVTL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTM------ FDYWGQGTLV TVSS


 


BMS2h-725-17 (SEQ ID NO: 384)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ LDYWGQGTLV TVSS


 


BMS2h-725-18 (SEQ ID NO: 385)


EVQLSESGGG LVQPGGSLRL TCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FVYWGQGTLV TVSS


 


BMS2h-725-19 (SEQ ID NO: 386)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FVYWGQGTLV TVSS


 


BMS2h-725-2 (SEQ ID NO: 387)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FVYWGQGTPV TVSS


 


BMS2h-725-3 (SEQ ID NO: 388)


VQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSRNMLY LQMKSLRAED TAVYYCADPS DPTK------ FVYWGQGTQV TVSS


 


BMS2h-725-4 (SEQ ID NO: 389)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FVYWGQGTLV TVSS


 


BMS2h-725-5 (SEQ ID NO: 390)


EVQLLESGGG LLQPGGSLRL SCAASGFTFS DYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FDYWGRGTLV TVSS


 


BMS2h-725-6 (SEQ ID NO: 391)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FVYWGQGTLV TVSS


 


BMS2h-725-7 (SEQ ID NO: 392)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGTWTYY


ADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-8 (SEQ ID NO: 393)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY


ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-725-9 (SEQ ID NO: 394)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGMGLEWVSL IGDRGSWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FDYWGQGTLV TVSS


 


BMS2h-726 (SEQ ID NO: 395)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYKMYWVRQA PGKGLEWVSS ISEIGNLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIAL TR-------- FDYWGQGTLV TVSS


 


BMS2h-727 (SEQ ID NO: 396)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYRMYWVRQA PGKGLEWVSY IDPPGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSL NLSFPYIN-FDYWGQGTLV TVSS


 


BMS2h-728 (SEQ ID NO: 397)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYEMLWVRQA PGKGLEWVSR ISHSGRTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQLD GP-------- FDYWGQGTLV TVSS


 


BMS2h-729 (SEQ ID NO: 398)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYYMDWVRQA PGKGLEWVSR INHNGSVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMP QGTSDWYY-FDYWGQGTLV TVSS


 


BMS2h-73 (SEQ ID NO: 399)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS KYDMSWVRQA PGKGLEWVST ILEDGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RL-------- FDYWGQGTLV TVSS


 


BMS2h-74 (SEQ ID NO: 400)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYPMTWVRQA PGKGLEWVST ILSPGTETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAE KD-------- FDYWGQGTLV TVSS


 


BMS2h-741 (SEQ ID NO: 401)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE GGEMGWVRQA PGKGLEWVSM IPMDGSATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG EV-------- FDYWGQGTLV TVSS


 


BMS2h-742 (SEQ ID NO: 402)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR EYHMKWARQA PGKGLEWVSG ISRDGMNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIQL AL-------- FDYWGQGTLV TVSS


 


BMS2h-743 (SEQ ID NO: 403)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYEMLWARQA PGKGLEWVSG ILPSGGATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG SGNGPIL--- FDYWGQGTLV TVSS


 


BMS2h-744 (SEQ ID NO: 404)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK EHDMFWVRQA PGKGLEWVSG IGAEGVWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPT MSNGSQSR-FDYWGQGTLV TVSS


 


BMS2h-745 (SEQ ID NO: 405)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG IIEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-1 (SEQ ID NO: 406)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-10 (SEQ ID NO: 407)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNNLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-11 (SEQ ID NO: 408)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNFKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-12 (SEQ ID NO: 409)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSMNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS


 


BMS2h-745-13 (SEQ ID NO: 410)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG IIEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-14 (SEQ ID NO: 411)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-15 (SEQ ID NO: 412)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNALY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGLGTLV TVSS


 


BMS2h-745-16 (SEQ ID NO: 413)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS


 


BMS2h-745-17 (SEQ ID NO: 414)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG IIEDGNRTYY


ADSVKGRFTI SRDNSKNRLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-18 (SEQ ID NO: 415)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYHCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-19 (SEQ ID NO: 416)


EVQLLESGGG LVQPEGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG IIEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-2 (SEQ ID NO: 417)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ISEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED SAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS


 


BMS2h-745-3 (SEQ ID NO: 418)


EVQLLESGGG LVEPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMSSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-4 (SEQ ID NO: 419)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ISEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYHCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-5 (SEQ ID NO: 420)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFII SRDNSKNTLN LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-6 (SEQ ID NO: 421)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGRGLEWVSG VTEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-7 (SEQ ID NO: 422)


EVQLLESGGG LVQPGGSLRL SCEASGFTFD NTEMAWIRQA PGKGLEWVSG IIEDGNRTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-8 (SEQ ID NO: 423)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGDRTYY


ADSVKGRFTI SRDNSKSSLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-745-9 (SEQ ID NO: 424)


EVQLLESGGG SVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS


 


BMS2h-746 (SEQ ID NO: 425)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG SAEMGWVRQA PGKGLEWVSG ISRPGQVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-747 (SEQ ID NO: 426)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD DGTMGWARQA PGKGLEWVSL ILPSGSRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHS LTNRP----- FDYWGQGTLV TVSS


 


BMS2h-748 (SEQ ID NO: 427)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS KYDMRWARQA PGKGLEWVSD IDAVGTRTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIPG GT-------- FDYWGQGTLV TVSS


 


BMS2h-749 (SEQ ID NO: 428)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE MYGMMWARQA PGKGLEWVSS IEGAGHATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIVL GM-------- FDYWGQGTLV TVSS


 


BMS2h-75 (SEQ ID NO: 429)


EVQLLESGGG LVQPGGSLRL SCAASGFTFL QYPMGWVRQA PGKGLEWVST ISPVGLTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLF EGSRIQRDVG FDYWGQGTLV TVSS


 


BMS2h-750 (SEQ ID NO: 430)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE KYQMGWARQA PGKGLEWVSS IRGSGLVTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVH TTLHTEVIG- FDYWGQGTLV TVSS


 


BMS2h-751 (SEQ ID NO: 431)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS QYTMYWARQA PGKGLEWVSE ISHSGSNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAISG LH-------- FDYWGQGTLV TVSS


 


BMS2h-752 (SEQ ID NO: 432)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYAMAWVRQA PGKGLEWVSR IGVEGGDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLL RLYRLG---- FDYWGQGTLV TVSS


 


BMS2h-753 (SEQ ID NO: 433)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA KYDMTWVRQA PGKGLEWVSK INSDGGLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL HGRGFVI--- FDYWGQGTLV TVSS


 


BMS2h-754 (SEQ ID NO: 434)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS RYDMVWVRQA PGKGLEWVSR INSMGLATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDY SVAPHGYPLG FDYWGQGTLV TVSS


 


BMS2h-755 (SEQ ID NO: 435)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK DYSMMWVRQA PGKGLEWVST ITDNGTSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHM SLATYLQF-FDYWGQGTLV TVSS


 


BMS2h-756 (SEQ ID NO: 436)


EVQLLESGGG LVQPGGSLRL SCAASGFTFM EYDMLWVRQA PGKALEWVSR ISSDGLWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGV SALAPFDIG- FDYWGQGTLV TVSS


 


BMS2h-757 (SEQ ID NO: 437)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK EYNMAWVRQA PGKGLEWVSS INFAGRTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS LPLDIFS--- FDYWGQGTLV TVSS


 


BMS2h-758 (SEQ ID NO: 438)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FDYWGQGTLV TVSS


 


BMS2h-758-1 (SEQ ID NO: 439)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNMLY LRMNSLRAED TAVYYCAETS GY-------- YEYWGQGTLV TVSS


 


BMS2h-758-2 (SEQ ID NO: 440)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FEYWGQGTLV TVSS


 


BMS2h-758-3 (SEQ ID NO: 441)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS SY-------- FEYWGQGTLV TVSS


 


BMS2h-758-4 (SEQ ID NO: 442)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCAETS GY-------- YEYWGHGTLV TVSS


 


BMS2h-758-5 (SEQ ID NO: 443)


EVQLLESGGG LVQPGGSLRL SCAASGFAFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FEYWGQGTLV TVSS


 


BMS2h-758-6 (SEQ ID NO: 444)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFIYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FEYWGQGTLV TVSS


 


BMS2h-759 (SEQ ID NO: 445)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR EYVMGWVRQA PGKGLEWVST INGLGNVTYY


ADSVKGRFTI SRDNTKNTLY LQMNSLRAEE TAVYYCAIQL PN-------- FDYWGQGTLV TVSS


 


BMS2h-760 (SEQ ID NO: 446)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG NDGMWWVRQA PGKGLEWVSF INVDGRETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS PGRVQ----- FDYWGQGTLV TVSS


 


BMS2h-761 (SEQ ID NO: 447)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG GWDMAWVRQA PGKGLEWVSS IAHEGGETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYV PGSPL----- FDYWGQRTLV TVSS


 


BMS2h-762 (SEQ ID NO: 448)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD QGWMYWVRQA PGKGLEWVSG IGSNGPRTSY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG EY-------- FDYWGQGTLV TVSS


 


BMS2h-763 (SEQ ID NO: 449)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR QSDMWWVRQA PGKGLEWVSV IGNNGEFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDN WLL------- FDYWGQGTLV TVSS


 


BMS2h-764 (SEQ ID NO: 450)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD LSTMYWVRQA PGKGLEWVST IGGDGSHTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGT QY-------- FDYWGQGTLV TVSS


 


BMS2h-765 (SEQ ID NO: 451)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMEWVRQA PGKGLEWVSS IGVTGYDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGG QG-------- FDYWGQGTLV TVSS


 


BMS2h-766 (SEQ ID NO: 452)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMSWVRQA PGKGLEWVSY IDPLGRLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEDL SSLQYGVSPN FDYWGQGTLV TVSS


 


BMS2h-767 (SEQ ID NO: 453)


EVQLLESGGG LVQPGGSLRL SCAASGFTFF HYSMSWVRQA PGKGLEWVSS IGPVGRETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMI QSPLFKD--- FDYWGQGTLV TVSS


 


BMS2h-768 (SEQ ID NO: 454)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE WYDMYWVRQA PGKGLEWVSR IDSGGNQTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEAS LWKWRL---- FDYWGQGTLV TVSS


 


BMS2h-77 (SEQ ID NO: 455)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYGMAWVRQA PGKGLEWVST ISPLGISTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHA TSQESLRS-FDYWGQGTLV TVSS


 


BMS2h-770 (SEQ ID NO: 456)


EVQLLESGGG LVQPGGSLRL SCAASGFTFS KYEMMWVRQA PGKGLEWVSA ISGSGGSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP LPDAFWTRG- FDYWGQGTLV TVSS


 


BMS2h-771 (SEQ ID NO: 457)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG TYSMAWVRQA PGKGLEWVST IDRHGLATYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTP GSSWQTV--- FGYWGQGTLV TVSS


 


BMS2h-772 (SEQ ID NO: 458)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE SYPMGWVRQA PGKGLEWVSS IDHHGHSTYY


ADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLL RVSMIFG--- FDYWGQGTLV TVSS


 


BMS2h-773 (SEQ ID NO: 459)


EVQLLESGGG LVQPGGSLRL SCAASGFTFV QYGMSWVRQA PGKGLEWVSW ISSSGTYTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS RM-------- FDYWGQGTLV TVSS


 


BMS2h-774 (SEQ ID NO: 460)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR EYDMGWVRQA PGKGLEWVSL ISPPGRTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVV ILGYTNR--- FDYWGQGTLV TVSS


 


BMS2h-775 (SEQ ID NO: 461)


EVQLLESGGG LVQPGGSLRL SCAASGFTFP NYGMLWVRQA PGKGLEWVSS INSSGMETYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFF RLNDHNSVFG FDYWGQGTLV TVSS


 


BMS2h-776 (SEQ ID NO: 462)


EVQLLESGGG LVQPGGSLRL SCAASGFTFK DYKMMWIRQA PGKGLEWVSS IVGSGSMTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP GY-------- FDYWGQGTLV TVSS


 


BMS2h-777 (SEQ ID NO: 463)


EVQLLESGGG LVQPGGSLRL SCAASGFTFH NYAMGWVRRA PGKGLEWVSS IDEHGTITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS LDRVWI---- FDYWGQGTLV TVSS


 


BMS2h-778 (SEQ ID NO: 464)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYPMTWVRQA PGKGLEWVSS IYSAGSPTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLY HREPILFG-FDYWGQGTLV TVSS


 


BMS2h-78 (SEQ ID NO: 465)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYQMAWVRQA PGKGLEWVST ISSDGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG HR-------- FDYWGQGTLV TVSS


 


BMS2h-780 (SEQ ID NO: 466)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG SYTMMWVRQA PGKGLEWVSE IDRTGERTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPG FASLP----- FDYWGQGTLV TVSS


 


BMS2h-781 (SEQ ID NO: 467)


EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYTMYWVRQA PGKGLEWVSK ISPSGRSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDP FG-------- FDYWGQGTLV TVSS


 


BMS2h-782 (SEQ ID NO: 468)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD DAEMFWVRQA PGKGLEWVSS IDARGLTTYY


ADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEAT SAMYP----- FDYWGQGTLV TVSS


 


BMS2h-783 (SEQ ID NO: 469)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYDMGWVRQA PGKGLEWVST ISPLGHFTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG FHEYTEG--- FDYWGQGTLV TVSS


 


BMS2h-784 (SEQ ID NO: 470)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD RAGMGWVRQA PGKGLEWVSL IGRGGDITYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS


 


BMS2h-80 (SEQ ID NO: 471)


EVQLLESGGG LVQPGGSLRL SCAASGFTFG RYQMAWVRQA PGKGLEWVSS ISSDGGGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS RR-------- FDYWGQGTLV TVSS


 


BMS2h-81 (SEQ ID NO: 472)


EVQLLESGGG LVQPGGFLRL SCAASGFTFE LYPMAWVRQA PGKGLEWVSS ISPVGFLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGH EGSYTPRSA- FDYWGQGTLV TVSS


 


BMS2h-82 (SEQ ID NO: 473)


EVQLLESGGG LVQPGGSLRL SCAASGFTFV AYPMAWVRQA PGKGLEWVST IAPLGGNTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRP EGLQIDSQN- FDYWGQGTLV TVSS


 


BMS2h-83 (SEQ ID NO: 474)


EVQLLESGGG LVQPGGSLRL SCAASGFTFA LYQMAWVRQA PGKGLEWVSS IDSSGSDTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPE RD-------- FDYWGQGTLV TVSS


 


BMS2h-84 (SEQ ID NO: 475)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR QYQMAWARQA PGKGLEWVST IASDGVSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG RD-------- FDYWGQGTLV TVSS


 


BMS2h-85 (SEQ ID NO: 476)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE QYDMRWVRQA PGKGLEWVSW IDEAGHETYY


ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKGM DG-------- FDYWGQGTLV TVSS


 


BMS2h-92 (SEQ ID NO: 477)


EVQLLESGGG LVQPGGSLRL SCAASGFTFV DYPMGWVRQA PGKGLEWVST ISTGGFSTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAR YYYLSQIKN- FDYWGQGTLV TVSS


 


BMS2h-93 (SEQ ID NO: 478)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD IYGMTWVRQA PGKGLEWVSS ISPLGLVTYY


ADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLK EHGDVP---- FDYWGQGTLV TVSS


 


BMS2h-94 (SEQ ID NO: 479)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE LYPMSWVRQA PGKGLEWVST ISPTGLLTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFK RSGKTDDTN- FDYWGQGTLV TVSS


 


BMS2h-95 (SEQ ID NO: 480)


EVQLLESGGG LVQPGGSLRL SCAASGFTFR EYDMLWVRQA PGKGLEWVST IVGDGNGTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD RQ-------- FDYWGQGTLV TVSS


 


BMS2h-97 (SEQ ID NO: 481)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYGMSWVRQA PGKGLEWVST ISPIGVTTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNA YDRKSN---- FDYWGQGTLV TVSS


 


BMS2h-98 (SEQ ID NO: 482)


EVQLLESGGG LVQPGGSLRL SCAASGFTFD RYVMVWVRQA PGKDLEWVSG ITPSGRRTYY


ADSVKGRFTI SRDNSKDTLY LQMNSLRAED TAVYYCAKVL GRHFDPLLPS FDYWGQGTLV TVSS


 


BMS2h-99 (SEQ ID NO: 483)


EVQLLESGGG LVQPGGSLRL SCAASGFTFE DYAMSWVRQA PGKGLEWVST ITPGGFWTYY


ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTS SGELQLVED-FDYWGQGTLV TVSS
















TABLE 2





Human Anti-CD40L VH Domain Encoding


Nucleotide Sequences















BMS2h-10 (SEQ ID NO: 484)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTAGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGCTTATGATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGG


ATTGATGAGTGGGGTCTGCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGACG


CCTGAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-11 (SEQ ID NO: 485)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTGATGGTGAGGGTTCTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGGG


AGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-111 (SEQ ID NO: 486)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGTTATCCTA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTCATGGTTCTGGTAGTGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCG


TATACTAGTCGGCATAATAGTCTTGGGCATTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-112 (SEQ ID NO: 487)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATTATCCTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGCCTGTTGGTATGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATGGG


GGGACTAGTGGTAGGCATAATACTAAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-113 (SEQ ID NO: 488)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGAGTATCCTA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTT


ATTTCTCCTCTTGGTTTTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACT


GGTGGGAGTGGTATTTTGAATTCTTCTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-114 (SEQ ID NO: 489)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTTAGGGTTAGCAATTACGATT


TGACCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAACC


ATTAGTGCCACAAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGGCAGTGACG


TGGTGGTTGTTGCGTCATAACGACAACTTGGGGTTTTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-115 (SEQ ID NO: 490)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTTAGCATTAGCTATAAGAATA


TGGCCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAGCC


ATTAAGGCGGCAAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGACAGGGAGT


CAGAAGAAGCGGACCTACACGTTCGACTTTTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-12 (SEQ ID NO: 491)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTTGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTGATATTTTGGGTTCGAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCTG


TCGTGGCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-120 (SEQ ID NO: 492)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTCTTATACGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAATCCTATGGGTTATCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACATGGG


GTGGGGAAGGGTACTAAGCCGCATAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-121 (SEQ ID NO: 493)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTGTATAGGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTAGTGGTAGTGGTTTTCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTCTG


CATGATAAGACTCAGCATCATCAGGAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-123 (SEQ ID NO: 494)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGAGTATCCTA


TGCGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTT


ATTTCTCCGTCTGGTGTGTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT


GAGTCTAGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-124 (SEQ ID NO: 495)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATGATA


TGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGGGAGTTCGGGTTATCCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGGATG


CCTGGTTATTTTCCTGGGTTTGCTCGGCAGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-125 (SEQ ID NO: 496)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTGGCGGTATGCTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTAATGATGAGGGTCGGGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGCGG


GTGTCTAGTTCTGTGAATGCTCCGTATGAGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-126 (SEQ ID NO: 497)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATAGTA


TGAGTTGGGTCCGCCAGGCCCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGATCGTCTTGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGCTG


GCTGATCTTATTGCTGGGCATGCGGAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-127 (SEQ ID NO: 498)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGTCGTATGATA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTTCGAGGTCTGGTTCTATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATTTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGTT


GATGCGCATGTTTATTATATGGAGCCTTTTTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-128 (SEQ ID NO: 499)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTAGTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


ACTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-129 (SEQ ID NO: 500)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACATTTCCGAAGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATGGTGATGGTAAGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGAT


CAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-13 (SEQ ID NO: 501)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTTATTATTCGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTTCGCCTTTTGGTTGGGGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGGACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG


GAGACGAGTGGTCCGATTTCTGAGAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-130 (SEQ ID NO: 502)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTGCGGGTTATCAGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTAATGAGGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


AAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-131 (SEQ ID NO: 503)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATGAGA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTACGTCGGATGGTCTGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


ATTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-132 (SEQ ID NO: 504)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGTTGATGATGGTCTTATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT


GTTGCTTTTGACTACTGGGGTCAGGGGACCCTGGTCACCGTCTCGAAC


 


BMS2h-133 (SEQ ID NO: 505)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGGTTATGCTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGGTCCTTTGGGTGCGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCCT


GCTGGTACGAGTAGTCATAGTGTGGATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-134 (SEQ ID NO: 506)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCG


GTTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-135 (SEQ ID NO: 507)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAGGTATGTTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTGAGGCTGATGGTCGTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCTT


ACGGATCAGCATGTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-136 (SEQ ID NO: 508)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTTATCGTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGCTCCGGATGGTAATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTGG


GGGATGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-137 (SEQ ID NO: 509)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTATCCGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGGTCCTATTGGTTTTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAATGAAG


TCGCCTTATAAGCCGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-138 (SEQ ID NO: 510)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTGGCTTATTGGA


TGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTCCGTCGGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGAAATATACT


GAGCCGGGGTTGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-139 (SEQ ID NO: 511)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTG


ATTTCTGAGGTGGGTTCTCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCAT


GATAGTTCGATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-14 (SEQ ID NO: 512)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTGGTCTTATGATA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTATGGCTTCGGGTGATGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGAT


CGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-15 (SEQ ID NO: 513)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGTTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTTCTCCTATTGGTCTGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTCCT


TTGATTATTCTTCCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-16 (SEQ ID NO: 514)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGCGA


TGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATT


ATTTCTCCGCTTGGTTTGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAG


GATTCGTCTGATAGTCAGTATACGAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-17 (SEQ ID NO: 515)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGGGA


TGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGGTCCTCTGGGTCTTTGGACATACTACGCAGACTCCGCGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCG


CTTGAGGGTTTGATTACGAATTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-176 (SEQ ID NO: 516)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATT


ATTGATTGGGATGGTAATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG


GATAATGTTGGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-177 (SEQ ID NO: 517)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATTATA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCG


ATTGATGAGTGGGGTTTTGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTGG


GAGTTTACGTCTGATACGTCGCGTTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-178 (SEQ ID NO: 518)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTTTGATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAATGATCAGGGTTCTCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT


CAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-179 (SEQ ID NO: 519)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGATA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGG


ATTAGTCCTCAGGGTCAGCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


GGGCAGTCGCGGATTCCTATGAGGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-18 (SEQ ID NO: 520)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGATA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATAT


ATTAGTTCTGATGGTTATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGCAT


GGGAGTCCGCGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-180 (SEQ ID NO: 521)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACTAGTTTGGGTGAGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


CGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-181 (SEQ ID NO: 522)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTTTTATCCTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTGATGCTACGGGTACGAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTAAT


TATGGGAGTTCGTATACTATGGGGGTTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-182 (SEQ ID NO: 523)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGGTCCTTCTGGTCCGAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCG


TATTTTGATGTTATTCCTAGTTATTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-183 (SEQ ID NO: 524)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTACGGTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTCAGTCGTCGGGTTTGCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGGCT


AATTCTCGTAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-184 (SEQ ID NO: 525)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACTAGTCATGGTGGGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAT


AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-185 (SEQ ID NO: 526)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCATTATCCGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGGTAGGCTGGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTGCT


ACGCCTGTGCCGATTAAGGGTTTGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-186 (SEQ ID NO: 527)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGACTCACCTTTGGGAGGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATTCGGATGGTTGGGTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCGGAT


TCGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-187 (SEQ ID NO: 528)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAGTTATTCTA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTAATCGGGGTGGTACTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTGG


AGGAGGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-188 (SEQ ID NO: 529)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTTATAGGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGG


ATTTCGAGGGATGGTTATCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTATG


ACTGCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-189 (SEQ ID NO: 530)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGATGTATCCGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTGAGCCGGCTGGTGATCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAG


GAGCAGCCTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-19 (SEQ ID NO: 531)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCCCCTTTCCGCAGTATCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTACTTCTGATGGTCTTGATACATATTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAG


CCTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-190 (SEQ ID NO: 532)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTATGTATGATA


TGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTTGTCTGATGGTACGGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG


GCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-191 (SEQ ID NO: 533)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTTGTATCCGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATGCGGGGGGTCATGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATTGG


TGGGATTATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-192 (SEQ ID NO: 534)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATCCGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAATCGTTCGGGTATGCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGCAT


CAGGCGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-193 (SEQ ID NO: 535)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGGGTATGCTA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAATGCGAATGGTATTCGGACATACTACGCCGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGGG


GTTTGGAGGTGGGGGACTGGGCATAAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-194 (SEQ ID NO: 536)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATGATA


TGCGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGCAGAATGGTACTAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGG


ACTGGTAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-195 (SEQ ID NO: 537)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGACTTATGATA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGG


ATTAATTGGCAGGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGG


TTTGGTCATTATGTTGATGGTCTTGGGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-196 (SEQ ID NO: 538)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACTGATATGGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGG


ACTGCGTTTGACTACTGGGGTCCGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-197 (SEQ ID NO: 539)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAAGTATAAGA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTCCGAAGGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAGGCCG


ATGACTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-198 (SEQ ID NO: 540)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATAATA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTCGGCCGCGGGGTGGGAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGG


CGGGAGGGGTATACTGGTTCTAAGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-199 (SEQ ID NO: 541)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATGGTA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTTGGCCGAGGGGTCAGAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAAT


AGTCGGTATGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-2 (SEQ ID NO: 542)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTTCGGATGGTATTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAGTGGG


AGGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-20 (SEQ ID NO: 543)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGGTTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTAGTTCGGAGGGTCTTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGG


CGTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-200 (SEQ ID NO: 544)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTAATTATAGTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTCGTCCTAATGGTACTAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGTCG


TCTGCGCATCTTCAGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-201 (SEQ ID NO: 545)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATTCGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGGTCGTCATGGTGGGCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGGGG


AGTACTTATCCTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-202 (SEQ ID NO: 546)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTTCGCATTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGAGCCTTTTGGTGGTGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGTAT


CCTCAGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-203 (SEQ ID NO: 547)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATACTA


TGGGGTGGGTCCGTCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTCGGCCTGATGGTAAGATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGTTTAT


TCTTCGTGTGCGATGTGTACTCCGCTTTTGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-204 (SEQ ID NO: 548)


GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATTCGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAT


ATTGGGCCGAGGGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGGT


CGTGGTCAGCGTGATACTAGTCAGCCGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-205 (SEQ ID NO: 549)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTACTTCGGGTGGTCTTAGTACGTACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


AGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-206 (SEQ ID NO: 550)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGTGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTTCTTCTGATGGTCTGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


GTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-207 (SEQ ID NO: 551)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTGATAAGTATTTGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGT


ATTGAGCCTCTGGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCT


TCGGGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-208 (SEQ ID NO: 552)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTACTGAGTATGAGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATAATGTGGGTAGTAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG


AAGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-209 (SEQ ID NO: 553)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCG


ATTTCTAGGCAGGGTTTTGCTACATACTACGCAGACTCCGTGAAAGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCTG


GAGCGGGATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-21 (SEQ ID NO: 554)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATGAGA


TGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTT


ATTTCTGAGTGGGGTTATTCTACATACTACGCAGACTCCGCGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGTG


GGTGGGACTCAGTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-22 (SEQ ID NO: 555)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGAGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCTTCGGGTGGTTCTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


GTTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-23 (SEQ ID NO: 556)


GAGGTGCAGCTGTTGGAGTCCGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCTGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACGGGTGATGGTATTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGG


AGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-24 (SEQ ID NO: 557)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTAGTGAGGGTGGTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


AAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-24-1 (SEQ ID NO: 558)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCAGA


TGGCGTGGGTTCGCCAGGCTCCAGGGAAGGGACTAGAGTGGGTCTCAAGT


ATTACTAGTGAGGGTGGTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACAGTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


AAGAATTTCGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-25 (SEQ ID NO: 559)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACGTCGCAGGGTACTAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


CGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-26 (SEQ ID NO: 560)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAGTTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTACGTCGGATGGTGGTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


AAGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-27 (SEQ ID NO: 561)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT


TCTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-28 (SEQ ID NO: 562)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATGATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAGTGATAATGGTAATGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-29 (SEQ ID NO: 563)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG


CGGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-30 (SEQ ID NO: 564)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAGGTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTTCTGATGATGGTGATTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGGAT


AAGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-300 (SEQ ID NO: 565)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATGATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTGATACGACGGGTGGGCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


AAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-301 (SEQ ID NO: 566)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGAGTGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTCTTGATGAGGGTTCTGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-302 (SEQ ID NO: 567)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCG


ATTACTGATGATGGTGATGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTAAT


GCGGGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-303 (SEQ ID NO: 568)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATGATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTGTTAATGATGGTTCTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-304 (SEQ ID NO: 569)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATACGGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGCGGATGATGGTTCTAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


CAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-31 (SEQ ID NO: 570)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGGATGATGGTTCTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


CTTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-32 (SEQ ID NO: 571)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATCAGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTT


ATTGTGCCTGGGGGTGATTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTGG


CCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-4 (SEQ ID NO: 572)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACGAGTGATGGTACTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAAT


CCGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-40 (SEQ ID NO: 573)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCGTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAG


ATTGGGAGGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCGT


CGGTATGCTATTTTTACTTTTGATCGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-400 (SEQ ID NO: 574)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCCGA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCTACTAATGGTGTGAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACG


GATATTATTTCGTCTTCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-401 (SEQ ID NO: 575)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTAATTATGATA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTT


GTGTGGTCGGCTGATATTGATTTTGATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-402 (SEQ ID NO: 576)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGTGGTATGATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAT


ATTGCGAGTTGGGGTGGTAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGACG


GTGAAGGATGGGGGGTATCTGATGGATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-403 (SEQ ID NO: 577)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGCTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTGGGCGGGATGGTGCGGTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGAAG


GCGGCGAAGGAGCGGGGTTCTTGGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-404 (SEQ ID NO: 578)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGCTTATCAGA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACT


ATTAGTCCTAATGGTCTTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTG


AGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-407 (SEQ ID NO: 579)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTCGCCTCGTGGTGTTGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAAT


TGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-408 (SEQ ID NO: 580)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTACGTATATGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAATACGAATGGTCGTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT


AGTAATATGTCGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-409 (SEQ ID NO: 581)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATTCGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAATGCGTCGGGTACTCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGGT


AATAGGTCTGAGGTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-41 (SEQ ID NO: 582)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTGAGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGCGAATGATGGTTCGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


CGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-410 (SEQ ID NO: 583)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATTATTTGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTAATCAGGATGGTACTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGTTCT


CCGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-411 (SEQ ID NO: 584)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGCGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAGTCGGGATGGTCATGTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCT


TCTAAGGGGGGGACGTTTGCTAGTTCTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-412 (SEQ ID NO: 585)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTGTTCCGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCG


ATTACGGATGATGGTCTTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCAT


ATTTATGGGGATTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-413 (SEQ ID NO: 586)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATAGGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTAGTAGTGATGGTGATACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACATTGG


TTGGGTACTACGTTGTCTTTGAGGGATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-414 (SEQ ID NO: 587)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTATCGTTATACGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAG


ATTTCGCCTAGGGGTAATATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGGT


GTGGCGGGGGCGGAGTCGCCTGAGTATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-415 (SEQ ID NO: 588)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGTTTGGTGCAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTGGGTTATTATA


TGAGTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGGGCCGATTGGTGGTGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCAG


AATATTTATGGTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-416 (SEQ ID NO: 589)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTAGTCGTGATGGTGGGCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTAT


CCTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-417 (SEQ ID NO: 590)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGCAGTATAGTA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACT


ATTTCGCCTCTGGGTTCTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATGAGT


AAGTTGTTGCTGTCGAGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-418 (SEQ ID NO: 591)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTCGCCTCGTGGTGTTGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAAT


TGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-419 (SEQ ID NO: 592)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTCATGGTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACGCCTACTGGTAATACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGCT


CATGATGAGGGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-42 (SEQ ID NO: 593)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCCGTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGTTGGTGATGGTCTGGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT


CGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-420 (SEQ ID NO: 594)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAGTACGCCTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTAGGGATACGGGTCTGGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGTGTTTCG


TTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-421 (SEQ ID NO: 595)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATCTGGGGGATA


TGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTAGTGGGACGGGTCATACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTATG


AATGATCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-422 (SEQ ID NO: 596)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATGAGGATA


TGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGG


ATTAATTCGCTGGGTACTCATACATACTACGCAGACTCCGTGAAGGGCCG


ATTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCGTTT


ATGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-423 (SEQ ID NO: 597)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAATTATCAGA


TGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGATGCGACTGGTCGGGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGATCTACT


AGGTCATTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-424 (SEQ ID NO: 598)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGAATGCGGATA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT


TTGACTTCGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-425 (SEQ ID NO: 599)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGTCGGGTCTTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCT


CAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-426 (SEQ ID NO: 600)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATGAGGGTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTAATCAGCAGGGTTCGGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGATT


GGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-427 (SEQ ID NO: 601)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATCAGCCGA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGGGGCGCGTGGTGGGCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTT


GATATTATTGCTTGGGATCCTTTTAGTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-428 (SEQ ID NO: 602)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATCAGTATCCTA


TGATGTGGGTTCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTCCTTCTGGTTTTTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAT


CCTTTTATTACTACGTTTGACTACTGGGGTCAGGGAACCCTGGTGACCGT


CTCGAGC


 


BMS2h-429 (SEQ ID NO: 603)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGAT


TATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-43 (SEQ ID NO: 604)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGGTAGTGATGGTGGGCCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACCTGAT


AGGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-430 (SEQ ID NO: 605)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGCGGAGCAGA


TGACTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGCATGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGG


ACTTTGGTTGATTGGCCTACGAGTGAGTCGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-44 (SEQ ID NO: 606)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGTCTTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGAGCCTACTGGTATTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCAT


TTTACTGAGCTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-449 (SEQ ID NO: 607)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGGGAGCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACGCTGCCTGGTCCGTATACATTCTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAAT


GGGACGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-45 (SEQ ID NO: 608)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGCGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAG


ATTGGGGCGCAGGGTCTTCATACATACTACGCAGGCTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGACG


ACGATGGATTATGAGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-450 (SEQ ID NO: 609)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGGTTGATA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGCT


ATTGGTAATAATGGTCTTAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCT


CTGTCGTATAGGCCTCCTGTTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-451 (SEQ ID NO: 610)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGATACTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACGCTTAAGGGTCCGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGG


GATGGGTTGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-452 (SEQ ID NO: 611)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTCTCCGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGGTCGGGATGGTAGTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTTCG


CCTTATCGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-453 (SEQ ID NO: 612)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATTCGA


TGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTGTGAGTCATGGTGGTACTACATACTACGCAGACTCCGTGAAGGGCCG


ATTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAAG


GGTTATAATGCGCAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-454 (SEQ ID NO: 613)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGAT


TATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-455 (SEQ ID NO: 614)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATGATA


TGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAGTTCGCATGGTGATAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGAT


GTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-456 (SEQ ID NO: 615)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCG


GATTCTTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-457 (SEQ ID NO: 616)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTCAGTCTAATGGTAATATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTAAT


TCTCAGGTTGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-458 (SEQ ID NO: 617)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGTGGAGCCTA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAT


ATTGGTCGTGATGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGG


AAGCATGGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-459 (SEQ ID NO: 618)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGGAGTATCGGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGG


ATTGATGAGCGGGGTTCGCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGGCGG


AAGGGTACTAAGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-46 (SEQ ID NO: 619)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATGCTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGGTGCTGTGGGTGAGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCT


AATAATCTTTCTGATAATCTTGTGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-460 (SEQ ID NO: 620)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTCG


GTTGAGTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-461 (SEQ ID NO: 621)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAGTTATACGA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTAATCCTTGGGGTAGTCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTG


GTGCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-462 0 (SEQ ID NO: 622)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTGATATGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACTCAGCTTGGTAGTAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGAAT


TGGCGGACTCTTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-463 (SEQ ID NO: 623)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTAATGCTTATGGGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTCTTTCTGATGGTGTTATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGCT


CGGGGTGCGAATTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-464 (SEQ ID NO: 624)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATATGA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTACGCCTCATGGTACGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTAAT


GCTATTTTTAGTGAGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-465 (SEQ ID NO: 625)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGTCGGGTCTTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCT


CAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-466 (SEQ ID NO: 626)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTTTATGCGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTGGGAGGGATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACGGCGGTATATTACTGTGCGAAATTGGCT


GGTTCGCTGAGGGGTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-467 (SEQ ID NO: 627)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGGCTAGTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACGCCTCATGGTTCGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGCGG


TGGGGTGTTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-468 (SEQ ID NO: 628)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGGGTATAGTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGCTGGGCGTGGTGGTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTG


TATATTTATCATAGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-469 (SEQ ID NO: 629)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGCTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGGTATGGAGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTACTGGGACTGGTAGTACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT


CATCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-470 (SEQ ID NO: 630)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGATGGTGGCTA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGCTCGGGATGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGAAAGTTTCG


CCGACTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-471 (SEQ ID NO: 631)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGGATA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTACGGATGATGGTGAGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGAT


TATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-472 (SEQ ID NO: 632)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATAATA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAG


ATTACGAGGGATGGTTCTAGGACATACTACGCAGACTCCGTGAGGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACTGTCG


AATATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-473 (SEQ ID NO: 633)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATTCTA


TGATTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACGCCGTATGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACTGAT


TATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-474 (SEQ ID NO: 634)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATAGTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACT


ATTACTCCTTATGGTAGTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGGT


CTGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-475 (SEQ ID NO: 635)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGACTCTCCTGTGCAGCCTCCGGATTCACCTTTACTACGGGTCCTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCG


ATTGGTATTGGGGGTGATACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGAAATTGACT


CCGTCTAATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-476 (SEQ ID NO: 636)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCAGA


TGATGTGGGTTCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTCCTTCTGGTTTTTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAT


CCTTTTATTAGTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-477 (SEQ ID NO: 637)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGATA


TGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTTCTGCTTTGGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAACGA


ACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATGGCGT


AGTGCTATTACTGGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-478 (SEQ ID NO: 638)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATCAGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCGCCGTCGGGTATGAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGCGG


TCGGTTGTTCGTCCTTGGCCGGGTGTGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-479 (SEQ ID NO: 639)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGAGAGTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACTCCTCATGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTCAT


CTTAAGTTGTATGAGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-480 (SEQ ID NO: 640)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTCCGATGGATGGTAGTGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGG


AGTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-481 (SEQ ID NO: 641)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATTTTATGCCGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGAGGGATGGTGCTTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGCT


TCGCCGGCGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-482 (SEQ ID NO: 642)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGAGCCTA


TGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGGGTACGGGTACGACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAAT


CAGGGTGATTTTATTAATCGGTTTCACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-483 (SEQ ID NO: 643)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATGCGTATAATA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCTCCGCGGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCCG


CCGCCTTCGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-5 (SEQ ID NO: 644)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACGAGTGATGGTACGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


CTGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-505 (SEQ ID NO: 645)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATATGA


TGTATTGGGTCCACCAGGCTCCGGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTCCTCAGGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTCGT


GAGCTTCCTCGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-506 (SEQ ID NO: 646)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGCTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGATGCGAGTGGTGGTCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGAAT


GGGAAGAAGTTTCCTTTTACTAAGTATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-507 (SEQ ID NO: 647)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAGTGTGCATA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTAATCTGACGGGTGTTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGCT


ACTACTAGGCAGGCGCATCCGTTGTATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-515 (SEQ ID NO: 648)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGGGTGAGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGACTAATGGTCTTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTACT


CGTGATCTGGGTTTTGCCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-516 (SEQ ID NO: 649)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGAGA


TGGCTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTT


ATTTCTCCTCGTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGCT


AAGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-517 (SEQ ID NO: 650)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATGAGA


TGCTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGT


ATTTCTGTTGATGGTAGTATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACGCGG


ATGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-518 (SEQ ID NO: 651)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGCTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAT


ATTTCTCGTGATGGTTCGAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGCAG


TCTGGGGGGCTTCGGTCGGGTTTGACTACGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-519 (SEQ ID NO: 652)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGACTCCGGATTCACCTTTAGCAGCTATGCCA


TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGAGGGATGGTGCTTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGG


CCGAAGGGTATTGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-520 (SEQ ID NO: 653)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCCGCATGCTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGT


ATTGATGGGGGGGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGAT


CCTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-521 (SEQ ID NO: 654)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTCATGCGGGGGAGA


TGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACGCTGCCTGGTGATATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGAAT


ACTGGGTATACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-522 (SEQ ID NO: 655)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAATTATGGTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCGTGGGATGGTTCTCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAAATACG


CGGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-523 (SEQ ID NO: 656)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATGATGCGGATA


TGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTTGTCTCCGGGTGAGGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGGT


CTGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-524 (SEQ ID NO: 657)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTACTGATCAGA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCTCCTAGTGGTGCGTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTT


GGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-525 (SEQ ID NO: 658)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCATCTTTGAGCAGTATCAGA


TGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTTCGCCTGATGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAGT


TTGCGTAAGATGGAGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-526 (SEQ ID NO: 659)


GAGGTGCAGCTGTTGGAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGAGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGCGTCTGATGGTATGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCTGGG


AAGAATTTTGACCACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-527 (SEQ ID NO: 660)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGCGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACTACTGGGGGTGAGCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTTGG


AATCTGTATACGGAGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-528 (SEQ ID NO: 661)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGGTCAGCCGA


TGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGCTCCTGATGGTATTCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAATTTG


GGTCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-529 (SEQ ID NO: 662)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATCAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCTCCTAGTGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAG


GCGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-530 (SEQ ID NO: 663)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTCATTCGACTA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTT


ATTTTGCCGTCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTCT


GATGAGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-531 (SEQ ID NO: 664)


GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGGGAATA


TGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTCTAGTGATGGTGTGACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGG


GGTCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-532 (SEQ ID NO: 665)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTGATGATTATATGA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTAGTCCGCATGGTGTTTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGTTG


CATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-533 (SEQ ID NO: 666)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATACGA


TGGCGTGGGGCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTT


ATTGCTGGTCCGGGTAATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


AGTACTGCGACGTATAATAATGGTCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-534 (SEQ ID NO: 667)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGAGTATAGTA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTAGTGGGAGTGGTCGTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCTT


AAGCTGGTTAGGGCTCCTAATCCGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-535 (SEQ ID NO: 668)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTCTAAGACTGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCG


CATTCGTTGGGGCCTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-54 (SEQ ID NO: 669)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGCGTATAGGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTTCGCCTTCTGGTTCGGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTTTG


ACGGATTCGCCGTCGGGGCATTATGAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-55 (SEQ ID NO: 670)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGG


ATTACTGCTCAGGGTCTTGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAACTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATCTT


ACTGATTTTAGTAGTGGGCATCAGGAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-553 (SEQ ID NO: 671)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATTATGGTA


TGTCGTGGGTCCGCCAGGTTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGT


ATTAGTCATAATGGTATGTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATTGG


CCGTCTACTAGTTGGGAGACTGATTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-554 (SEQ ID NO: 672)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAATGAGCCTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGAGATGCAGGGTAAGAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGG


GGTCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-555 1 (SEQ ID NO: 673)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGT


ATTGATAATCTGGGTAGTCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGAAAACGATT


TCTCATCAGTATGATAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-556 (SEQ ID NO: 674)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGATGAGGGGGGTCGGTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGACG


CCGCATAAGCAGTTGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-557 (SEQ ID NO: 675)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAGCTTTGCTGATGAGTATA


TGGTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTGATCCGTTGGGTACTGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG


ACGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-558 (SEQ ID NO: 676)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTACGCATGATA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTTCTGATGATGGTATTAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAT


ATGTCTCTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-559 (SEQ ID NO: 677)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTACTCCGA


TGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTAGTGGTGATGGTAGGAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTTAT


GCGCTTACTTCGTCTAAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-56 (SEQ ID NO: 678)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTCATGGGACTGGTGGTCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTTG


GCTGATAGGAGTGGGGGGGTTGTTGAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-560 (SEQ ID NO: 679)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGGAGACGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGT


ATTAGTAATGATGGTAATACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGTCT


CTGATTAGTCCTGGTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-561 (SEQ ID NO: 680)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGAGTATA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAATGAGACTGGTTATATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCT


ACGAGGGGGGTGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-562 (SEQ ID NO: 681)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTCGTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGCCTATGGGTGTTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTAAT


CAGCATGCTCATGATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-563 (SEQ ID NO: 682)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTTCGCCTATGGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGCT


TTGACTGAGCCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-564 (SEQ ID NO: 683)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCTCTTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTCCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGCTGAG


GAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-565 (SEQ ID NO: 684)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCGCCTTTCCTAGGTATGGTA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAT


ATTGATCAGTTTGGTATGAAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTAT


GCTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-566 (SEQ ID NO: 685)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAAGTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGCCTATGGGTGTTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCGG


GGTAATACTTCGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-567 (SEQ ID NO: 686)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATGATA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTGGGGCGGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTTT


CCGCGTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-568 (SEQ ID NO: 687)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGAAGTATGAGA


TGAGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTGGTCTGGATGGTTCGCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGG


GATCCGAATGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-569 (SEQ ID NO: 688)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGACTAGTGAGA


TGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGT


ATTGGGCCTGATGGTTTGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCG


GATTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-57 (SEQ ID NO: 689)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGAGTATGATA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTGATACTGATGGTGGGGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


CTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-570 (SEQ ID NO: 690)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTGAGAATGCTTCTA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGAGGGGCAGGGTAATGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTCG


TCTTGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-571 (SEQ ID NO: 691)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTAATGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACGCCGACTGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGGAT


CCTGGTAATAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-572 (SEQ ID NO: 692)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-1 (SEQ ID NO: 693)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGTTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGGACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-10 (SEQ ID NO: 694)


GAGGTGCAGCTGTTGGAGTCTGGTGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-11 (SEQ ID NO: 695)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCAGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGATTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCAGGTCACCGTCTC


GAGC


 


BMS2h-572-12 (SEQ ID NO: 696)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-13 (SEQ ID NO: 697)


GAGGTGCAGTTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGACCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCTAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTAGGG


AAGGAGAGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-14 (SEQ ID NO: 698)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGC


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCAGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-15 (SEQ ID NO: 699)


GAGGTGCGGCTATTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAACTTTAATTGGCAGCTGA


TGGGTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCAGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-16 (SEQ ID NO: 700)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACGGCCTGGGGGGTC


ACTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-17 (SEQ ID NO: 701)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGACTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTATAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGATGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCACGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-18 (SEQ ID NO: 702)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCAAGGCTCCTGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-19 (SEQ ID NO: 703)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCCCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-2 (SEQ ID NO: 704)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAAGTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-21 (SEQ ID NO: 705)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGAATCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-22 (SEQ ID NO: 706)


GAGGTGCAGCTGTTTGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGGACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-23 (SEQ ID NO: 707)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCACCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCGGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCATCATCTCCCGCGACAATTCCAAGAACACGCTATATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-24 (SEQ ID NO: 708)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCGGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCACGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTGAATTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-3 (SEQ ID NO: 709)


GAGGTGCGGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCACCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-4 (SEQ ID NO: 710)


GAGGTGCAGCTGTTGGTGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-5 (SEQ ID NO: 711)


GAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGA


ACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-6 (SEQ ID NO: 712)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-601 (SEQ ID NO: 713)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCA


TGGGGTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACCCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-602 (SEQ ID NO: 714)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCACCTGA


TGGGGTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAGTTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-603 (SEQ ID NO: 715)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACCTGA


TGGCCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-604 (SEQ ID NO: 716)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGA


TGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTCGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-605 (SEQ ID NO: 717)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGA


TGGCCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-606 (SEQ ID NO: 718)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACTTGA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-607 (SEQ ID NO: 719)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCA


TGGGGTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-608 (SEQ ID NO: 720)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-609 (SEQ ID NO: 721)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCAGCTCA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-610 (SEQ ID NO: 722)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-611 (SEQ ID NO: 723)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCGGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGG


AAGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-612 (SEQ ID NO: 724)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGG


AAGGACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-613 (SEQ ID NO: 725)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGCACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-614 (SEQ ID NO: 726)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-615 (SEQ ID NO: 727)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGCCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACAAGAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-616 (SEQ ID NO: 728)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGAGAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-617 (SEQ ID NO: 729)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AGGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-618 (SEQ ID NO: 730)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCGGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGG


AAGTACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-619 (SEQ ID NO: 731)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-620 (SEQ ID NO: 732)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACGACAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-621 (SEQ ID NO: 733)


GAGGTGCAGCTGTTGGAGTTTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CTTGCGTTTTTCCTGTGCAGCTTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGTTCCGGCAGGCTCCAGGGAAGGGTTTAGAGTGGGTTTCAGGT


ATTGAGGGTCCAGGTGATGTTACATATTACGCAGATTCCGTGAAGGGCCG


GTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCTTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AGGGACAGCAATTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-622 (SEQ ID NO: 734)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACAGCACCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-623 (SEQ ID NO: 735)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGAGAGCAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-624 (SEQ ID NO: 736)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCGCGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-625 (SEQ ID NO: 737)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGC


AACGACAGCTACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-626 (SEQ ID NO: 738)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACAGCAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-627 (SEQ ID NO: 739)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGATATATTACTGTGTGAAAGTGGGC


AAGGACAGCGCGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-630 (SEQ ID NO: 740)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGA


TGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-631 (SEQ ID NO: 741)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGA


TGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-632 (SEQ ID NO: 742)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGA


TGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-633 (SEQ ID NO: 743)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG


AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-634 (SEQ ID NO: 744)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-635 (SEQ ID NO: 745)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGA


TGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC


AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATC


GAGC


 


BMS2h-572-7 (SEQ ID NO: 746)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGATGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGTCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTACAAATGA


ACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-572-8 (SEQ ID NO: 747)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCGCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTCGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTTTC


GAGC


 


BMS2h-572-9 (SEQ ID NO: 748)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG


AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-573 (SEQ ID NO: 749)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTGGGAGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATGAGTCTGGTCTTAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTGCG


CCGCAGTATCAGATTACATTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-574 (SEQ ID NO: 750)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGGGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATAT


ATTTCGCGGAGGGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGTCG


CATTATATGAATAATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-575 (SEQ ID NO: 751)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGGATTATACGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTAGTCCGATTGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCT


TATGGGATGGAGGATGGTCTGACGTGGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-576 (SEQ ID NO: 752)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGATA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACG


ATTACGTCGGAGGGTCTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAGT


GATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-577 (SEQ ID NO: 753)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCGTGGGGGTTGGTTCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACG


AGTCAGTCGTCTACGGGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-578 (SEQ ID NO: 754)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTCGGTATGATA


TGCTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTTCGCCTACGGGTGCTCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTGGT


TCGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-579 (SEQ ID NO: 755)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTCCGTATTATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCGGGTACGGGTGGGCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGACG


CAGAATGCGACGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-58 (SEQ ID NO: 756)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTTTATACTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACG


ATTGATGAGTCTGGTCGTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


GTTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-580 (SEQ ID NO: 757)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTTTTATAAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACTCCTAAGGGTCATCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTT


AAGGGTAAGGGTTGGACTCGTCCGAGTGGGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-581 (SEQ ID NO: 758)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATAGTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGAGGCGTGGTTGGCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGTG


CTGCTGGATTCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-582 (SEQ ID NO: 759)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTGCGCGTGGTCCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAGG


CATTGGCTTCGTAATGGTCGTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-583 (SEQ ID NO: 760)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTATGCAGTCGA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTACTGATGATGGTACTAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT


CGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-584 (SEQ ID NO: 761)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGCGGCTGATA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTG


ATTACTAATGATGGTATTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT


GATCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-586 (SEQ ID NO: 762)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATAGGA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATAGTTCTGGTGAGCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGGTT


CCGATGGGGAATCAGACTTTTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-587 (SEQ ID NO: 763)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATACTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACGTCTCAGGGTGCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTACG


GGTACGGATTCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-588 (SEQ ID NO: 764)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGAGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGT


ATTGGGCCGGGGGGTAAGCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGAT


GGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-589 (SEQ ID NO: 765)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATGATA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCTTCGAGGGGTTGGCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCG


GGGGGTCGTCGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-59 (SEQ ID NO: 766)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCTGGATTATGCGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTTCTCCGATGGGTATGGGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGT


GCTATTTCGTTTACTTCTGATATTTCTAATTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-590 (SEQ ID NO: 767)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCCGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCTTGGTCTGGTTTTCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGT


GTTGCGAGGATGCCTACTGGGATTGCTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-591 (SEQ ID NO: 768)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGAGA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATAGTGCTGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGGAACCTTTT


GGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-592 (SEQ ID NO: 769)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGAGTATCCGA


TGAAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGATCGGCAGGGTGATCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGGTG


CGGAGGGGTCTTCCTCGTCCGAGTCGTTATTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-593 (SEQ ID NO: 770)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTTCGCCTATGGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCTG


AGTGTGTATTCGGGTCTTGATTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-594 (SEQ ID NO: 771)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTTCTCATTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGAT


ATTGATTATATTGGTAAGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCTCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCG


GATGAGGTGGGTGTTAATACTTCCAAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-595 (SEQ ID NO: 772)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGATA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCTACTGGTGTGTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTT


GAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-596 (SEQ ID NO: 773)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCTTATCCGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTG


ATTTCTCATACGGGTCATGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCAT


TGGCCTTTTGACTACCGGGGTCAGGGAACCCTGATCACCGTCTCGAGC


 


BMS2h-597 0 (SEQ ID NO: 774)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCAGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATGAGTGGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAT


ATTAGCCCGGGTGGTTGGACTACATACTACGCCGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT


CGTCCGTTTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-598 (SEQ ID NO: 775)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGAGTCACCTTTGATGCTATTGAGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCG


ATTTCGCGTCATGGTGAGTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATGCT


TGGTCTCGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-599 (SEQ ID NO: 776)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAGTACGGATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTTGGATAATGGTAGTAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGA


ATAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGGCG


AGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-600 (SEQ ID NO: 777)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTGGTAGGCAGAGTA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATGATGATGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT


CCGTGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-601 (SEQ ID NO: 778)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTAGTGATACGCAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGATGATGGGGGTGTGAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT


CGTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-602 (SEQ ID NO: 779)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTACGACGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGTG


ATTTCGGATGATGGTGGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGAT


GGTTATGGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-603 (SEQ ID NO: 780)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGGAGTGGGGATA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACGAATGATGGTACGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTGAT


TCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-61 (SEQ ID NO: 781)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGCTTATGCTA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATAT


ATTAGTCCGAATGGTACGGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATATGTG


GGGATGCGTTGGAATTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-62 (SEQ ID NO: 782)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAGTTATGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACGAGTCTTGGTACTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


AGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-65 (SEQ ID NO: 783)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACTAGTGAGGGTAGTGGGACATACTACGCAGACTCCGTAAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTAAT


GGTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-66 (SEQ ID NO: 784)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGA


TGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTACTAGTGAGGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGG


ACTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-67 (SEQ ID NO: 785)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGAGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGATTCTGATGGTAGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


GTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-68 (SEQ ID NO: 786)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTTCTACTGGTCAGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT


AATAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-69 (SEQ ID NO: 787)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCTTGATTATGGTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTTCGCCTCTTGGTCTTAGTACATACTACGCAGACTCCGTGAAGAGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGAGGTG


AGGGTGGGTAGGGGTGTTCATCCTCCGAAGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-7 (SEQ ID NO: 788)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGG


GTGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-70 (SEQ ID NO: 789)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAATTATGCTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGCTCCGCTGGGTGTTCCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAAGAAG


GTTGGGGCGTGGCTGCAGTCGCGGAGTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-701 (SEQ ID NO: 790)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATTATGAGA


TGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGGTGCTTCTGGTCATTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCTT


GATATGCTGCTGTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-702 (SEQ ID NO: 791)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGAGA


TGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGT


ATTGCTGGTAATGGTTCTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAATGCTT


TCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-703 (SEQ ID NO: 792)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTATAATTATGATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGATTCGATGGGTCTTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGTCT


AATGCGAGTGATTGGGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-704 (SEQ ID NO: 793)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTCGTATCATA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGCGGATACGGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATTGCGT


GGGATGGCTCGGGTTTGGGGGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-705 (SEQ ID NO: 794)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTATTATGATA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGATCTCATCT


ATTTCGGATCGTGGTCTTCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTACG


GAGATTCCGTTGGATTGGTTGGAGGTGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-706 (SEQ ID NO: 795)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTTATAAGA


TGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTACTAATTCTGGTACTGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGATG


TATCCGGATTTGGAGATTGTGCATTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-707 (SEQ ID NO: 796)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGACTTATCGTA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTGATCAGGAGGGTTCTGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAATAGT


GGGACGAGGCCGGGGCTTCGGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-708 (SEQ ID NO: 797)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGATA


TGCTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGG


ATTGATGCGAGTGGTTATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGTTG


AAGCTGTCGTTGAATCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-709 1 (SEQ ID NO: 798)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGCAGCTATGCCA


TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTCATAATACTGGTTTGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACT


CAGCATCGTTTTGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-71 (SEQ ID NO: 799)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATCCTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAGTCCTTTGGGTCCTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTGTTG


ATGGGGGAGTATTTGAATTCTAGGACGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-710 (SEQ ID NO: 800)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATACGTATAGTA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGG


ATTGATGCTGATGGTTGGGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACTGGG


CATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-711 (SEQ ID NO: 801)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGA


TGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGG


ATTGTGGATCCTGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT


GATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-712 (SEQ ID NO: 802)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGAGA


TGAAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGTCGGGTGGTCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGATACCTCTT


TCTAGTTTTGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-713 (SEQ ID NO: 803)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAATTATGTGA


TGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTT


ATTAATGGTGCTGGTGATATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGGGT


GCGCGTTCGTTTGGGGTTCCGCCTAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-714 (SEQ ID NO: 804)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGA


TGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGG


ATTGTGGATCCTGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT


GATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-715 (SEQ ID NO: 805)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTACGCTGTATAATA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGTT


ATTTCTAGTAAGGGTGATAGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACGAGT


AGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-716 (SEQ ID NO: 806)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATTATA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGTTAATAATGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCT


GTTCATCCTTCGTATAGGGCGGAGTTGTTCGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-717 (SEQ ID NO: 807)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGAGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGT


ATTGAGCCTGATGGTAGTAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCG


GATAATTTTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-718 (SEQ ID NO: 808)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATATGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATAGTCTTGGTCATTATACATACTACGCAGACTCTGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGGAG


TTTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719 (SEQ ID NO: 809)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-1 (SEQ ID NO: 810)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC


 


BMS2h-719-10 (SEQ ID NO: 811)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTGCAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-11 (SEQ ID NO: 812)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCAAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCGAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT


ACTGAGTTTGACTATTGGGGTCAGGGTACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-12 (SEQ ID NO: 813)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-13 (SEQ ID NO: 814)


GAGGTGCAGCTGTTGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCGTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTACAGATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTT


ACTGAGCTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-14 (SEQ ID NO: 815)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACGGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTTCTGTGCAGATCCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-15 (SEQ ID NO: 816)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCGCCTTTAAGAGGTATGAGA


TGACATGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCATATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT


ACTGAGATTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-16 (SEQ ID NO: 817)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCCCCTTTAAGAGGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACCGGGCTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-17 (SEQ ID NO: 818)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCTTCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT


ACTGAGATTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC


 


BMS2h-719-18 (SEQ ID NO: 819)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACATCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGACGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACGGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-19 (SEQ ID NO: 820)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTGGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCAGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-2 (SEQ ID NO: 821)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-20 (SEQ ID NO: 822)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACTCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGATTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-202 (SEQ ID NO: 823)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAAGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-203 (SEQ ID NO: 824)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACAGCTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-21 (SEQ ID NO: 825)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCATTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-213 (SEQ ID NO: 826)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTC


ACGGAGATGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-214 (SEQ ID NO: 827)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTC


ACGGAGTTCGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-215 (SEQ ID NO: 828)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTATCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAGCCGTTC


ACGGAGTTGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-218 (SEQ ID NO: 829)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCCCCAGGGAAGGGTCTGGAGTGGGTCTCATCG


ATTTCGTCCGACGGTTCCTTCACGTACTACGCCGAGTCGGTCAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-225 (SEQ ID NO: 830)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACACGTATGAGA


TGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-226 (SEQ ID NO: 831)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACAAGTATGAGA


TGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-3 (SEQ ID NO: 832)


GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-4 (SEQ ID NO: 833)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGACTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGGCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCAGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCAAGC


 


BMS2h-719-5 (SEQ ID NO: 834)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGGAAATGA


ACAGCATGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACAACTGGGGTCAGGGAACCCTCGTCACCGTCTCGAGC


 


BMS2h-719-6 (SEQ ID NO: 835)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCAGAACCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC


 


BMS2h-719-7 (SEQ ID NO: 836)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAACTTTAAGAGGTATGAGA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCAGACCCGTTT


ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-8 (SEQ ID NO: 837)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-719-9 (SEQ ID NO: 838)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCT


ATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT


ACTGAGTTTGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-72 (SEQ ID NO: 839)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATCCTA


TGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTCCCCTCTTGGTTTGTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTAGT


GCTGGGGCGGAGACTCATGTTTATCGGCTTTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-720 (SEQ ID NO: 840)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGGGTGTTGGGTCATACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTATG


TCGTTGAGGACGTTTGAGAATCTTTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-722 (SEQ ID NO: 841)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGAAGTATCCTA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTGATGCTAATGGTAATAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGACT


TGGCGTAGGCATTTTGCGATTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-723 (SEQ ID NO: 842)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTGTATGATA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTGATCTGGGTACGCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAATGGT


TTTAGGGTTACGAGTAATGATCGTAGGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-724 (SEQ ID NO: 843)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGGGGATA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTGAGGGTGGTGGTGTGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTGAT


CTTCGGACGGGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-725 (SEQ ID NO: 844)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-1 (SEQ ID NO: 845)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCATCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTTCTGTGCGGATCCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-10 (SEQ ID NO: 846)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-11 (SEQ ID NO: 847)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


GCAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-12 (SEQ ID NO: 848)


GAGGTGCAGCTGTTGGAGTCTGGGGGTGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTCCCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACGATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTTGTCACCGTCTC


GAGC


 


BMS2h-725-13 (SEQ ID NO: 849)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCTCTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-14 (SEQ ID NO: 850)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCATCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCA


GATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-15 (SEQ ID NO: 851)


GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCATGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCATGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-16 (SEQ ID NO: 852)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCACACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-17 (SEQ ID NO: 853)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCG


GATCCTACTAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-18 (SEQ ID NO: 854)


GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCACCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG


GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-19 (SEQ ID NO: 855)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCAGATCCGTCG


GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-2 (SEQ ID NO: 856)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCG


GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCCGGTCACCGTCTC


GAGC


 


BMS2h-725-3 (SEQ ID NO: 857)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCGCTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACATGCTGTATCTGCAAATGA


AAAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGATCCGTCG


GATCCTACTAAGTTTGTCTACTGGGGTCAAGGAACCCAGGTCACCGTCTC


GAGC


 


BMS2h-725-4 (SEQ ID NO: 858)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG


GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-5 (SEQ ID NO: 859)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGTTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTAAGTTCGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-6 (SEQ ID NO: 860)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCC


GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-7 (SEQ ID NO: 861)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTACTTGGACATATTACGCAGACCCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACTGCGGTATATTATTGTGCGGATCCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-8 (SEQ ID NO: 862)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-725-9 (SEQ ID NO: 863)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTA


TGGGTTGGGTCCGCCAGGCTCCAGGGATGGGTCTGGAGTGGGTCTCACTT


ATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG


GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTC


GAGC


 


BMS2h-726 (SEQ ID NO: 864)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCCGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATAAGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTTCGGAGATAGGTAATCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAGCTCTG


ACGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-727 (SEQ ID NO: 865)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAGTTATCGTA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATAT


ATTGATCCGCCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTTG


AATTTGTCGTTTCCTTATATTAATTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-728 (SEQ ID NO: 866)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATGAGA


TGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGT


ATTTCTCATTCGGGTCGGACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGGAT


GGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-729 (SEQ ID NO: 867)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATTATA


TGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGG


ATTAATCATAATGGTTCTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATGCCG


CAGGGTACTTCTGATTGGTATTATTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-73 (SEQ ID NO: 868)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAAGTATGATA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTCTGGAGGATGGTCTGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG


CGTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-74 (SEQ ID NO: 869)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATCCTA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTCTGTCTCCGGGTACGGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGAG


AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-741 (SEQ ID NO: 870)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATG


ATTCCGATGGATGGTAGTGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT


GAGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-742 (SEQ ID NO: 871)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATCATA


TGAAGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTAGTAGGGATGGTATGAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACAGCTT


GCTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-743 (SEQ ID NO: 872)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGAGA


TGCTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTCTTCCGTCGGGTGGGGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGT


TCGGGGAATGGGCCTATTCTTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-744 (SEQ ID NO: 873)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGCATGATA


TGTTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTGGGGCTGAGGGTGTTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGACG


ATGTCTAATGGTTCTCAGTCGCGTTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-745 (SEQ ID NO: 874)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-1 (SEQ ID NO: 875)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-10 (SEQ ID NO: 876)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTTCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAACCTGCGTGCCGAAGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-11 (SEQ ID NO: 877)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTTCAAGAACACGCTGTATCTGCAGATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-12 (SEQ ID NO: 878)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGATTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCATGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-13 (SEQ ID NO: 879)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CTTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAACACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-14 (SEQ ID NO: 880)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-15 (SEQ ID NO: 881)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCAGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACGCGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCTGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-16 (SEQ ID NO: 882)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-17 (SEQ ID NO: 883)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCCTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACAGGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGCAC


CCTGGTCACCGTTTCGAGC


 


BMS2h-745-18 (SEQ ID NO: 884)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTCGTCACCGTCTCGAGC


 


BMS2h-745-19 (SEQ ID NO: 885)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGAGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-2 (SEQ ID NO: 886)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTAGTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCAGAGGACTCCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-3 (SEQ ID NO: 887)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCTGGGAAGGGTCTCGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


GCAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-4 (SEQ ID NO: 888)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTAGTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-5 (SEQ ID NO: 889)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCTGACTCCGTGAAGGGCCG


GTTCATCATCTCCCGCGACAATTCCAAGAACACGCTGAATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-6 (SEQ ID NO: 890)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAGGGGTCTAGAGTGGGTCTCAGGT


GTTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAATTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-745-7 (SEQ ID NO: 891)


GAGGTGCAGCTGTTGGAGTCAGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGAAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGT


 


BMS2h-745-8 (SEQ ID NO: 892)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAGCTCGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCCAGC


 


BMS2h-745-9 (SEQ ID NO: 893)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACTCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-746 (SEQ ID NO: 894)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGTCGGCTGAGA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGT


ATTTCGAGGCCTGGTCAGGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-747 (SEQ ID NO: 895)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGGTACTA


TGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTT


ATTTTGCCGTCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTCG


CTGACTAATCGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-748 (SEQ ID NO: 896)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGATA


TGCGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAT


ATTGATGCTGTTGGTACTCGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACCGGGG


GGGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-749 (SEQ ID NO: 897)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGATGTATGGTA


TGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGAGGGTGCGGGTCATGCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGATAGTGCTT


GGTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-75 (SEQ ID NO: 898)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCGGGATTCACCTTTTTGCAGTATCCGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCTGTTGGTTTGACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTGTTT


GAGGGGTCGAGGATTCAGCGTGATGTGGGTTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-750 (SEQ ID NO: 899)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAAGTATCAGA


TGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTCGGGGGTCTGGTCTTGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGCAT


ACTACGCTGCATACGGAGGTGATTGGGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-751 (SEQ ID NO: 900)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCGGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATACGA


TGTATTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTTCTCATAGTGGTTCTAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATATCGGGG


CTGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-752 (SEQ ID NO: 901)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATGCGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACGT


ATTGGTGTGGAGGGTGGGGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGTTG


CGGCTTTATCGTCTGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-753 (SEQ ID NO: 902)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTAAGTATGATA


TGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAG


ATTAATTCTGATGGTGGTCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGTTG


CATGGTAGGGGGTTTGTTATTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-754 (SEQ ID NO: 903)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATGATA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGG


ATTAATTCTATGGGTCTGGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATTAT


TCGGTTGCGCCGCATGGGTATCCTTTGGGTTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-755 (SEQ ID NO: 904)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATTCGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTACTGATAATGGTACGTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATATG


TCGCTTGCTACTTATCTGCAGTTTTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-756 (SEQ ID NO: 905)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGATA


TGCTTTGGGTCCGCCAGGCTCCAGGGAAGGCTCTAGAGTGGGTCTCACGT


ATTTCGTCGGATGGTCTTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGTG


AGTGCGCTTGCTCCTTTTGATATTGGTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-757 (SEQ ID NO: 906)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATAATA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTAATTTTGCTGGTCGGACGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGTCT


CTTCCTTTGGATATTTTTTCTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-758 (SEQ ID NO: 907)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-1 (SEQ ID NO: 908)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCGAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTATTATGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-2 (SEQ ID NO: 909)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-3 (SEQ ID NO: 910)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCCCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


AGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-4 (SEQ ID NO: 911)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTTTCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTATTATGAGTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-5 (SEQ ID NO: 912)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCTGCCTCCGGATTCGCCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-758-6 (SEQ ID NO: 913)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTA


TGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACAT


ATTTCTTCTAATGGTCGTTTTATATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT


GGTTACTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-759 (SEQ ID NO: 914)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATGTTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTAATGGTTTGGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGAGACCGCGGTATATTACTGTGCGATACAGCTG


CCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-760 (SEQ ID NO: 915)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATGATGGGA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTT


ATTAATGTTGATGGTAGGGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCT


CCTGGGCGGGTTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-761 (SEQ ID NO: 916)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGGTTGGGATA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGCTCATGAGGGTGGTGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGTT


CCTGGGTCTCCTCTGTTTGACTACTGGGGTCAGAGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-762 (SEQ ID NO: 917)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCAGGGTTGGA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGG


ATTGGTTCGAATGGTCCTCGGACATCCTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGGG


GAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-763 (SEQ ID NO: 918)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGAGTGATA


TGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTT


ATTGGTAATAATGGTGAGTTTACATACTACGCAGACTCGGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAAT


TGGCTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAG


C


 


BMS2h-764 (SEQ ID NO: 919)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTTAGTACTA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTGGTGGGGATGGTAGTCATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAAGGTACG


CAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-765 (SEQ ID NO: 920)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCGTATACGA


TGGAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGGGGTTACGGGTTATGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGGT


CAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-766 (SEQ ID NO: 921)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGATTATGGGA


TGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATAT


ATTGATCCTCTGGGTCGTCTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATTTG


TCGTCGCTGCAGTATGGGGTGTCGCCTAATTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-767 (SEQ ID NO: 922)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTCATTATTCTA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGGTCCGGTTGGTCGGGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATGATT


CAGTCGCCGTTGTTTAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-768 (SEQ ID NO: 923)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTGGTATGATA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGT


ATTGATAGTGGGGGTAATCAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGTCG


CTTTGGAAGTGGAGGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-77 (SEQ ID NO: 924)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCGCTGGGTATTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCT


ACGTCTCAGGAGTCTTTGCGGTCTTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-770 (SEQ ID NO: 925)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGAGA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCT


ATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCT


CTGCCTGATGCGTTTTGGACTAGGGGTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-771 (SEQ ID NO: 926)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTACTTATTCTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTGATCGGCATGGTTTGGCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTCCT


GGTTCTTCTTGGCAGACTGTTTTTGGCTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-772 (SEQ ID NO: 927)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTCGTATCCTA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATCATCATGGTCATTCGACATACTACGCAGACTCCGCGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCTT


AGGGTTTCGATGATTTTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-773 (SEQ ID NO: 928)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGCAGTATGGGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTAGTAGTAGTGGTACGTATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTACGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTCT


AGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-774 (SEQ ID NO: 929)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCGGCCTCCGGATTCACCTTTCGGGAGTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTT


ATTTCGCCTCCTGGTCGTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTTGTG


ATTCTGGGTTATACGAATAGGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-775 (SEQ ID NO: 930)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTACGGGA


TGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTAATTCTTCGGGTATGGAGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTTTT


CGTCTGAATGATCATAATTCTGTGTTTGGTTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-776 (SEQ ID NO: 931)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATAAGA


TGATGTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGTTGGGTCTGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCT


GGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-777 (SEQ ID NO: 932)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGCTA


TGGGGTGGGTCCGCCGGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTGATGAGCATGGTACTATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGT


CTGGATCGGGTTTGGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-778 (SEQ ID NO: 933)


GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATCCGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGT


ATTTATTCTGCGGGTTCTCCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTTAT


CATCGGGAGCCGATTCTTTTTGGGTTTGACTACTGGGGTCAGGGAACCCT


GGTCACCGTCTCGAGC


 


BMS2h-78 (SEQ ID NO: 934)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGA


TGGCGTGGGTCCGCCAGGCTCCGGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTAGTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT


CATCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-780 (SEQ ID NO: 935)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTTCTTATACTA


TGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAG


ATTGATCGGACGGGTGAGCGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTGGG


TTTGCTTCTCTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-781 (SEQ ID NO: 936)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATACTA


TGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAG


ATTTCTCCGAGTGGTCGTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCCG


TTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-782 (SEQ ID NO: 937)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGCGGAGA


TGTTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTGATGCTCGTGGTTTGACGACATACTACGCAGACCCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGACG


TCGGCTATGTATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGT


CTCGAGC


 


BMS2h-783 (SEQ ID NO: 938)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCTCTTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCTGGG


TTTCATGAGTATACTGAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGT


CACCGTCTCGAGC


 


BMS2h-784 (SEQ ID NO: 939)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCGTGCGGGTA


TGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTG


ATTGGGCGTGGTGGTGATATTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT


AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-80 (SEQ ID NO: 940)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCT


ATTTCTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCT


CGTCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-81 (SEQ ID NO: 941)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTT


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATCCGA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCG


ATTTCTCCGGTTGGTTTTCTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGCAT


GAGGGGTCGTATACTCCGCGGTCGGCTTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-82 (SEQ ID NO: 942)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGGCGTATCCTA


TGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACT


ATTGCGCCTCTGGGTGGTAATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGGCCG


GAGGGGCTGCAGATTGATTCTCAGAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-83 (SEQ ID NO: 943)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTTGTATCAGA


TGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCG


ATTGATTCTTCTGGTAGTGATACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAG


CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-84 (SEQ ID NO: 944)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGTACCAGA


TGGCTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGCGTCGGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGT


CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-85 (SEQ ID NO: 945)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATA


TGAGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGG


ATTGATGAGGCGGGTCATGAGACATACTATGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGATG


GATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-92 (SEQ ID NO: 946)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTTGATTATCCGA


TGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCTACGGGGGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGCGG


TATTATTATCTTAGTCAGATTAAGAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-93 (SEQ ID NO: 947)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATATTTATGGGA


TGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGT


ATTTCGCCTCTTGGTCTTGTTACATACTACGCAGACCCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGAAG


GAGCATGGGGATGTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-94 (SEQ ID NO: 948)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATCCGA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTTCTCCTACGGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAAG


AGGAGTGGGAAGACTGATGATACTAATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC


 


BMS2h-95 (SEQ ID NO: 949)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGGGAGTATGATA


TGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTGTGGGGGATGGTAATGGTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGGAT


CGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC


 


BMS2h-97 (SEQ ID NO: 950)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACG


ATTTCGCCTATTGGTGTTACTACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAATGCT


TATGATCGGAAGTCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCAC


CGTCTCGAGC


 


BMS2h-98 (SEQ ID NO: 951)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCGGTATGTGA


TGGTGTGGGTCCGCCAGGCTCCAGGGAAGGATCTAGAGTGGGTCTCAGGT


ATTACTCCGAGTGGTAGGAGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGGACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGTTG


GGGCGTCATTTTGATCCTCTTCTGCCTTCGTTTGACTACTGGGGTCAGGG


AACCCTGGTCACCGTCTCGAGC


 


BMS2h-99 (SEQ ID NO: 952)


GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC


CCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGCTA


TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACT


ATTACTCCGGGTGGTTTTTGGACATACTACGCAGACTCCGTGAAGGGCCG


GTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGA


ACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACGTCT


AGTGGGGAGTTGCAGTTGGTTGAGGATTTTGACTACTGGGGTCAGGGAAC


CCTGGTCACCGTCTCGAGC
















TABLE 3





Anti-human CD40L VK Domain Amino Acid Sequences















BMS2h-100 (SEQ ID NO: 953)


DIQMTQSPSS LSASVGDRVT ITCRASQNIK HSLRWYQQKP GKAPRLLIYH RSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VRHRPYTFGQ GTKVEIKR


 


BMS2h-101 (SEQ ID NO: 954)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VALFPYTFGQ GTKVEIKR


 


BMS2h-102 (SEQ ID NO: 955)


DIQMTQSPSS LSASVGDRVT ITCRASQHIG HHLRWYQQKP GKAPKLLIYH RSHLQSGVPS


RFSGSGSGTD FTLTISSLQP EDSATYYCQQ WDRPPYTFGQ GTKVEIKR


 


BMS2h-103 (SEQ ID NO: 956)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH


RSKLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VRAVPYTFGQ GTKVEIKR


 


BMS2h-104 (SEQ ID NO: 957)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VRFSPYTFGQ GTKVEIKR


 


BMS2h-105 (SEQ ID NO: 958)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYARPVTFGQ GTKVEIKR


 


BMS2h-106 (SEQ ID NO: 959)


DIQMTQSPSS LSASVGDRVT ITCRASQSIN HRLYWYQQKP GKAPKLLIYH RSRLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKVRPNTFGQ GTKVEIKR


 


BMS2h-107 (SEQ ID NO: 960)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSSPHTFGQ GTKVEIKR


 


BMS2h-108 (SEQ ID NO: 961)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RAVRPFTFGQ GTKVEIKR


 


BMS2h-109 (SEQ ID NO: 962)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYYRPLTFGQ GTKVEIKR


 


BMS2h-110 (SEQ ID NO: 963)


DIQMTQSPAS LSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYA GSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TSIRPYTFGQ GTKVEIKR


 


BMS2h-116 (SEQ ID NO: 964)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-1 (SEQ ID NO: 965)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDILWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-10 (SEQ ID NO: 966)


DIQITQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-11 (SEQ ID NO: 967)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGRGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-12 (SEQ ID NO: 968)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR


 


BMS2h-116-13 (SEQ ID NO: 969)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVTFGQ GTKVVIKR


 


BMS2h-116-1312 (SEQ ID NO: 970)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP EDLATYYCQQ YWAFPVTFGK GTKVVIKR


 


BMS2h-116-1313 (SEQ ID NO: 971)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVTFGR GTKVVIKR


 


BMS2h-116-1314 (SEQ ID NO: 972)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYRQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVTFGQ GTKVVIKR


 


BMS2h-116-1319 (SEQ ID NO: 973)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSIMRSGVPS


RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR


 


BMS2h-116-1320 (SEQ ID NO: 974)


DIQMTQSPSS LSAYVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP EDFAKYYCQQ YWAFPVTFGQ GTKVVIKR


 


BMS2h-116-138 (SEQ ID NO: 975)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSETD FTLTISNLQP VDFATYYCQQ YWAFPVTFGQ GTKVVIKR


 


BMS2h-116-14 (SEQ ID NO: 976)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWFQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-15 (SEQ ID NO: 977)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYRQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR


 


BMS2h-116-16 (SEQ ID NO: 978)


DIQMTQSPSS LSASVGDRVT ITCRASQPID PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSGTV FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-17 (SEQ ID NO: 979)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-2 (SEQ ID NO: 980)


DIQMTQSPSS LSASVGDRVT ITCRASQPIE PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWASPVTFGQ GTKVEIKR


 


BMS2h-116-3 (SEQ ID NO: 981)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ


TSILQSGVPS RFSGSESGTD FTLTISSLQP EDIATYYCQQ YWAFPVTFGQ GTRVEIKR


 


BMS2h-116-4 (SEQ ID NO: 982)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-5 (SEQ ID NO: 983)


DIQMTQSPSS LSASVGDRVA ITCRASQPIG PDILWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSGTD FTLTISSLQP EDSATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-6 (SEQ ID NO: 984)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSGSVTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVGIKR


 


BMS2h-116-7 (SEQ ID NO: 985)


DIQMTQSPSS LSASVGDRVT ITCRASQPID PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSRTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-8 (SEQ ID NO: 986)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS


RFSGSGSGTD FTLTISGLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-116-9 (SEQ ID NO: 987)


DIQMTQSPSS LSASVGDRVT ITCRASMPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS


RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR


 


BMS2h-141 (SEQ ID NO: 988)


DIQMTQSPSS LSASVGDRVT ITCRASQWIG DTLTWYQQKL GKAPKLLIYG GSELQSGVPP


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ CISSPCTFGQ GTKVEIKR


 


BMS2h-142 (SEQ ID NO: 989)


DIQMTQSPSS LSASVGDRVT ITCRASQFIG DSLSWYQQKP GKAPKLLIYF SSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHTSPTTFGR GTKVKIKR


 


BMS2h-143 (SEQ ID NO: 990)


DIQMTQSPSS LSASVGDRVT ITCRASQTIE TNLEWYQQKP GKAPKLLIYD SSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YHGYPTTFGQ GTKVEIKR


 


BMS2h-144 (SEQ ID NO: 991)


DIQMTQSPSS LSASVGDRVT ITCRASQMID QDLEWYQQKP GKAPKLLIYN ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHGYPITFGQ GTKVEIKR


 


BMS2h-145 (SEQ ID NO: 992)


DIQMTQSPSS LSASVGDRVT ITCRASQTIY TSLSWYQQKP GKAPKLLIHY GSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDSATYYCQQ VHQAPTTFGQ GTKVEIKR


 


BMS2h-146 (SEQ ID NO: 993)


DIRMTQSPSS LSASVGDRVT ITCRASQWIG DSLAWYQQKP GKAPKLLIYG ISELQSGVPS


RFSGSGSGTD FTLTISSLQP EDSATYYCQL SSSMPHTFGQ GTKVEIKR


 


BMS2h-147 (SEQ ID NO: 994)


DIQMTQSPSS LSASVGDRVT ITCRASQEIE TNLEWYQQKP GKAPKLLIYD SSHLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHQNPPTFGQ GTKVEIKR


 


BMS2h-149 (SEQ ID NO: 995)


DIQMTQSPSS LSASVGDRVT ITCRASQWIG RQLVWYQQKP GKAPKLLIYG ATELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ QSKGPLTFGH GTKVEIKR


 


BMS2h-150 (SEQ ID NO: 996)


DIQMTQSPSS LSASVGDRVT ITCRASQGIG TDLNWYQQKP GKAPKLLIYM GSYLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ IYSFPITFGQ GTKVEIKR


 


BMS2h-154 (SEQ ID NO: 997)


DIQMTQSPSS LSASVGDRVT ITCRASQDIE EMLHWYQQKP GKAPKLLIYF GSLLQSGVPS


RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HHTRPYTFGQ GTKVEIKR


 


BMS2h-155 (SEQ ID NO: 998)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG MDLEWYQQIP GKVPKLLIYD ASYLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHKLPATFGQ GTKVEIKR


 


BMS2h-156 (SEQ ID NO: 999)


DIQMTQSPSS LSASVGDRVT ITCRASQDIM DNLEWYQQKP GKAPKLLIYA ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHKLPVTFGQ GTKVEIKR


 


BMS2h-157 (SEQ ID NO: 1000)


DIQMTQSPSS LSASVGDRVT ITCRASQNIG EDLEWYQQKP GNAPKLLIYS ASHLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSYPVTFGQ GTKVEIKR


 


BMS2h-158 (SEQ ID NO: 1001)


DIQMTQSPSS LSASVGDRVT ITCRASQPID EDLEWYQQKP GNAPKLLIYS ASYLQSGVPS


RFSGSGSGTD FTLTISRLQP EDFATYYCQQ YHLLPATFGQ GTKVEIKR


 


BMS2h-159 (SEQ ID NO: 1002)


DIQMIQSPSS LSASVGDRVT ITCRASQDIN EDLEWYQQKP GKAPKLLIYN ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP KDFATYYCQQ YHTNPTTFGQ GTKVEIKR


 


BMS2h-160 (SEQ ID NO: 1003)


DIQMTQSPSS LSASVGDRVT ITCRASQDIE ADLEWYQQKP GKAPKLLIYH SSELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHMSPVTFGQ GTKVEIKR


 


BMS2h-161 (SEQ ID NO: 1004)


DIQMTQSPSS LSASVGDRVT ITCRASQDID SDLEWYQQKP GKAPMLLIYS SSDLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPVTFGQ GTKVEIKR


 


BMS2h-162 (SEQ ID NO: 1005)


DIQMTQSPSS LSASVGDRVT ITCRASQDIS DDLEWYQQKP GKAPKLLIYN SSFLQSGVPS


RFSGSGSGAD FTLTISSLQP EDFATYYCQQ YHSLPVTFGQ GTKVEIKR


 


BMS2h-163 (SEQ ID NO: 1006)


DIQMTQSPSS LSASVGDRVT ITCRASQDIE GNLEWYQQKP GKAPKLLIYD SSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHHLPTTFGQ GTKVEIKR


 


BMS2h-164 (SEQ ID NO: 1007)


DIQMTQSPSS LSASVGDRVT ITCRASQSID TDLEWYQQKP GKAPKLLIYD GSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YRWIPVTFGQ GTKVEIKR


 


BMS2h-165 (SEQ ID NO: 1008)


DIQMTQSPSS LSASVGDRVT ITCRASQSIS TDLEWYQQKL GKAPKLLIYD ASLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSLPVTFGQ GTKVEIKR


 


BMS2h-166 (SEQ ID NO: 1009)


DIQMTQSPSS LSASVGDRVT ITCRASQPIT TSLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWVTPVTFGQ GTKVEIKR


 


BMS2h-167 (SEQ ID NO: 1010)


DIQMTQSPSS LSASVGDRVT ITCRASQNIH TNLEWYQQKP GKAPKLLIYD GSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSANPVTFGQ GTKVGIKR


 


BMS2h-168 (SEQ ID NO: 1011)


DIQMTQSPSS LSASVGDRVT ITCRASQWIH TDLEWYQQKP GKAPKLLIYD GSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSVSPVTFGQ GTKVEIKR


 


BMS2h-169 (SEQ ID NO: 1012)


DIQMTQSPSS LSASVGDRVT ITCRASQSID NNLEWYQQKP GEAPKLLIYD GSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHLHPVTFGQ GTKVEIKR


 


BMS2h-170 (SEQ ID NO: 1013)


DIQMTQSPSS LSASVGDRVT ITCRASQDID TNLEWYQQKP GEAPKLLIYD RSTLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDSYPVTFGQ GTKVEIKR


 


BMS2h-171 (SEQ ID NO: 1014)


DIQMTQSPSS LSASVGDRVT ITCRASQSIE SNLEWYQQKP GKAPKLLIYN ASELQSGVPS


RFSGSGSGTD FTLTISSLRP EDFATYYCQQ YDQWPTTFGQ GTKVEIKR


 


BMS2h-172 (SEQ ID NO: 1015)


DIQMTQSPSS LSASVGDRVT ITCRASQAIG NTLRWYQQKP GKAPKLLIYL SSRLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LKKPPYTFGQ GTKVEIKR


 


BMS2h-173 (SEQ ID NO: 1016)


DIQMTQSPSS LSASVGDRVT ITCRASQKIK NRLAWYQQKP GKAPKLLIYE VSHLQSGVPS


RFSGSGSGTD FTLTIGSLQP EDFATYYCQQ RRQSPYTFGQ GTKVEIKR


 


BMS2h-174 (SEQ ID NO: 1017)


DIQMTQSPSS LSASVGDRVT ITCRASEDIG EELFWYQQKP GKAPKLLIYS ASTLQSEVPS


RFSGSGSGTD FTLTISSLQH EDFATYYCQQ VYEWPYTFGQ GTKVEIKR


 


BMS2h-175 (SEQ ID NO: 1018)


DIQMTQSPSS LSASVGDRVT ITCRASQPIS GGLRWYQQKP GKAPKLLIYS TSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYSAPYTFGQ GTKVEIKR


 


BMS2h-305 (SEQ ID NO: 1019)


DIQMTQSPSS LSASVGDRVT ITCRASQDID QDLEWYQQKP GKAPKLLIYN VSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSMNPVTFGQ GTKVEIKR


 


BMS2h-306 (SEQ ID NO: 1020)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG NQLKWYQQKP GKAPKLLIYQ ASGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDLRPQTFGQ GTKVEIKR


 


BMS2h-307 (SEQ ID NO: 1021)


DIQMTQSPSF LSASVGDRVT ITCRASQKIS TSLEWYQQKP GKAPRLLIYD SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YEYNPITFGQ GTKVEIKR


 


BMS2h-33 (SEQ ID NO: 1022)


DIQMTQSPSS LSASVGDRVT ITCRASQTIG ESLHWYQQKP GKAPRLLIYF ASLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HHMLPSTFGQ GTKVEIKR


 


BMS2h-35 (SEQ ID NO: 1023)


DIQMTQSPSS LSASVGDRVT ITCRASQFIG DSLSWYQQKP GKAPKLLIYF SSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YMDIPITFGQ GTKVEIKR


 


BMS2h-36 (SEQ ID NO: 1024)


DIQMTQSPSS LSASVGDRVT ITCRASQDID HNLEWYQQKP GKAPKLLIYD SSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSIPVTFGQ GTKVEIKR


 


BMS2h-37 (SEQ ID NO: 1025)


DIQMTQSPSS LSASVGDRVT ITCRASQQIE TNLEWYQQKP GKAPKLLIYD GSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPATFGQ GTKVEIKR


 


BMS2h-38 (SEQ ID NO: 1026)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG NNLEWYQQKP GKAPRLLIYH GSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDFNPTTFGQ GTKVEIKR


 


BMS2h-39 (SEQ ID NO: 1027)


DIQMTQSPSS LSASVGDCVT ITCRASQNID GLLWWYQQKP GKAPKLLIYA GSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ KAFEPFTFGQ GTKVEIKR


 


BMS2h-405 (SEQ ID NO: 1028)


DIQMTQTPSS LSASVGDRVT ITCRASQSIG HDLEWYQQKP GKAPKLLIYN VSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSHNPPTFGQ GTKVEIKR


 


BMS2h-406 (SEQ ID NO: 1029)


DIQMTQSPSS LSASVGDRVT ITCRASQHIE NDLEWYQQKP GKAPKLLIYS ASHLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHLQPTTFGP GTKVEIKR


 


BMS2h-431 (SEQ ID NO: 1030)


DIQMTQSPSS LSASVGDRVT ITCRASQVIE GSLNWYQQKP GKAPKLLIYH RSILQSGVPS


RFSGRGSGTD FTLTISSLQP EDFATYYCQQ TYQLPLTFGQ GTKVEIKR


 


BMS2h-432 (SEQ ID NO: 1031)


DIQMTQSPSS LSASVGDRVT ITCRASRPIN GKLFWYQQKP GKAPKLLIAF ASALQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCVQ QAVYPITFGQ GTKVEIKR


 


BMS2h-433 (SEQ ID NO: 1032)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE TNLEWYQQKP GKAPKLLIYD GSLLQSGVPS


RFSGRGSGTD FTLTISSLQP EDFATYYCQQ YHYQPATFGQ GTKVEIKR


 


BMS2h-434 (SEQ ID NO: 1033)


DIQMTQSPSS LSASVGDRVT ITCRASQDIE HDLEWYQQKP GKAPKLLIYS ASQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YQQQPTTFGQ GTKVEIKR


 


BMS2h-435 (SEQ ID NO: 1034)


DIQMTQSPSS LSASVGDRVT ITCRASSQIE ESLWWYQQKP GKAPKLLIAD VSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ GVVEPRTFGQ GTKVEIKR


 


BMS2h-436 (SEQ ID NO: 1035)


DIQMTQSPSS LSASVGDRVT ITCRASQYIG LDLEWYQQKP GKAPKLLIYA ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFRQPITFGQ GTKVEIKR


 


BMS2h-437 (SEQ ID NO: 1036)


DIQMTQSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVEIKR


 


BMS2h-437-1 (SEQ ID NO: 1037)


DIQLTQSPTS LSATVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRHPATFGQ GTKVEIKR


 


BMS2h-437-2 (SEQ ID NO: 1038)


DIQMTQSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVGIKR


 


BMS2h-437-3 (SEQ ID NO: 1039)


DIQMTQSPSS LSASVGDRVT ITCRVSTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPP


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVEIKR


 


BMS2h-437-4 (SEQ ID NO: 1040)


DIQMTQSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS


RFSGCGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVEIKR


 


BMS2h-437-5 (SEQ ID NO: 1041)


DIQMTQSPSS LSASVGDRVT ITCRASTPIG TMIDWYQQKP GKAPKLLIGH SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGK GTKVEIKR


 


BMS2h-438 (SEQ ID NO: 1042)


DIQMTQSPSS LSASVGDRVT ITCRASQYID TNLEWYQQKP GKAPRLLIYD GSQLQSGVPS


RFSGSGSGTD FTLIISSLQP EDFATYYCQQ YQVVPVTFGQ GTKVEIKR


 


BMS2h-439 (SEQ ID NO: 1043)


DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPRLLIVD SSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ DRWSPATFGQ GTKVEIKR


 


BMS2h-440 (SEQ ID NO: 1044)


DIQMTQSPSS LSASVGDRVT ITCRASSRIQ HMLSWYQQKP GKAPKLLIGG HSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ SCAWPLTFGQ GTKVEIKR


 


BMS2h-441 (SEQ ID NO: 1045)


DIQMTQSPSS LSASVGDRVT ITCRASRGID GDLWWYQQKP GKAPKLLIAD SSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVRPMTFGQ GTKVEIKR


 


BMS2h-442 (SEQ ID NO: 1046)


DIQMTQSPSS LSASVGDRVT ITCRASRGID TDLWWYQQKP GKAPKLLIAD SSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVRPMTFGQ GTKVEIKR


 


BMS2h-443 (SEQ ID NO: 1047)


DIQMTQSPSS LSASVGDRVT ITCRASYTIP VALDWYQQKP GKAPKLLIAD ASLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ GWPGPQTFGQ GTKVEIKR


 


BMS2h-444 (SEQ ID NO: 1048)


DIQMTQSPSS LSASVGDRVT ITCRASQSIA TDLEWYQQKP GKAPKLLIYD TSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSYNPSTFGQ GTKVEIKR


 


BMS2h-445 (SEQ ID NO: 1049)


DIQMTQSPSS LSASVGDRVT ITCRASVPIT EGLSWYQQKP GKAPKLLIQA NSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WEHVPATFGQ GTKVEIKR


 


BMS2h-446 (SEQ ID NO: 1050)


DIQMTQSPSS LSASVGDRVT ITCRASSMIL YGLDWYQQKP GKAPKLLIGG TSALQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WETVPATFGQ GTKVEIKR


 


BMS2h-447 (SEQ ID NO: 1051)


DIQMTQSPSS LSASVGDRVT ITCRASQPIN GLLIWYQQKP GKAPKLLIYA MSSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LARIPFTFGQ GTKVGIKR


 


BMS2h-448 (SEQ ID NO: 1052)


DIQMTQSPSS LSASVGDRVT ITCRASQLIR TYLAWYQQKP GKAPKLLIYQ SSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPDTFGQ GTKVEIKR


 


BMS2h-47 (SEQ ID NO: 1053)


DIQMTQSPSS LSASVGDRVT ITCRASQWIG DSLSWYQQKP GKAPKLLIYF GSYLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLHTPSTFGQ GTKVEIKR


 


BMS2h-484 (SEQ ID NO: 1054)


DIQMTQSPSS LSASVGDRVT ITCRASQDIE ADLEWYQQKP GKAPKLLIYH SSELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YGFNPPTFGQ GTKVEIKR


 


BMS2h-485 (SEQ ID NO: 1055)


DIQMTQSPSS LSASVGDRVT ITCRASSPIE YGLDWYQQKP GKAPKLLIGG GSALQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WEVQPATFGQ GTKVEIKR


 


BMS2h-486 (SEQ ID NO: 1056)


DIQMTQSPSS LSASVGDRVT ITCRASQRID TDLEWYQQKP GKAPKLLIYD SSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSAPATFGQ GTKVEIKR


 


BMS2h-487 (SEQ ID NO: 1057)


DIQMTQSPSS LSASVGDRVT ITCRASGWIG MSLEWHQQKP GKAPKLLIRG ASSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCSQ SRWPPVTFGQ GTKVEIKR


 


BMS2h-488 (SEQ ID NO: 1058)


DIQMTQSPSS LSASVGDRVT ITCRASRNIS NALSWYQQKP GKAPKLLILG ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCTQ VWDRPFTFGQ GTKVEIKR


 


BMS2h-489 (SEQ ID NO: 1059)


DIQMTQSPSS LSASVGDRVT ITCRASQDIM SALSWYQQKP GKAPKLLIYS TSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VYLLPVTFGQ GTKVEIKR


 


BMS2h-490 (SEQ ID NO: 1060)


DIQMTQSPSS LSASVGDRVT ITCRASQEIG IDLEWYQQKP GKAPKLLIYA ASYLQSGVPS


RFSSSGSGTD FTLTISSLQP EDFATYYCQQ YASNPPTFGR GTKVEIKR


 


BMS2h-491 (SEQ ID NO: 1061)


DIQMTQSPSS LSASVGDRVT ITCRASQMIG DWLNWYQQKP GKAPKLLIYR SSELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYFWPRTFGQ GTKVEIKR


 


BMS2h-492 (SEQ ID NO: 1062)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE LNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDVYPPTFGQ GTKVEIKR


 


BMS2h-492-1 (SEQ ID NO: 1063)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YDAYPPTYGQ GTKVEIKR


 


BMS2h-492-2 (SEQ ID NO: 1064)


DIQMTQSPSS LSASVGDRVT ITCRASRAIE TNLEWYQQKP GKAPKLLFYD ASMLQSGVPS


RFGGSGSGTD FTLTISSLQP EDFATYYCLQ YDVYPPTFGQ GTKVEIKR


 


BMS2h-492-3 (SEQ ID NO: 1065)


DIQMTQSPSS LSATVGDRVT ITCRASQAIE TNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR


 


BMS2h-492-4 (SEQ ID NO: 1066)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGRGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR


 


BMS2h-492-5 (SEQ ID NO: 1067)


DIQMNQSPSS LSASVGDRVS ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR


 


BMS2h-492-6 (SEQ ID NO: 1068)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE SNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDVYPPTFGQ GTKVEIKR


 


BMS2h-492-7 (SEQ ID NO: 1069)


DIQMTQSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR


 


BMS2h-493 (SEQ ID NO: 1070)


DIQMTQSPSS LSASVGDRVT ITCRASQGID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFQYPPTFGQ GTKVEIKR


 


BMS2h-494 (SEQ ID NO: 1071)


DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFQYPPTFGQ GTKVEIKR


 


BMS2h-494-1 (SEQ ID NO: 1072)


DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSQYPPTFGQ GTKVEIKR


 


BMS2h-494-2 (SEQ ID NO: 1073)


DIQMTQSPSS LSASVGDRVT ITCRASQSIE EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFQYPPTFGH GTKVEIKR


 


BMS2h-494-3 (SEQ ID NO: 1074)


DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYFCQQ YFQYPPTFGQ GTKVEIKR


 


BMS2h-494-4 (SEQ ID NO: 1075)


EIQMTQSPSS LSASVGDRVT MTCRASQSID KDLEWYQQKP GKAPRLLIYS SSWLQRGVPS


RFSGSGSGTD FTLTISSLRP EDFATYYCQQ YFQYPPTLGQ GTKVEIKR


 


BMS2h-494-5 (SEQ ID NO: 1076)


DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS


RFSGSGSGTD FTLTISGLQP EDIATYYCKQ YSQYPPTFGQ GTKVEIKR


 


BMS2h-494-6 (SEQ ID NO: 1077)


DIQMTQSPPS LSASVGDRVT ITCRASQSID KDLEWYQQKP GKAPRLLIYS SSWLQRGVPS


RFSGSGSGTD FTLTISSLQP EDFATYHCQQ YFQYPPTFGQ GTKVEIKR


 


BMS2h-495 (SEQ ID NO: 1078)


DIQMTQSPSS LSASVGDRVT ITCRASEYIN AELAWYQQKP GKAPKLLIYG SSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCLQ NAMWPITFGQ GTKVEIKR


 


BMS2h-496 (SEQ ID NO: 1079)


DIQMTQSPSS LSASVGDRVT ITCRASLDIN NGLIWYQQKP GKAPRLLILG ASGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCSQ VRSRPFTFGQ GTKVEIKR


 


BMS2h-497 (SEQ ID NO: 1080)


DIQMTQSPSS LSASVGDRVT ITCRASQDIL SALAWYQQKP GKAPKLLIYG SSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ NYSLPITFGQ GTKVEIKR


 


BMS2h-498 (SEQ ID NO: 1081)


DIQMTQSPSS LSASVGDRVT ITCRASSPIE SYLRWYQQKP GKAPKLLIRY VSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WFRAPVTFGQ GTKVEIKR


 


BMS2h-499 (SEQ ID NO: 1082)


DIQMTQSPSS LSASVGDRVT ITCRVSESIN AELHWYQQKP GKAPKLLISG FSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCVQ FAMWPFTFGQ GTKVEIKR


 


BMS2h-500 (SEQ ID NO: 1083)


DIQMTQSPSS LSASVGDRVT ITCRASMMIR FGLDWYQQKP GKAPKLLIGG GSSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HERWPATFGQ GTKVEIKR


 


BMS2h-501 (SEQ ID NO: 1084)


DIQMTQSPSS LSASVGDRVT ITCRASQSIG TLLRWYQQKP GKAPKLLIYL TSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MVYRPYTFGQ GTKVEIKR


 


BMS2h-502 (SEQ ID NO: 1085)


DIQMTQSPSS LSASVGDRVT ITCRASQTIE TNLEWYQQKP GKAPKLLIYD SSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDKVPATFGQ GTKVEIKR


 


BMS2h-503 (SEQ ID NO: 1086)


DIQMTQSPSS LSASVGDRVT ITCRASHHIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPPTFGQ GTKVEIKR


 


BMS2h-503-1 (SEQ ID NO: 1087)


DIQMTQSPSS LSASVGDRVT ITCRASHHIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR


 


BMS2h-503-2 (SEQ ID NO: 1088)


DIQMTQSPSS LSASVGDRVT ITCRASHDIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR


 


BMS2h-504 (SEQ ID NO: 1089)


DIQMTQSPSS LSASVGDRVT ITCRASQYID TNLEWYQQKP GKAPKLLIYD GSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVVPVTFGQ GTKVEIKR


 


BMS2h-508 (SEQ ID NO: 1090)


DIQMTQSPSS LSASVGDRVT ITCRASQDIA FDLEWYQQKP GKAPKLLIYS ASMLQSGVPS


RFSGSGSGSD FTLTISSLQP EDFATYYCQQ YNLQPPTFGQ GTKVEIKR


 


BMS2h-509 (SEQ ID NO: 1091)


DIQMTQSPSS LSASVGDRVT ITCRASQNIA TLLRWYQQKP GKAPKLLIYA GSMLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MWQRPYTFGQ GTKVEIKR


 


BMS2h-51 (SEQ ID NO: 1092)


DIQMTQSPSS LSASVGDRVT ITCRASQPIV DELDWYQQKP GKAPKLLIYA ASILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCHQ WSTYPTTFGQ GTKVEIKR


 


BMS2h-510 (SEQ ID NO: 1093)


DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIDG VSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ DWDWPRTFGQ GTKVEIKR


 


BMS2h-511 (SEQ ID NO: 1094)


DIQMTQSPSS LSASVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDW GSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ TWDDPLTFGQ GTKVEIKR


 


BMS2h-511-1 (SEQ ID NO: 1095)


DIQMTQSPSS LSAFVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDW GSELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ TWYDPLTFGH GTKVEIKR


 


BMS2h-512 (SEQ ID NO: 1096)


DIQMTQSPSS LSASVGDRVT ITCRASIDIH GGLTWYQQKP GKAPKLLIVG VSGLQSGVPS


RFSGSGSGTD FTLTISNLQP EDFATYYCAQ VWRRPFTFGQ GTKVEIKR


 


BMS2h-513 (SEQ ID NO: 1097)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG SSLSWYQQKP GKAPKLLIYA SSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYALPVTFGQ GTKVEIKR


 


BMS2h-514 (SEQ ID NO: 1098)


DIQMTQSPSS LSASVGDRVT ITCRASQQIE TNLEWYQQKP GKAPKLLIYD GSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKYLPVTFGQ GTKVEIKR


 


BMS2h-52 (SEQ ID NO: 1099)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG SALRWYQQKP GKAPKLLIYL GSDLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TQYFPTTFGQ GTKVEIKR


 


BMS2h-53 (SEQ ID NO: 1100)


DIQMTQSPSS LSASVGDRVT ITCRASQAIY GGLRWYQQKP GKAPKLLIYG ESMLQSGVPS


RFSGSGSGTD FTLTISSLHP EDFATYYCQQ VYHKPFTFGQ GTKVEIKR


 


BMS2h-536 (SEQ ID NO: 1101)


DIQMTQSPSS LSASVGDRVT ITCRASQRIG VWLDWYQQKP GKAPKLLIYD GSFLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TFSSPSTFGQ GTKVEIKR


 


BMS2h-537 (SEQ ID NO: 1102)


DIQMTQSPSS LSASVGDRVP ITCRASQWIG DELYWYQQKP GKAPKLLIYS SSTLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFQFPYTFGQ GTKVEIKR


 


BMS2h-538 (SEQ ID NO: 1103)


DIQMTQSPSS LSASVGDRVT ITCRASSNIT GPLEWYQQKP GKAPKLLIPG WSTLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ VWGEPVTFGQ GTKVEIKR


 


BMS2h-539 (SEQ ID NO: 1104)


DIQMTQSPSS LSASIGDRVT ITCRASQRIA YGLHWYQQKP GKAPRLLIGG RSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCVQ PGMPPDTFGQ GTKVEIKR


 


BMS2h-540 (SEQ ID NO: 1105)


DIQMTQSPSS LSASVGDRVT ITCRASKQIV GGLSWYQQKP GKAPKLLIGR HSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCVQ GVWAPGTFGQ GTKVEIKR


 


BMS2h-541 (SEQ ID NO: 1106)


DIQMTQSPSS LSASVGDRVT ITCRASPAIA AKLDWYQQKP GKAPKLLIGA DSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWAGPPTFGQ GTKVEIKR


 


BMS2h-542 (SEQ ID NO: 1107)


DIQMTQSPSS LSASVGDRVT ITCRASRTIA DGLDWYQQKP GKAPKLLIGA YSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWEGPPTFGQ GTKVEIKR


 


BMS2h-543 (SEQ ID NO: 1108)


DIQMTQSPSS LSASVGDRVT ITCRASQRIY GFLDWYQQKP GKAPKLLIYG VSSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLAWPFTFGQ GTKVEIKR


 


BMS2h-544 (SEQ ID NO: 1109)


DIQMTQSPSS LSASVGDRVT ITCRASQDIR DWLMWYQQKP GKAPKLLIYW GSFLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYDTPYTFGQ GTKVEIKR


 


BMS2h-545 (SEQ ID NO: 1110)


DIQMTQSPSS LSASVGDRVT ITCRASQNIN TGLDWYQQKP GKAPKLLIYD SSALQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TSYYPYTFGQ GTKVEIKR


 


BMS2h-546 (SEQ ID NO: 1111)


DIQMTQSPSS LSASVGDRVT ITCRASQKIF GWLDWYQQKP GKAPKLLIYG TSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VYSLPYTFGQ GTKVEIKR


 


BMS2h-547 (SEQ ID NO: 1112)


DIQMTQSPSS LSASVGDRVT ITCRASSNIG ADLDWYQQKP GKAPKLLIGG ASGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWNGPPTFGQ GTKVEIKR


 


BMS2h-548 (SEQ ID NO: 1113)


DIQMTQSPSS LSASVGDRVT ITCRASSPIY DGLDWYQQKP GKAPKLLISG ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWLGPPTFGQ GTKVEIKQ


 


BMS2h-549 (SEQ ID NO: 1114)


DIQMTQSPSS LSASVGDRVT ITCRASSRIY NGLHWYQQKP GKAPKLLIGG RSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ VGEAPSTFGQ GTKVEIKR


 


BMS2h-550 (SEQ ID NO: 1115)


DIQMTQSPSS LSASVGDRVT ITCRASRFIN EELDWYQQKP GKAPKLLISW SSWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCVQ PGGGPGTFGQ GTKVEIKR


 


BMS2h-551 (SEQ ID NO: 1116)


DIQMTQSPSS LSASVGDRVT ITCRASRDIL DELDWYQQKP GKAPRLLIGG GSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWHGPPTFGQ GTKVEIKR


 


BMS2h-552 (SEQ ID NO: 1117)


DIQMTQSPSS LSASVGDRVT ITCRASSPIY TGLHWYQQKP GKAPKLLIGG RSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCMQ VGTAPATFGQ GTKVEIKR


 


BMS2h-585 (SEQ ID NO: 1118)


DIRMTQSPSS LSASVGDRVT ITCRASQNIS RRLLWYQQKP GKAPKLLIYS SSRLQSGVPS


RFGGSGSGTD FTLTISSLQP EDFATYYCQQ TYSYPHTFGQ GTKVEIKR


 


BMS2h-604 (SEQ ID NO: 1119)


DIQMTQSPSS LSASVGDRVT ITCRASSPIP QDLYWYQQKP GKAPKLLIVG ISQLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWSAPATFGQ GTKVEIKR


 


BMS2h-605 (SEQ ID NO: 1120)


DIQMTQSPSS LSASVGDRVT ITCRASKSID GMLDWYQQKP GKAPKLLIPG FSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SVEAPWTFGQ GTKVEIKR


 


BMS2h-606 (SEQ ID NO: 1121)


DIQMTQSPSS LSASVGDRVT ITCRASRYIA HPLDWYQQKP GKAPKLLIPG SSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SVVVPWTFGQ GTKVEIKR


 


BMS2h-607 (SEQ ID NO: 1122)


DIQMTQSPSS LSASVGDRVT ITCRASRTIE GGLDWYQQKP GKAPKLLIMG GSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWVGPPTFGQ GTKVEIKR


 


BMS2h-608 (SEQ ID NO: 1123)


DIQMTQSPSS LSASVGDRVT ITCRASKFIR DELYWYQQKP GKAPRLLIGG SSLLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWRAPATFGQ GTKVEIKR


 


BMS2h-609 (SEQ ID NO: 1124)


DIQMTQSPSS LSASVGDRVT ITCRASKPIY GGLEWYQQKP GKAPRLLIGG GSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ VWGGPVTFGQ GTKVEIKR


 


BMS2h-610 (SEQ ID NO: 1125)


DIRMTQSPSS LSASVGDRVT ITCRASRPIS GCLDWYQQKP GKAPKLLIDG ASGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWEYPPTFGQ GTKVEIKR


 


BMS2h-611 (SEQ ID NO: 1126)


DIQMTQSPSS LSASVGDRVT ITCRASKPIV RDLEWYQQKP GKAPKLLIHG VSTLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LEAAPATFGQ GTKVEIKR


 


BMS2h-612 (SEQ ID NO: 1127)


DIQMTQSPSS LSASVGDRVT ITCRASRDIG DWLYWYQQKP GKAPRLLIVW ASVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ WGTPPTTFGQ GTKVEIKR


 


BMS2h-613 (SEQ ID NO: 1128)


DIQMTQSPSS LSASVGDRVT ITCRASNRIE YGLDWYQQKP GKAPKLLISG SSRLQSGVPS


RFSSSGSGTD FTLTISSLQP EDFATYYCGQ LEAAPATFGQ GTKVEIKR


 


BMS2h-614 (SEQ ID NO: 1129)


DIQMTQSPSS LSASVGDRVT ITCRASRNIG HFLDWYQQKP GKAPKLLILG GSSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LVEPPATFGQ GTKVEIKR


 


BMS2h-615 (SEQ ID NO: 1130)


DIQMTQSPSS LSASVGDRVT ITCRASSSIY SDLYWYQQKP GKAPKLLIDG WSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LHRAPATFGQ GTKVEIKR


 


BMS2h-616 (SEQ ID NO: 1131)


DIQMTQSPSS LSASVGDRVT ITCRASRFIT DRLDWYQQKP GKAPKLLIGG VSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SSELPWTFGQ GTKVEIKR


 


BMS2h-617 (SEQ ID NO: 1132)


DIQMTQSPSS LSASVGDRVT ITCRASRKIG SELYWYQQKP GKAPKLLIGG RSRLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWEPPATFGQ GTKVEIKR


 


BMS2h-618 (SEQ ID NO: 1133)


DIQMTQSPSS LSASVGDRVT ITCRASRNIG NGLDWYQQKP GKAPKLLIGE GSRLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWHTPPTFGQ GTKVEIKR


 


BMS2h-619 (SEQ ID NO: 1134)


DIQMTQSPSS LSASVGDRVT ITCRASRNIY GWLSWYQQKP GKAPRLLIGG WSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCAQ DYTLPGTFGQ GTKVEIKR


 


BMS2h-730 (SEQ ID NO: 1135)


DIQMTQSPSS LSASVGDRVT ITCRASQDIK DWLHWYQQKP GKAPKLLIYF ASGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDSATYYCQQ HYSTPYTSGQ GTKVEIKR


 


BMS2h-731 (SEQ ID NO: 1136)


DIQMTQSPPS LSASVGDRVT ITCRASQLIS SHLDWYQQKP GKAPKLLVYD ASELQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HRSLPFTFGQ GTKVEIKR


 


BMS2h-732 (SEQ ID NO: 1137)


DIQMTQSPSS LSASVGDRVT ITCRASQWIG GALAWYQQKP GKAPRLLIYQ ISVLQSGIPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YIRSPFTFGQ GTKVEIKR


 


BMS2h-733 (SEQ ID NO: 1138)


DIQMTQSPSS LSASVGDRVT ITCRASQSIG AALNWYQQKP GKAPKLLIYG LSSLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LFRLPLTFGQ GTKVEIKR


 


BMS2h-734 (SEQ ID NO: 1139)


DIQMTQSPSS LSASVGDRVT ITCRASQPIG GRLVWYQQKP GKAPKLLIYG SSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YAEAPITFGQ GTKVEIKR


 


BMS2h-735 (SEQ ID NO: 1140)


DIQMTQSPSS LSASVGDRVT ITCRASQNIG SSLIWYQQKP GKAPTLLIYY SSKLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SLSSPYTVGQ GTKVEIKR


 


BMS2h-736 (SEQ ID NO: 1141)


DIQMTQSPSS LSASVGDRVT ITCRASQWIG SELAWYQQKP GKAPKLLIYW TSNLQSGVPS


RFSGSGSGTD FTLTISNLQP EDFATYYCQQ ILETPLTFGQ GTKVEIKR


 


BMS2h-737 (SEQ ID NO: 1142)


DIQMTQSPSS LSASVGDRVT ITCRASQKIW DALYWYQQKP GKAPKLLIYR GSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYRWPHTFGQ GTKVEIKR


 


BMS2h-738 (SEQ ID NO: 1143)


DIQMTQSPSS LSASVGDRVT ITCRASQHIE DSLRWYQQKP GKAPKLLIYY GSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MYKFPITFGQ GTKVEIKR


 


BMS2h-739 (SEQ ID NO: 1144)


DIQTTQSPSS LSASVGDRVT ITCRASQRIN SSLLWYQQKP GKAPKLLIYD TSTLQSGVPS


RFSGSRSGTD FTLTISSLQP EDFATYYCQQ IWGSPPTFGQ GTKVEIKR


 


BMS2h-740 (SEQ ID NO: 1145)


DIQMTQSPSS LSASVGDRVT ITCRASQSIP VGLNWYQQKP GKAPRLLIYS GSTLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ DWYYPNTFGQ GTKVEIKR


 


BMS2h-785 (SEQ ID NO: 1146)


DIQMTQSPSS LSASVGDRVT ITCRASQPIY GWLNWYQQKP GKAPKLLIYL TSGLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ IHSSPFTFGQ GTKVEIKR


 


BMS2h-8 (SEQ ID NO: 1147)


DIQMTQSPSS LSASVGDRVT ITCRASQFID TSLEWYQQKP GKAPKLLIYD GSHLQSGVPS


RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YWVLPLTFGQ GTKVEIKR


 


BMS2h-86 (SEQ ID NO: 1148)


DIQMTQSPSS LSASVGDRVT ITCRASQDIG DALFWYQQKP GKAPKLLIYY SSMLQSGVPS


RFSGGGSGTD FTLTISSLQP EDFATYYCQQ RHSTPATFGQ GTKVEIKR


 


BMS2h-87 (SEQ ID NO: 1149)


DIQMTQSPSS LSASVGDRVT ITCRASQDID ESLMWYQQKP GKAPRLLIYG VSYLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RWKAPFTFGQ GTKVEIKR


 


BMS2h-88 (SEQ ID NO: 1150)


DIQMTQSPSS LSASVGDRVT ITCRASQEIV EDLYWYQQKP GKAAKLLIYG ASWLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TRRRPYTFGQ GTKVEIKR


 


BMS2h-89 (SEQ ID NO: 1151)


DIQMTQSPAS LSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYA GSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLVTPYTFGQ GTKVEIKR


 


BMS2h-90 (SEQ ID NO: 1152)


DIQMTQSPSS LSASVGDRVT ITCRASQSIS DALFWYQQKP GKAPRLLIYY GSVLQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RFQEPVTFGQ GTKVEIKR


 


BMS2h-91 (SEQ ID NO: 1153)


DIQMTQSPSS LSASVGDRVT ITCRASQQIS DELNWYQQKP GKAPKLLIYA VSILQSGVPS


RFSGSGSGTD FTLTISSLQP EDFATYYCQQ WLSFPSTFGQ GTKVEIKR
















TABLE 4





Human Anti-CD40L VK Domain


Encoding Nucleotide Sequences















BMS2h-100 (SEQ ID NO: 1154)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGAGCAAGTCAGAATATTAAGCATTCGTTAC


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATCAT


CGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTAGGCATCGTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-101 (SEQ ID NO: 1155)


GACATCCAGATGACCCAGTCTCCATCCTCTCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTGCTTTGTTTCCCTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-102 (SEQ ID NO: 1156)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCATATTGGTCATCATTTAA


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCCAAGCTCCTGATCTATCAT


AGGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTG


CTACGTACTACTGTCAACAGTGGGATAGGCCGCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-103 (SEQ ID NO: 1157)


GACATCCAGATGACCCAGTCCCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTGCGGGCTGTGCCTTATACGTTTGGCCAA


GGGACCAAGGTGGAAATTAAACGG


 


BMS2h-104 (SEQ ID NO: 1158)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTCGTTTTTCTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-105 (SEQ ID NO: 1159)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTCTTATGCTAGGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-106 (SEQ ID NO: 1160)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAAAGTATTAATCATAGGTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAGGATTTTG


CTACGTACTACTGTCAACAGTATAAGGTTAGGCCTAATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-107 (SEQ ID NO: 1161)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATTTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTATTCGTCTCCTCATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-108 (SEQ ID NO: 1162)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTACAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGAGGGCGGTGAGGCCTTTTACGTTCGGCCAA


GGGACCAAAGTGGAAATCAAACGG


 


BMS2h-109 (SEQ ID NO: 1163)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


CGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTATTATCGTCCTCTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-110 (SEQ ID NO: 1164)


GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAA


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCG


GGTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTAGTATTAGGCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116 (SEQ ID NO: 1165)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-1 (SEQ ID NO: 1166)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATCTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-10 (SEQ ID NO: 1167)


GACATCCAGATAACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATATTGCGAAGTGGAGTCCCATCACGTTTCAGTGGCAGTGGGTC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATCTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-11 (SEQ ID NO: 1168)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTTCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGAGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-12 (SEQ ID NO: 1169)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAACCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCTTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGCGGATC


TGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-13 (SEQ ID NO: 1170)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGTAATCAAACGG


 


BMS2h-116-1312 (SEQ ID NO: 1171)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATCTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCAAA


GGGACCAAGGTGGTAATCAAACGG


 


BMS2h-116-1313 (SEQ ID NO: 1172)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCGA


GGGACCAAGGTGGTAATCAAACGG


 


BMS2h-116-1314 (SEQ ID NO: 1173)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGAGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCGGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGTGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGTAATCAAACGG


 


BMS2h-116-1319 (SEQ ID NO: 1174)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTATGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-1320 (SEQ ID NO: 1175)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATATGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACCCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTAAGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGTGATCAAACGG


 


BMS2h-116-138 (SEQ ID NO: 1176)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGTAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTAGTAATCAAACGG


 


BMS2h-116-14 (SEQ ID NO: 1177)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTTCCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-15 (SEQ ID NO: 1178)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATCGGTCCTGATTTAC


TGTGGTACCGGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-16 (SEQ ID NO: 1179)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGACTTAC


TGTGGTACCAGCAGAAACCAGGTAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGTTTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCATTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-17 (SEQ ID NO: 1180)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCAGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-2 (SEQ ID NO: 1181)


GACATCCAGATGACCCAGTCTCCATCATCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGAACCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTCTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-3 (SEQ ID NO: 1182)


GACATCCAGATGACCCAGTCACCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCTAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGCGGCAGTGAATC


CGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATATTG


CAACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAGGGTGGAAATCAAACGG


 


BMS2h-116-4 (SEQ ID NO: 1183)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCTTCACGTTTCAGTGGCAGTGAATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-5 (SEQ ID NO: 1184)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCGCCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGTCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-6 (SEQ ID NO: 1185)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCGTCACGTTTCAGTGGCAGTGGATC


TGTGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGGAATCAAGCGG


 


BMS2h-116-7 (SEQ ID NO: 1186)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TAGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-8 (SEQ ID NO: 1187)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAGCAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-116-9 (SEQ ID NO: 1188)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTATGCCTATTGGTCCTGATTTAC


TGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATCAG


ACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-141 (SEQ ID NO: 1189)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATACGTTAA


CGTGGTACCAGCAGAAACTAGGGAAAGCCCCTAAGCTCCTGATCTATGGT


GGTTCCGAGTTGCAAAGTGGGGTCCCACCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTGTATTAGTAGTCCTTGTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-142 (SEQ ID NO: 1190)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTAT


CTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTT


TCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATACTTCGCCTACTACGTTCGGCCGA


GGGACCAAGGTGAAAATCAAACGG


 


BMS2h-143 (SEQ ID NO: 1191)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


TCTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTAG


CTACGTACTACTGTCAACAGTATCATGGGTATCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-144 (SEQ ID NO: 1192)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGATGATTGATCAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


GCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGCGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATGGTTATCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-145 (SEQ ID NO: 1193)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGACGATTTATACTTCGTTAA


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATTAT


GGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTG


CTACGTACTACTGTCAACAGGTTCATCAGGCTCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-146 (SEQ ID NO: 1194)


GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCTTTAG


CGTGGTACCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTATGGT


ATTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTG


CTACGTACTACTGTCAACTGTCTAGTAGTATGCCTCATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-147 (SEQ ID NO: 1195)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGAGATTGAGACGAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


TCGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATCAGAATCCTCCGACGTTCGGCCAA


GGAACCAAGGTGGAAATCAAACGG


 


BMS2h-149 (SEQ ID NO: 1196)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGAGGCAGTTAG


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


GCGACCGAGTTGCAAAGTGGGGTCCCATCACGTTTTAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCAGTCGAAGGGTCCTCTTACGTTCGGCCAT


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-150 (SEQ ID NO: 1197)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGGGATTGGTACTGATTTAA


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATATG


GGTTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATTTATTCTTTTCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-154 (SEQ ID NO: 1198)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGAGATGTTAC


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTT


GGTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTAGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCATCATACTCGTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-155 (SEQ ID NO: 1199)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGATGGATTTAG


AGTGGTACCAGCAGATACCAGGGAAAGTCCCTAAGCTCCTGATCTATGAT


GCGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAAGCTTCCTGCGACGTTTGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-156 (SEQ ID NO: 1200)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTATGGATAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCG


GCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAAGTTGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-157 (SEQ ID NO: 1201)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGAGCAAGTCAGAATATTGGGGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAATGCCCCTAAGCTCCTGATCTATAGT


GCGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTCTAGTTATCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-158 (SEQ ID NO: 1202)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCCGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCGATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAATGCCCCTAAGCTCCTGATCTATAGT


GCGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGACTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATCTTCTGCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-159 (SEQ ID NO: 1203)


GACATCCAGATGATCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTAATGAGGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTAAAGATTTTG


CTACGTACTACTGTCAACAGTATCATACTAATCCTACTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-160 (SEQ ID NO: 1204)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


TCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGAAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATATGTCGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-161 (SEQ ID NO: 1205)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATAGTGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTATGCTCCTGATCTATTCT


TCGTCCGATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAGTCTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-162 (SEQ ID NO: 1206)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTTCGGATGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


TCGTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGGCAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAGTTTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-163 (SEQ ID NO: 1207)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGGTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


TCGTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGGTC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATCATCTTCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-164 (SEQ ID NO: 1208)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATACGGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCGGTGGATTCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-165 (SEQ ID NO: 1209)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTAGTACTGATTTAG


AGTGGTACCAGCAGAAACTAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GCTTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTCGAGTCTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-166 (SEQ ID NO: 1210)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTACGACGTCTTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GCGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTGGGTTACGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-167 (SEQ ID NO: 1211)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACCTGCCGGGCAAGTCAGAATATTCATACGAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTCGGCTAATCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGGAATCAAACGG


 


BMS2h-168 (SEQ ID NO: 1212)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTCATACGGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAGTGTGTCGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-169 (SEQ ID NO: 1213)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATAATAATTTAG


AGTGGTACCAGCAGAAACCAGGGGAAGCCCCTAAGCTCCTGATCTATGAT


GGGTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATCTTCATCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-170 (SEQ ID NO: 1214)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATACGAATTTAG


AGTGGTATCAGCAGAAACCAGGGGAAGCCCCTAAGCTCCTGATCTATGAT


CGTTCCACGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATTCTTATCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-171 (SEQ ID NO: 1215)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTCTATTGAGTCTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


GCGTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATCAGTGGCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-172 (SEQ ID NO: 1216)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACTATCACTTGCCGGGCAAGTCAGGCTATTGGTAATACTTTAC


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCTT


AGTTCCAGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCTGAAGAAGCCTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-173 (SEQ ID NO: 1217)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTAAGAATCGGTTAG


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAG


GTTTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCGGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGAGGAGGCAGTCGCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-174 (SEQ ID NO: 1218)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTGAGGATATTGGGGAGGAGTTAT


TTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCG


GCGTCCACGTTGCAAAGTGAGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACATGAAGATTTTG


CTACGTACTACTGTCAACAGGTTTATGAGTGGCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-175 (SEQ ID NO: 1219)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTTCTGGGGGTTTAA


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCT


ACTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCTTTATTCTGCTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-305(SEQ ID NO: 1220)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


GTTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTCTATGAATCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-306 (SEQ ID NO: 1221)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGAATCAGTTAA


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


GCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATTTGAGGCCTCAGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-307 (SEQ ID NO: 1222)


GACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGTGA


CCGTGTCACCATCACTTGCCGGGCGAGTCAGAAGATTTCTACGTCTTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGAT


TCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGAGTATAATCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-33 (SEQ ID NO: 1223)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGACGATTGGGGAGAGTTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTTT


GCTTCCCTGTTGCAAAGTGGGGTCCCATCGCGTTTCAGTGGCAGTGGATC


TGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCATCATATGCTTCCTTCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-35 (SEQ ID NO: 1224)


GACATCCAAATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTAT


CTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTT


TCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATATGGATATTCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-36 (SEQ ID NO: 1225)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCATAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


AGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATTCTATTCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-37 (SEQ ID NO: 1226)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAGTTTGCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-38 (SEQ ID NO: 1227)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGTAATAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATCAT


GGGTCCTGGTTGCAAAGTGGGGTCCCATCGCGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATTTTAATCCTACTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-39 (SEQ ID NO: 1228)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CTGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGATGGTCTGTTAT


GGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCG


GGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGAAGGCTTTTGAGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-405 (SEQ ID NO: 1229)


GACATCCAGATGACCCAGACTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGTCATGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAT


GTGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAGTCATAATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-406 (SEQ ID NO: 1230)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACTATCACTTGCCGGGCAAGTCAGCATATTGAGAATGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCT


GCTTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATCTTCAGCCTACGACGTTCGGCCCA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-431 (SEQ ID NO: 1231)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACTATCACTTGCCGGGCAAGTCAGGTTATTGAGGGTAGTTTAA


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


AGGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCCGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTATCAGCTTCCTTTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-432 (SEQ ID NO: 1232)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGTCCTATTAATGGTAAGTTAT


TTTGGTACCAGCAGAAACCAGGCAAAGCCCCTAAGCTCCTGATCGCGTTT


GCTTCCGCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGTGCAGCAGGCTGTGTATCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-433 (SEQ ID NO: 1233)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGAGACGAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGGTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGAGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATTATCAGCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-434 (SEQ ID NO: 1234)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGCATGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCG


GCGTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCAGCAGCAGCCTACTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-435 (SEQ ID NO: 1235)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCGCAGATTGAGGAGTCTTTAT


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGAT


GTTTCCCTGTTGCAAAGTGGAGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCTCAGGGTGTGGTGGAGCCTCGTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-436 (SEQ ID NO: 1236)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTATATTGGTCTGGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


GCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTTCGGCAGCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-437 (SEQ ID NO: 1237)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-437-1 (SEQ ID NO: 1238)


GACATCCAGTTGACCCAGTCTCCAACCTCCCTGTCTGCAACTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAG


ATTGGTACCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGTGCGTCATCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAGCGG


 


BMS2h-437-2 (SEQ ID NO: 1239)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGACAGCATGTGCGTCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGGAATCAAACGG


 


BMS2h-437-3 (SEQ ID NO: 1240)


GACATCCAGATGACCCAGTCTCCGTCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGTAAGTACGCCGATTGGTACTATGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCACCACGTTTCAGTGGCAGCGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-437-4 (SEQ ID NO: 1241)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCTGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-437-5 (SEQ ID NO: 1242)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGATAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCAT


TCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCAAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-438 (SEQ ID NO: 1243)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGAT


GGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCATCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCAGGTTGTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-439 (SEQ ID NO: 1244)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAA


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGTGGAT


TCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGGATCGTTGGTCTCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-440 (SEQ ID NO: 1245)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCGCGGATTCAGCATATGTTAT


CTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGG


CATTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCGCAATCGTGTGCGTGGCCTCTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-441 (SEQ ID NO: 1246)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGGGTATTGATGGTGATTTAT


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGAT


TCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGGGGGCTGTTCGGCCTATGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-442 (SEQ ID NO: 1247)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGGGTATTGATACTGATTTAT


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGAT


TCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGGGGGCTGTTCGGCCTATGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-443 (SEQ ID NO: 1248)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTATACTATTCCGGTTGCTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCTGAT


GCGTCCTTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCGCAGGGTTGGCCGGGGCCTCAGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-444 (SEQ ID NO: 1249)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGCGACGGACTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


ACTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAGTTATAATCCTTCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-445 (SEQ ID NO: 1250)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTGTGCCTATTACTGAGGGTTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCAGGCT


AATTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGGAGCATGTTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-446 (SEQ ID NO: 1251)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGTATGATTCTTTATGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGT


ACTTCCGCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGGAGACGGTTCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-447 (SEQ ID NO: 1252)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTAATGGGCTTTTAA


TTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCG


ATGTCCAGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTTGGCTCGGATTCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGGAATCAAACGG


 


BMS2h-448 (SEQ ID NO: 1253)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGAGCAAGTCAGCTGATTCGGACTTATTTAG


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG


TCTTCTCAGTTGCAAAGTGGTGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAATTCTTATCCTGATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-47 (SEQ ID NO: 1254)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCGTTAA


GTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTT


GGTTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTGCATACTCCTTCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-484 (SEQ ID NO: 1255)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAT


TCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGGTTTTAATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-485 (SEQ ID NO: 1256)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCTCCTATTGAGTATGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGGG


GGGTCCGCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGGAGGTTCAGCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-486 (SEQ ID NO: 1257)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCGGATTGATACTGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


AGTTCACAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATCATAGTGCGCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-487 (SEQ ID NO: 1258)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTGGGTGGATTGGTATGTCTTTAG


AGTGGCACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCGTGGG


GCTTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTAGTCAGTCTCGGTGGCCGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-488 (SEQ ID NO: 1259)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGTAATATTTCGAATGCTTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGGG


GCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTACTCAGGTGTGGGATAGGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-489 (SEQ ID NO: 1260)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTATGTCGGCTTTAT


CTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCT


ACTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTTATTTGCTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-490 (SEQ ID NO: 1261)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGAGATTGGGATTGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


GCTTCTTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTAGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGCTTCTAATCCTCCTACGTTCGGCCGA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-491 (SEQ ID NO: 1262)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGATGATTGGGGATTGGTTAA


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATCGT


AGTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTTGTATTTTTGGCCTCGTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492 (SEQ ID NO: 1263)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGCTTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-1 (SEQ ID NO: 1264)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCCAGTCAGGCGATTGAGCATAATTTAG


AGTGGTACCAGCAGAAGCCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTCCAACCTGAAGATTTAG


CTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTACGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-2 (SEQ ID NO: 1265)


GACATCCAGATGACACAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGGCGATAGAGACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGTTCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCGGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCTACAGTATGATGTTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-3 (SEQ ID NO: 1266)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAACTGTAGGAGA


CCGTGTCACCATCACTTGTCGTGCAAGTCAGGCGATTGAGACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGACTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-4 (SEQ ID NO: 1267)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGCATAACTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGAGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-5 (SEQ ID NO: 1268)


GACATCCAGATGAACCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCTCCATCACTTGCAGGGCAAGTCAGGCTATTGAGCATAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGCTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-6 (SEQ ID NO: 1269)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGTCTAATTTAG


AGTGGTACCAGCAAAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-492-7 (SEQ ID NO: 1270)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGTGCAAGTCAGGCGATTGAGCATAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGAT


GCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-493 (SEQ ID NO: 1271)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGGTATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494 (SEQ ID NO: 1272)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-1 (SEQ ID NO: 1273)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCAGGGCAAGTCAGAGTATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-2 (SEQ ID NO: 1274)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGAAGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGGAGTGGCTC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAT


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-3 (SEQ ID NO: 1275)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTTCTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-4 (SEQ ID NO: 1276)


GAGATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATGACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGAGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTGGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-5 (SEQ ID NO: 1277)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGAGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCTGAAGATATCG


CTACGTACTACTGTAAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-494-6 (SEQ ID NO: 1278)


GACATCCAGATGACCCAGTCCCCACCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


AGTTCCTGGTTGCAAAGAGGGGTCCCATCACGTTTCAGTGGGAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACCACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-495 (SEQ ID NO: 1279)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTGAGTATATTAATGCTGAGTTAG


CTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


AGTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCTGCAGAATGCGATGTGGCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-496 (SEQ ID NO: 1280)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCTGGATATTAATAATGGTTTAA


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTTGGGT


GCGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTTCGCAGGTGCGTTCTCGGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-497 (SEQ ID NO: 1281)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTCTGAGTGCGTTAG


CTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


AGTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


AGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGAATTATAGTCTTCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-498 (SEQ ID NO: 1282)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCTCCTATTGAGTCGTATTTAA


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCAGGTAT


GTGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGTTTCGGGCGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-499 (SEQ ID NO: 1283)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGTAAGTGAGTCTATTAATGCTGAGTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGG


TTTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGTGCAGTTTGCGATGTGGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-500 (SEQ ID NO: 1284)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTATGATGATTAGGTTTGGGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGT


GGGTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCATGAGCGGTGGCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-501 (SEQ ID NO: 1285)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGTACTCTTTTAC


GTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCTT


ACTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATGGTTTATCGTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-502 (SEQ ID NO: 1286)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


TCTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGATAAGGTTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-503 (SEQ ID NO: 1287)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGG


GGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-503-1 (SEQ ID NO: 1288)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGG


GGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-503-2 (SEQ ID NO: 1289)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCATGATATTCAGAGGTATTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGG


GGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-504 (SEQ ID NO: 1290)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGGGGGCTGTTGTGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-508 (SEQ ID NO: 1291)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGCTTTTGATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCG


GCGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGTCAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAATCTTCAGCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-509 (SEQ ID NO: 1292)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGCTACGCTGTTAC


GTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


GGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATGTGGCAGCGTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-51 (SEQ ID NO: 1293)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGTTGATGAGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


GCGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCATCAGTGGTCTACTTATCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATTAAACGG


 


BMS2h-510 (SEQ ID NO: 1294)


GACATCCAGATGACCCAATCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAA


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTAATCGATGGT


GTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGGATTGGGATTGGCCTCGTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-511 (SEQ ID NO: 1295)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTAC


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATTGG


GGGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCTCAGACGTGGGATGATCCTCTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-511-1 (SEQ ID NO: 1296)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATTTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTAC


GGTGGTACCAACAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATTGG


GGGTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCTCAGACGTGGTATGATCCTCTGACGTTCGGCCAC


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-512 (SEQ ID NO: 1297)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTATTGATATTCATGGTGGTTTAA


CTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGTGGGG


GTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCGCAGGTGTGGCGTAGGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-513 (SEQ ID NO: 1298)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGAGTTCGTTAT


CTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


TCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTATGCTCTTCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-514 (SEQ ID NO: 1299)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATAAGTATCTGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-52 (SEQ ID NO: 1300)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGTGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGTCTGCGTTAA


GGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTG


GGTTCCGATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACGCAGTATTTTCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-53 (SEQ ID NO: 1301)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTTATGGGGGGTTAC


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


GAGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCATCCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTTATCATAAGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-536 (SEQ ID NO: 1302)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACGTGCCGGGCAAGTCAGCGTATTGGGGTGTGGTTAG


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGTTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTTTTCGAGTCCTTCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-537 (SEQ ID NO: 1303)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCCCCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATGAGTTAT


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAGT


TCTTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTCGTTTCAGTTTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-538 (SEQ ID NO: 1304)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGTAATATTACGGGGCCGTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCTGGT


TGGTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGGTGTGGGGGGAGCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-539 (SEQ ID NO: 1305)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCGTCTATAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCGTATTGCTTATGGTTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGGGGG


CGGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGTGCAGCCTGGGATGCCGCCTGATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-540 (SEQ ID NO: 1306)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAAGCAGATTGTTGGTGGTTTAT


CTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCGT


CATTCTGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGTGCAGGGGGTTTGGGCTCCTGGGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-541 (SEQ ID NO: 1307)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCCTGCTATTGCTGCTAAGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGCG


GATTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGCTGTGGGCGGGGCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-542 (SEQ ID NO: 1308)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGTACTATTGCTGATGGGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGCG


TATTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGCTTTGGGAGGGTCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-543 (SEQ ID NO: 1309)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGGATTTATGGGTTTTTAG


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


GTGTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTTAGTGGCAGCGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACTTTGGCGTGGCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-544 (SEQ ID NO: 1310)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTCGGGATTGGTTAA


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTGG


GGTTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCTGTATGATACTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-545 (SEQ ID NO: 1311)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTAATACGGGTTTAG


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


AGTTCCGCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACGTCGTATTATCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-546 (SEQ ID NO: 1312)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTTTTGGTTGGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


ACTTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGTTTATTCGCTTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-547 (SEQ ID NO: 1313)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCGAATATTGGGGCGGATTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGGG


GCGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTGTGGAATGGGCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-548 (SEQ ID NO: 1314)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGTCCGATTTATGATGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGT


GCTTCCTGGTTGCAAAGTGGGGTCCCATCACGCTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGTTGTGGTTGGGTCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACAG


 


BMS2h-549 (SEQ ID NO: 1315)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCGCGTATTTATAATGGTTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGT


CGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCTCAGGTGGGGGAGGCTCCTTCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-550 (SEQ ID NO: 1316)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGTTTATTAATGAGGAGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCGTGG


TCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGTGCAGCCGGGGGGTGGTCCTGGGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-551 (SEQ ID NO: 1317)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGGATATTCTGGATGAGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGG


GGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGCTGTGGCATGGGCCTCCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-552 (SEQ ID NO: 1318)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGTCCTATTTATACGGGTTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGG


CGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTATGCAGGTTGGGACGGCTCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-585 (SEQ ID NO: 1319)


GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTTCTAGGCGGTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCT


TCTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCGGTGGCAGTGGATC


TGGGACGGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACGTATAGCTATCCTCATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-604 (SEQ ID NO: 1320)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGTCCGATTCCGCAGGATTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGTTGGG


ATTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTTGTGGAGTGCGCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-605 (SEQ ID NO: 1321)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAAGTCTATTGATGGGATGTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCTGGT


TTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTCGGTTGAGGCGCCTTGGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-606 (SEQ ID NO: 1322)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGTATATTGCTCATCCTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCGGGT


TCGTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGTCAGTCGGTTGTGGTGCCTTGGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-607 (SEQ ID NO: 1323)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGACGATTGAGGGTGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCATGGGG


GGTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTTGTGGGTGGGTCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-608 (SEQ ID NO: 1324)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAAGTTTATTAGGGATGAGTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGT


TCGTCCTTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTGTGGCGGGCGCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-609 (SEQ ID NO: 1325)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAAGCCGATTTATGGTGGTTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGGGGG


GGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGGTGTGGGGGGGTCCTGTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-610 (SEQ ID NO: 1326)


GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGCCGATTAGTGGTTGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATGGG


GCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTGGTGGGAGTATCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-611 (SEQ ID NO: 1327)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAAGCCTATTGTGAGGGATTTAG


AGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATGGT


GTGTCCACGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTTGAGGCGGCGCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-612 (SEQ ID NO: 1328)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGGATATTGGTGATTGGTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGTTTGG


GCGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCGCAGTGGGGGACTCCTCCTACGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-613 (SEQ ID NO: 1329)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAATCGTATTGAGTATGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCGGGG


TCTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTAGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTTGAGGCGGCGCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-614 (SEQ ID NO: 1330)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGAATATTGGGCATTTTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTGGGG


GGGTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGCGGGTC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTTGGTGGAGCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-615 (SEQ ID NO: 1331)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTTCGAGTATTTATAGTGATTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATGGG


TGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTGCATCGTGCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-616 (SEQ ID NO: 1332)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGTTTATTACTGATCGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGT


GTTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGAGTTCGGAGTTGCCTTGGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-617 (SEQ ID NO: 1333)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGTAAGATTGGTAGTGAGTTAT


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGT


AGGTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGTTGTGGGAGCCTCCTGCGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-618 (SEQ ID NO: 1334)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTGGTAATGGTTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGAG


GGGTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGGGCAGCTTTGGCATACTCCTCCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-619 (SEQ ID NO: 1335)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCGGAATATTTATGGTTGGTTAT


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGG


TGGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTGCGCAGGATTATACGTTGCCTGGTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-730 (SEQ ID NO: 1336)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTAAGGATTGGTTAC


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTT


GCGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTG


CTACGTACTACTGTCAACAGCATTATAGTACGCCTTATACGTCCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-731 (SEQ ID NO: 1337)


GACATCCAGATGACCCAGTCTCCACCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTTGATTTCTTCTCATTTAG


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGGTCTATGAT


GCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCATCGCAGTCTGCCTTTTACGTTCGGCCAA


GGGACCAAGGTAGAAATCAAACGG


 


BMS2h-732 (SEQ ID NO: 1338)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGTGGGGCGTTAG


CGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTTATCTATCAG


ATTTCCGTTTTGCAAAGTGGGATCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATATTCGGTCTCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-733 (SEQ ID NO: 1339)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGGGCGGCGTTAA


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGT


CTGTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCTGTTTAGGCTTCCTTTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-734 (SEQ ID NO: 1340)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGGGGTCGTTTAG


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGG


TCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTATGCTGAGGCTCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-735 (SEQ ID NO: 1341)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGGGTCTAGTTTAA


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTACGCTCCTGATCTATTAT


TCGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTCTTTGTCGAGTCCTTATACGGTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-736 (SEQ ID NO: 1342)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGAGTGAGTTAG


CGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTGG


ACGTCCAATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATTCTGGAGACTCCTTTGACGTTTGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-737 (SEQ ID NO: 1343)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTTGGGATGCTTTAT


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCGT


GGGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTTTTATCGGTGGCCTCATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-738 (SEQ ID NO: 1344)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCATATTGAGGATTCTTTAC


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTAT


GGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATGTATAAGTTTCCTATTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-739 (SEQ ID NO: 1345)


GACATCCAGACGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCGGATTAATTCTTCTTTAC


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


ACTTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTAGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTCG


CTACGTACTACTGTCAACAGATTTGGGGTTCGCCTCCTACGTTCGGCCAG


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-740 (SEQ ID NO: 1346)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTCGATTCCTGTTGGTTTAA


ATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCT


GGGTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGGATTGGTATTATCCTAATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-785 (SEQ ID NO: 1347)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTTATGGTTGGTTAA


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTG


ACGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGATTCATAGTTCTCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-8 (SEQ ID NO: 1348)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGATACGTCGTTAG


AGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAT


GGGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTAG


CTACGTACTACTGTCAACAGTATTGGGTTCTTCCTCTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-86 (SEQ ID NO: 1349)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGGATGCTTTAT


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTAT


TCTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCGGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCGGCATAGTACTCCTGCTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-87 (SEQ ID NO: 1350)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATGAGTCTTTAA


TGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGGG


GTGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTCG


CTACGTACTACTGTCAACAGCGGTGGAAGGCTCCTTTTACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-88 (SEQ ID NO: 1351)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTTACCATCACTTGCCGGGCAAGTCAGGAGATTGTGGAGGATTTAT


ATTGGTATCAGCAGAAACCAGGGAAAGCCGCTAAGCTCCTGATCTATGGT


GCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACGCGTAGGCGTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-89 (SEQ ID NO: 1352)


GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAA


GGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCG


GGTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGACGCTGGTGACTCCTTATACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-90 (SEQ ID NO: 1353)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGTCGATTTCGGATGCGTTAT


TTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTAT


GGTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGCGTTTTCAGGAGCCTGTGACGTTCGGCCAA


GGGACCAAGGTGGAAATCAAACGG


 


BMS2h-91 (SEQ ID NO: 1354)


GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGA


CCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTAGTGATGAGTTAA


ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT


GTGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC


TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTG


CTACGTACTACTGTCAACAGTGGTTGAGTTTTCCTTCGACGTTTGGCCAA


GGGACCAAGGTGGAAATCAAACGG









Example 1
Generation of Human Anti-CD40L Variable Domains BMS2h-2 Through BMS2h-785
The following example describes the generation of the 2h lineage of anti-human CD40L variable domains, designated BMS2h-2 through BMS2h-785. Following recombinant expression of a repertoire of single immunoglobulin variable domains on the surface of phage, selection is performed by contacting the phage repertoire with immobilized target antigen, washing to remove unbound phage, and propagating the bound phage. This process is frequently referred to as “panning.” It is applicable to the screening of single immunoglobulin variable domains, as well as other antibody fragments that can be expressed on a display library, e.g., scFv, Fab, and Fab′. Alternatively, phage may be pre-selected for the expression of properly folded member variants by panning against an immobilized generic ligand (e.g., protein A or protein L) that is only bound by folded members. This has the advantage of reducing the proportion of non-functional members, thereby increasing the proportion of members likely to bind a target antigen. Pre-selection with generic ligands is taught in WO 99/20749, for example. The screening of phage antibody libraries is generally described, for example, by Harrison et al., Meth. Enzymol. 267: 83-109 (1996).
Screening is commonly performed using purified antigen immobilized on a solid support, for example, plastic tubes or wells, or on a chromatography matrix, for example SepharoseTM (Pharmacia). Screening or selection can also be performed on complex antigens, such as the surface of cells (Marks et al., BioTechnology 11: 1145 (1993); de Kruif et al., Proc. Natl. Acad. Sci. USA 92: 3938 (1995)). Another alternative involves selection by binding biotinylated antigen in solution, followed by capture on streptavidin-coated beads.
dAb Selection for Clone BMS2h-719 and BMS2h-7xx Series:
Three rounds of selection using decreasing concentrations of antigen (500 nM at round 1; 50 nM at round 2; 50 nM or 5 nM at round 3 depending on the library output used) were performed in parallel against biotinylated (1.2 moles biotin/mole CD40L) human CD40L monomer triple mutant (T211E, S222Y, H224K, [108-261] Construct #7) provided by Bristol-Myers Squibb. Phage from the naïve 4G and 6G Domantis dAb libraries were combined into the pools a) to g) indicated below before initiating selections:
a) 4G VH CDR3 lengths between 7-10 amino acids.
b) 4G VH CDR3 lengths between 11-15 amino acids.
c) 4G VH CDR3 lengths between 7-15 amino acids.
d) 4G VK
e) 6G VH CDR3 lengths between 7-9
f) 6G VH CDR3 lengths between 10-15
g) 6G VK
Each round of selection involved adding the desired concentration of biotinylated CD40L to a mixture of 200 μl of phage (from one of the naïve library pools indicated above, or subsequent selection output phage) and 1000 μl of 2% MPBS (Phosphate Buffered Saline) containing 2% (w/v) Marvel [Premier Foods, UK]) and incubating at room temperature for 1 hour by mixing end-over-end. The biotinylated antigen phage complex was then captured by adding 100 μl of resuspended Dynabeads M-280 Streptavidin [Invitrogen, UK] and incubated for 5 minutes with mixing end-over-end at room temperature. The Dynabeads were then recovered using a KingFisher magnetic separator [Thermo Fisher Scientific, UK] and washed 7×1 ml PBST (PBS containing 0.1% (v/v) polyoxyethylenesorbitan 20 monolaurate [Sigma-Aldrich, UK]) followed by 1×1 ml PBS. Bound phage retained on the washed Dynabeads were eluted by incubation with 500 μl of trypsin-PBS (50 μl of 10 mg/ml trypsin [Sigma-Aldrich, UK] dissolved in 50 mM Tris-HCl pH 7.4, 1 mM CaCl2 added to 450 μl PBS). The phage-containing solution was recovered and 250 μl used to infect 1.75 ml of logarithmic growth phase E. coli TG1 (at an OD600 of 0.4) for 30 minutes at 37° C. The E. coli TG1 phage infected culture was centrifuged at 11,600 g in a micro centrifuge for 1 minute and the resulting cell pellet resuspended in 1 ml 2×TY (16 g Tryptone, 10 g Yeast Extract and 5 g NaCl in 1 liter, autoclaved for 15 minutes at 121° C.) and plated onto a 9 cm Petri dish containing TYE media supplemented with 15 μg/ml tetracycline. The plates were incubated overnight at 37° C. then 2 ml of 2×TY supplemented with 15% glycerol was added to each plate and cells loosened with a glass spreader and mixed thoroughly. Fifty microliters of the scraped bacteria was used to inoculate 50 ml of 2×TY supplemented with 15 μg/ml tetracycline and grown overnight at 37° C. with shaking at 250 rpm. The overnight culture was centrifuged at 3,300 g for 15 min to pellet the bacteria. To precipitate phage, 10 ml PEG/NaCl (20% Polyethylene glycol 8000, 2.5 M NaCl) was added to 40 ml supernatant. The phage/PEG solution was mixed and left on ice for 1 h, then spun at 3,300 g for 30 min at 4° C. and the supernatant discarded. The pellet was resuspended in 2 ml PBS and spun at 11,600 g for 10 min in a micro centrifuge to remove the remaining bacterial debris. The resultant supernatant containing phage was then used for the next round of selection against the appropriate concentration of biotinylated CD40L monomer triple mutant antigen.
Phage ELISA
Monoclonal phage ELISAs were carried out following selection rounds 2 and 3. All washes were performed using 3 washes of 250 μl PBST followed by 3 washes of 250 μl PBS. The plates were coated overnight at 4° C. with 50 μl/well of 1 μg/ml NeutrAvidin [Thermo Scientific, UK] in 0.2M carbonate-bicarbonate buffer, pH 9.4. The plates were washed and then blocked with 2% MPBS for 1 hour at room temperature. The plates were then washed and incubated with 50 μl/well of  ̃1.0 μg/ml biotinylated human CD40L monomer triple mutant in 2% MPBS. The plates were washed and 25 μl/well phage supernatants added to an equal volume of 2% MPBS and incubated for 1 hour at room temperature. The plates were washed and bound phage detected with 50 μl/well anti-M13-HRP conjugate [GE Healthcare, UK] diluted 1:5000 in 2% MPBS and incubated for 1 hour at room temperature. The plates were washed and the ELISA developed using 50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution [KPL Inc, USA]. The colorimetric reaction was stopped by the addition of an equal volume of 1 M HCl and the ELISA plate read at 450 nm. Specific phage were identified by comparison to wells coated with NeutrAvidin but without biotinylated CD40L monomer triple mutant.
Recovery of dAb Genes from MidiPrep pDOM4 Plasmid
The dAb V-genes from the following round 3 outputs were recovered by DNA restriction enzyme digestion of the phage vector pDOM4:
a) 4G VH CDR3 lengths between 7-10 amino acids (50 nM antigen concentration).
b) 4G VH CDR3 lengths between 11-15 amino acids (50 nM antigen concentration).
c) 4G VH CDR3 lengths between 11-15 amino acids (5 nM antigen concentration).
d) 4G VH CDR3 lengths between 7-15 amino acids (50 nM antigen concentration).
e) 4G VK (50 nM antigen concentration).
f) 4G VK (5 nM antigen concentration).
g) 6G VH CDR3 lengths between 7-9 (50 nM antigen concentration).
h) 6G VH CDR3 lengths between 10-15 (5 nM antigen concentration).
Approximately 20 μg of MidiPrep [Qiagen, UK] DNA was digested with SalI and NotI as follows: 20 μl DNA ( ̃1 μg/μl) was mixed with 1.5 μl SalI (20 U/μl) [NEB, UK] and 3 μl Nod (10 U/μl) [NEB, UK], 4 μl Buffer 3 [NEB, UK], 0.4 μl BSA (10 mg/ml) [NEB, UK] and tissue culture grade water [Sigma, UK] added to 40 μl. Samples were incubated for 5 hours at 37° C. in an air incubator following which the digested dAb genes were isolated by running the digestion mix on a 2% agarose gel [E-gel, Invitrogen, UK], the appropriate DNA bands excised and cleaned using a PCR purification kit [Qiagen, UK]. The purified V-genes were ligated into a SalI and NotI double digested pDOM5 expression vector.
Soluble dAb ELISA
Binding dAbs were identified as follows. Ninety-six individual colonies containing dAb V-genes cloned into the soluble dAb expression vector pDOM5 were picked from each output into 200 μl Terrific Broth containing OnEx Autoinduction media [Novagen, UK] and incubated overnight at 37° C. with shaking at 250 rpm in Costar 96 Well Cell Culture Clusters [Corning Incorporated, USA] sealed with a gas permeable adhesive plastic strip. The cultures were centrifuged to pellet the cells and the supernatants assayed by antigen binding ELISA for dAbs that bound to CD40L monomer triple mutant and IZ-CD40L mutant (CD40L containing an isoleucine zipper trimerization domain, supplied by Bristol-Myers Squibb). MaxiSorp 96 well immunoplates [Nunc, USA] were coated overnight at 4° C. with 50 μl/well of 1 μg/ml NeutrAvidin in 0.2 M carbonate-bicarbonate buffer, pH 9.4. All washes were as described for the phage ELISA. The plates were blocked for 1 hour at room temperature with 200 μl of PBS containing 1% Tween 20. The plate was then washed and incubated for 1 hour at room temperature with 50 μl/well of 1 μg/ml biotinylated human CD40L monomer triple mutant in PBST or 1 μg/ml biotinylated human IZ-CD40L mutant in PBST (both antigens supplied by Bristol-Myers Squibb). The ELISA plate was washed and dAb-containing culture supernatant clarified by centrifugation at 1,800 g for 10 min at 4° C., then added to the ELISA plate (30 μl/well) to which was added an equal volume of PBST. The plates were incubated for 1 hour at room temperature and then washed. Bound dAb was detected by adding 50 μl/well 9E10 [anti-myc IgG, Sigma-Aldrich, UK] diluted 1:2000 in PBST and incubating for 1 hour at room temperature; the ELISA plate was then washed and 50 μl/well anti-mouse Fc-HRP [Sigma-Aldrich, UK] diluted 1:2000 in PBST added and incubated for 1 hour at room temperature. The plates were washed and the ELISA developed by adding 50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution [KPL Inc, USA] and the colour allowed to develop. The colourimetric reaction was stopped by the addition of an equal volume of 1 M HCl and the ELISA plate read at 450 nm. Antigen binding dAbs were identified by comparison of the signal intensity from human CD40L monomer triple mutant and human IZ-CD40L mutant wells with control wells not containing antigen.
Expression & Purification of dAb at 50 ml Scale
Unique dAbs were identified by DNA sequencing ELISA positive clones. The unique dAbs identified were expressed as follows in 250 ml baffled flasks, to which was added:
a) 50 ml of Terrific Broth [Sigma-Aldrich, UK].
b) 100 μg/ml carbenicillin [Sigma-Aldrich, UK].
c) 1 drop of antifoam A204 [Sigma-Aldrich, UK].
d) Novagen Overnight Express Autoinduction Kit [Novagen, UK].
A bacterial scrape from a fresh confluent 9 cm diameter agar plate or from a glycerol stock of the desired dAb clone was used to inoculate the Terrific Broth, then the flask sealed with Milliwrap PTFE membrane [Millipore, UK], and incubated for 48 hrs, 250 rpm shaking at 30° C. The bacterial overnight culture was clarified by centrifugation and the VH or VK dAb purified using Streamline Protein A [GE Healthcare, UK] or Protein L agarose [generated in-house] respectively. The resulting purified proteins were assayed by RBA to determine which clones could inhibit the binding of CD40L for CD40.
CD40L Bead Receptor Binding Assay
Inhibitory dAbs were initially identified by screening purified dAb in a CD40L bead receptor binding assay (RBA). Sphero streptavidin polystyrene beads (0.5% w/v, 6.7 μm diameter) [Saxon, Europe] were prepared and washed according to the manufacturer's instructions. The beads were then pelleted at 11,600 g for 1 minute, the supernatant discarded and the beads resuspended in 1 ml PBS by vortexing. The washing step was repeated twice more, the supernatant discarded and the beads resuspended in 1 ml (0.5 mg/ml) of biotinylated human IZ-CD40L in PBS and incubated overnight at room temperature with end-over-end rotation. Following incubation, the beads were pelleted and washed three times with 1 ml PBS as before and then resuspended in 0.5 ml PBS containing 0.1% bovine serum albumin (BSA). The antigen coated beads were then diluted 1:10 in PBS containing 0.1% BSA prior to use. The reagents for the RBA assay were added as follows to duplicate wells in a 384-well black sided clear bottomed FMAT plate [Applied Biosystems, UK]:

    
    
        a) 12.5 μl dAb protein or buffer control. The dAb titration starting concentration was typically 10 μM (final concentration) which was diluted 1:3.3 (i.e., 30 μl sample added to 70 μl PBS containing 0.1% BSA) to produce an 8-point titration effect curve.
        b) 12.5 μl CD40-Fc [supplied by Bristol-Myers Squibb, USA; lot CY24Feb06-1] at 0.2 μg/ml (for a final concentration of 0.05 μg/ml) diluted in PBS containing 0.1% BSA.
        c) 12.5 μl Mixture of mouse anti-human Fc [Sigma-Aldrich, UK] at 2 μg/ml (for a final concentration of 0.5 μg/ml) and goat anti-mouse Alexa Fluor 647 [Invitrogen, UK] at 1 μg/ml (for a final concentration of 0.25 μg/ml) diluted in PBS containing 0.1% BSA.
        d) 12.5 μl IZ-CD40L coated beads described above were added to the centre of the well so they did not disperse to the edge of the well.
    
    


Following addition of the reagents to the 384 well plate, it was incubated at room temperature for 6 hours in the dark and then read in an AB8200 FMAT system [Applied Biosystems, UK].
Example 2
dAb Selection for Clone BMS2h-572
Three rounds of selection using decreasing concentrations of antigen (300 nM at round 1; 30 nM at round 2; 3 nM at round 3) were performed in parallel against biotinylated (1.42 moles biotin/mole trimer) human isoleucine zipper-CD40L (IZ-hCD40L) provided by Bristol-Myers Squibb. Phage from the naïve 4G and 6G Domantis dAb libraries were combined into the pools a) to h) indicated below before initiating selections:
a) 4G VH CDR3 lengths between 7-9 amino acids.
b) 4G VH CDR3 lengths between 10-12 amino acids.
c) 4G VH CDR3 lengths between 13-15 amino acids.
d) 4G VK
e) 6G VH CDR3 lengths between 7-9
f) 6G VH CDR3 lengths between 10-12
g) 6G VH CDR3 lengths between 13-15
h) 6G VK
Each round of selection involved adding the desired concentration of biotinylated CD40L to a mixture of phage (from one of the naïve library pools indicated above, or subsequent selection output phage) in 1000 μl of 2% MPBS (Phosphate Buffered Saline containing 2% (w/v) Marvel [Premier Foods, UK]) and incubating at room temperature for 1 hour by mixing end-over-end. The biotinylated antigen phage complex was then captured by adding 100 μl of resuspended Dynabeads M-280 Streptavidin [Invitrogen, UK] (rounds 1 and 3) or 50 μl of M-280 tosylactivated Dynabeads (Invitrogen) that had been coupled with NeutrAvidin [Thermo Fisher Scientific, UK] (round 2) and incubated for 5 minutes with mixing end-over-end at room temperature. The Dynabeads were then recovered using a KingFisher magnetic separator [Thermo Fisher Scientific, UK] and washed 7×1 ml PBST (PBS containing 0.1% (v/v) polyoxyethylenesorbitan 20 monolaurate [Sigma-Aldrich, UK]) followed by 1×1 ml PBS. Bound phage retained on the washed Dynabeads were eluted by incubation with 500 μl of trypsin-PBS (50 μl of 10 mg/ml trypsin [Sigma-Aldrich, UK] dissolved in 50 mM Tris-HCl pH 7.4, 1 mM CaCl2 added to 450 μl PBS). The phage-containing solution was recovered and 250 μl used to infect 1.75 ml of logarithmic growth phase E. coli TG1 (at an OD600 of 0.4) for 30 minutes at 37° C. The E. coli TG1 phage infected culture was centrifuged at 11,600 g in a micro centrifuge for 1 minute and the resulting cell pellet resuspended in 1 ml 2×TY (16 g Tryptone, 10 g Yeast Extract and 5 g NaCl in 1 liter, autoclaved for 15 minutes at 121° C.) and plated onto a 9 cm Petri dish containing TYE media supplemented with 15 μg/ml tetracycline. The plates were incubated overnight at 37° C. then 2 ml of 2×TY supplemented with 15% glycerol was added to each plate and cells loosened with a glass spreader and mixed thoroughly. Fifty microliters of the scraped bacteria was used to inoculate 50 ml of 2×TY supplemented with 15 μg/ml tetracycline and grown overnight at 37° C. with shaking at 250 rpm. The overnight culture was centrifuged at 3,300 g for 15 min to pellet the bacteria. To precipitate phage, 10 ml PEG/NaCl (20% Polyethylene glycol 8000, 2.5 M NaCl) was added to 40 ml supernatant. The phage/PEG solution was mixed and left on ice for 1 h, then spun at 3,300 g for 30 min at 4° C. and the supernatant discarded. The pellet was resuspended in 2 ml PBS and spun at 11,600 g for 10 min in a micro centrifuge to remove the remaining bacterial debris. The resultant supernatant containing phage was then used for the next round of selection against the appropriate concentration of biotinylated IZ-hCD40L.
Phage ELISA
Monoclonal phage ELISAs were carried out following selection rounds 2 and 3. All washes were performed using 3 washes of 250 μl PBST followed by 3 washes of 250 μl PBS. The plates were coated overnight at 4° C. with 50 μl/well of 1 μg/ml IZ-hCD40L in PBS. The plates were washed and then blocked with 2% MPBS for 1 hour at room temperature. The plates were washed and 25 μl/well phage supernatants added to an equal volume of 2% MPBS and incubated for 1 hour at room temperature. The plates were washed and bound phage detected with 50 μl/well anti-M13-HRP conjugate [GE Healthcare, UK] diluted 1:5000 in 2% MPBS and incubated for 1 hour at room temperature. The plates were washed and the ELISA developed using 50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution [KPL Inc, USA]. The colorimetric reaction was stopped by the addition of an equal volume of 1 M HCl and the ELISA plate read at 450 nm. Specific phage were identified by comparison to wells that were not coated with antigen but otherwise identically treated.
Recovery of dAb Genes from pDOM4 Plasmid
The dAb V-genes from round 2 and 3 outputs were recovered by SalI and NotI restriction enzyme digestion of the phage vector pDOM4 and ligated into a SalI and NotI double digested pDOM5 expression vector.
Soluble dAb ELISA
Binding dAbs were identified as follows. Ninety-six individual colonies containing dAb V-genes cloned into the soluble dAb expression vector pDOM5 were picked from each output into 200 μl Terrific Broth containing OnEx Autoinduction media [Novagen, UK] and incubated overnight at 37° C. with shaking at 250 rpm in Costar 96 Well Cell Culture Clusters [Corning Incorporated, USA] sealed with a gas permeable adhesive plastic strip. The cultures were centrifuged to pellet the cells and the supernatants assayed by antigen binding ELISA for dAbs that bound to IZ-hCD40L. MaxiSorp 96 well immunoplates [Nunc, USA] were coated overnight at 4° C. with 50 μl/well of 1 μg/ml IZ-hCD40L in PBS. All washes were as described for the phage ELISA. The plates were blocked for 1 hour at room temperature with 200 μl of PBS containing 1% Tween 20. The ELISA plate was washed and dAb-containing culture supernatant clarified by centrifugation at 1,800 g for 10 min at 4° C., then added to the ELISA plate (30 μl/well) to which was added an equal volume of PBST. The plates were incubated for 1 hour at room temperature and then washed. Bound dAb was detected by adding 50 μl/well 9E10 [anti-myc IgG, Sigma-Aldrich, UK] diluted 1:2000 in PBST and incubating for 1 hour at room temperature; the ELISA plate was then washed and 50 μl/well anti-mouse Fc-HRP [Sigma-Aldrich, UK] diluted 1:2000 in PBST added and incubated for 1 hour at room temperature. The plates were washed and the ELISA developed by adding 50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution [KPL Inc, USA] and the colour allowed to develop. The colorimetric reaction was stopped by the addition of an equal volume of 1 M HCl and the ELISA plate read at 450 nm. Antigen binding dAbs were identified by comparison of the signal intensity from IZ-hCD40L wells with control wells not containing antigen.
Example 3
Identification of Clones BMS2h-503-1, BMS2h-719-2, and BMS2h-572-6
BMS2h-503, BMS2h-719 and BMS2h-572 dAbs were subjected to error-prone affinity maturation to generate BMS2h-503, BMS2h-719 and BMS2h-572 lineages, respectively. This was performed using random mutagenesis where on average 3.6 amino acid changes were introduced per dAb. Phage libraries (average size 6×108) were selected using biotinylated monomeric and trimeric human CD40L with alternating streptavidin/neutravidin bead capture of the antigen (as described). Three rounds of selections using decreasing concentrations of antigen (100 nM at round 1; 10 nM at round 2; 1 nM at round 3) were performed. Sequencing was used to monitor diversity following each selection round. Selection outputs (round 2 selected on CD40L trimer for BMS2h-572; round 3 selected on CD40L trimer for BMS2h-503 and round 3 selected on CD40L monomer for BMS2h-719) were sub-cloned into soluble expression vector pDOM13 (no C terminal tag) (as described) and screened as monoclonal bacterial micro-culture supernatants by BIAcore for improved off-rates compared to parental clones on both monomeric and trimeric CD40L. Identified improved variants were DNA sequenced and unique dAbs expressed, purified and then assayed using the BMS2h bead RBA as well as cellular CD40L driven assays (as described). As a result, BMS2h-503-1 (sequence listed in TABLE 3), BMS2h-719-2 and BMS2h-572-6 dAbs (sequences listed in TABLE 1) were identified. Activities of these dAbs are listed in TABLE 5 below.
Formatting BMS2h-503-1, BMS2h-719-2 and BMS2h-572-6 as Fc Fusions
BMS2h-572-6, BMS2h-503-1 and BMS2h-719-2 dAbs were cloned into pDOM38 vector containing Fc tail derived from human IgG1 to create DMS0502, DMS0500 and DMS0501, respectively. BMS2h-572-6, BMS2h-503-1 and BMS2h-719-2 dAbs were also cloned into pDOM38 vector containing Fc tail derived from human IgG4 to create DMS0505, DMS0506 and DMS0504, respectively. The constructs were transiently expressed in HEK293 cells and the proteins were purified using Protein A. Purified Fc fusions were analysed by Biacore for binding to monomeric and trimeric CD40L as well as in various cell assays (as described).
Identification of Clones BMS2h-572-608, BMS2h-572-614 and BMS2h-572-619
BMS2h-572-6 dAb was subjected to affinity maturation using doped oligo approach. Four doped libraries were constructed for this dAb:
Library 1-5 residues in CDR1 diversified
Library 2-6 residues in CDR2 diversified
Library 3-13 residues in CDR2 diversified
Library 4-7 residues in CDR3 diversified
In each library, diversification was performed using nnS codons where n retained a large fraction of the parent base (85%) and split the rest between the equimolar amounts of the remaining three bases (5% each) and S stood for G or C. Phage libraries (average size 8×108) were selected using biotinylated monomeric and trimeric human CD40L with alternating streptavidin/neutravidin bead capture of the antigen (as described). Libraries 2 and 3 were pulled together during the selection process. Three rounds of selections using decreasing concentrations of antigen (50 nM at round 1; 5 nM at round 2; 1 nM at round 3 with 200 fold excess of competitor—non biotinylated CD40L trimer) were performed. Sequencing was used to monitor diversity following each selection round. Selection outputs (rounds 2 and 3) were sub-cloned into soluble expression vector pDOM13 (no C terminal tag) (as described) and screened as monoclonal bacterial micro-culture supernatants by BIAcore for improved off-rates compared to parental clones on both monomeric and trimeric CD40L. Identified improved variants were DNA sequenced and unique dAbs expressed, purified and then assayed using the BMS2h bead RBA as well as cellular CD40L driven assays (as described). As a result, BMS2h-572-608, BMS2h-572-614 and BMS2h-572-619 dAbs were identified.
Construction of Clone BMS2h-572-633
Sequence analysis revealed that all of the amino acid differences between BMS2h-572-608 and the parental dAb BMS2h-572-6 were located in CDR1 and the differences between BMS2h-572-614 and parental dAb BMS2h-572-6 were located in CDR3. Both matured dAbs shared CDR2 with the parental dAb BMS2h-572-6. This created an opportunity to construct a combination mutant which had CDR1 of BMS2h-572-608 and CDR3 of BMS2h-572-614. Firstly, CDR1 region of BMS2h-572-608 was PCR amplified. Secondly, CDR2+CDR3 fragment of BMS2h-572-614 was PCR amplified. This was followed by SOE PCR assembly of the two fragments to create a combination mutant BMS2h-572-633. The assembled dAb PCR product was cloned into soluble expression vector pDOM13 (no C terminal tag), sequence verified, expressed, purified and then assayed using the BMS2h bead RBA as well as cellular CD40L driven assays (as described).
Formatting BMS2h-572-633 as Fc Fusion
BMS2h-572-633 dAb was cloned into pDOM38 vector containing Fc tail derived from human IgG1 to create DMS0507. The construct was transiently expressed in HEK293 cells and the protein was purified using Protein A. Purified Fc fusion was analysed by Biacore for binding to monomeric and trimeric CD40L as well as in various cell assays (as described).
Example 4
CD40L Activity Cell Assays
Anti-human CD40L dAbs were assayed functionally for their ability to antagonize CD40L activities. The CD40L activities tested were B cell proliferation and cytokine production by hCD40L-driven activation of primary monocytes-derived dendritic cells (DCs). Unless otherwise noted, all assays were performed in RPMI media supplemented with 10% fetal calf serum (FCS). The results of various assays, described in detail below, are shown in TABLE 5 and TABLE 6.
Soluble 1Z-hCD40L-Driven Primary Human B Cell Proliferation:
1×105 tonsillar human B cells were incubated with 0.6 μg/ml of IZ-hCD40L along with varying titration of dAb or mAb in a final volume of 200 μl/well in a 96-well round bottom plate. The plates were incubated at 37° C. for 72 hours following which thymidine (3H; 0.5 μci/well) was added for 6 hours. B cell proliferation was quantified based on thymidine incorporation. All assays, unless otherwise noted, were performed in RPMI media supplemented with 10% fetal calf serum (FCS).
CHO-hCD40L-Driven Primary Human B Cell Proliferation:
CHO cells were transfected with human CD40L to generate a stable cell line expressing high levels of CD40L on the cell surface. CHO-CD40L cells were irradiated at 10,000 Rads before incubation with human B cells. 1×105 tonsillar human B cells were incubated with 1×103 CHO-CD40L cells (1:100 ratio of CHO-CD40L: human B cells) along with varying titration of dAb or mAb in a final volume of 200 μl/well in a 96-well round bottom plate. The plates were incubated at 37° C. for 72 hours following which thymidine (3H; 0.5 μci/well) was added for 6 hours. B cell proliferation was quantified based on thymidine incorporation. All assays, unless otherwise noted, were performed in RPMI media supplemented with 10% fetal calf serum (FCS).
Primary T Cell-Driven Human B Cell Proliferation:
T cells were isolated from human peripheral blood mononuclear cells (PBMCs) and enriched using via sheep red blood cell (SRBC) affinity. Enriched human T cells were cultured with PM-LCLs (EBV-transformed B cell line; irradiated at 10,000 Rads) at a 5:1 ratio (T:LCL) for 6 days at 37° C. to generate a population of allogeneic T cells. At day 6, the expanded T cells were isolated and irradiated at 3000 Rads, and then cultured (5×104 T cells/well) with primary human tonsillar B cells (1×105 B cells/well) at a 1:2 ratio in 96-well flat bottom plated coated with anti-CD3 mAb (OKT3). Varying titrations of dAbs/mAbs were added to each well; the final volume in each well was 200 μl. Test plates were incubated at 37° C. for 3 days. Human B cell proliferation was determined via the addition of thymidine (3H; 0.5 μci/well) to the cultures for the last 18 hours. All assays, unless otherwise noted, were performed in RPMI media supplemented with 10% fetal calf serum (FCS). In some instances, the supernatant was harvested and measured for the presence of IL-6.
CHO-hCD40L-Driven Activation of Primary Human Monocytes-Derived Dendritic Cells (DCs):
Human PBMCs were enriched for monocytes by depleting T cells via SRBC resetting. The monocyte-enriched PBMCs were cultured with 10 ng/ml GM-CSF and 5 ng/ml IL-4 in 6-well plates for six days at 37° C. The cultured plates were replenished with fresh media (with GM-CSF and IL-4) on days 2 and 5. The immature DCs were used in cell assays on day 6. 8×104 immature DCs were cultured with 4×103 CHO-hCD40L cells (irradiated at 10,000 Rads) along with varying titrations of dAbs/mAbs in a 96-well flat bottom plate. After 24 hours, supernatants were harvested and tested for the presence of various cytokines (IL-12, TNF, IL-23). DC activation was determined by the levels of cytokine production. All assays, unless otherwise noted, were performed in RPMI media supplemented with 10% fetal calf serum (FCS).







TABLE 5







Potency of Monomeric dAb Molecules in Various Primary Cell Assays












hIZCD40L-driven
CHO-hCD40L-driven





Human B Cell
Human B Cell
T-B cell
CHO-hCD40L-driven



Proliferation
Proliferation
MLR
DC Activation


Clone
EC50 (nM)
EC50 (nM)
EC50 (nM)
IL-12 EC50 (nM)





2h116-13
130.0 ± 40.0
1300.0, 700.0 

888.0, >2000.0,






1000.0


2h116-1312
23.0 ± 3.0
530.0 ± 300.0
234 ± 46
112.0 ± 47.0 


2h116-1313
29.0 ± 4.0
211.0, 334.0
258 ± 79
136.0 ± 51.0 


2h116-1314
 41.0 ± 10.0
1300.0, 4400.0
 1687 ± 1150
664.0 ± 353.0


2h116-1319
180.0 ± 57.0
>7000.0


2h116-1320
20.0 ± 7.0
138.0 ± 60.0 
191 ± 72
32.0 ± 10.0


2h437
5700.0 ± 1800 


2h437-4
203.0 ± 90.0
>7000.0

1329.0 ± 412.0 


2h492
>7000.0


2h492-3
1100.0 ± 400.0
>7000.0


2h492-4
1700.0 ± 900.0
>7000.0


2h492-5
2300.0 ± 700.0


2h492-6
 6300.0 ± 1400.0


2h492-7
1900.0 ± 600.0


2h494
 6100.0 ± 1200.0


2h494-2
 4800.0 ± 2300.0


2h494-3
>7000.0


2h494-4
 590.0 ± 250.0
>7000.0


2h494-6
 2000.0 ± 2100.0
>7000.0


2h503
4200.0 ± 316.0
>7000.0


2h503-1
24.0 ± 2.0
2300.0 ± 700.0 

756.0 ± 333.0


2h503-104
16.0, 19.0


2h503-2
44.0 ± 6.0
3000.0 ± 1000.0

1562.0 ± 96.0 


2h572
>7000.0


2h572-6
208.0 ± 73.0
>7000.0
>7000.0
>2000.0, 608.0






±260.0


2h572-604
254.0, 354.0
 >700.0

 387.0


2h572-608
 96.0 ± 19.0

>7000.0
152.0 ± 61.0 


2h572-610
109.0 ± 34.0

>7000.0
207.0 ± 87.0 


2h572-614
 93.0 ± 53.0

>7000.0
135.0 ± 54.0 


2h572-616
204.0, 340.0

>7000.0
608.0 ± 136.0


2h572-617
157.0, 189.0

>7000.0
338.0 ± 101.0


2h572-619
 90.0 ± 62.0
 421.0, 1496.0
>7000.0
188.0 ± 41.0 


2h572-622
301.0, 293.0

>7000.0
281.0 ± 127.0


2h572-623
181.0, 261.0

>7000.0
280.0 ± 73.0 


2h572-630
103.0 ± 71.0


246.0 ± 240.0


2h572-631
108.0 ± 77.0


230.0 ± 200.0


2h572-632
117.0 ± 91.0


241.0 ± 190.0


2h572-633
 20.0 ± 15.0


53.0 ± 60.0


2h572-634
 31.0 ± 18.0


77.0 ± 67.0


2h572-635
 29.0 ± 19.0


52.0 ± 26.0


2h572-9
324.0, 243.0


>2000.0


2h572-11
140.0 ± 33.0
>7000.0

671.0 ± 165.0


2h572-12
79.0, 76.0


 225.0, >2000.0


2h572-14
134.0 ± 12.0
>7000.0

882.0 ± 310.0


2h572-15
168.0 ± 67.0
>7000.0

876.0 ± 391.0


2h572-22
357.0, 305.05


2h702
>7000.0


2h703
>7000.0


2h706
>7000.0


2h707
>7000.0


2h710
>7000.0


2h712
>7000.0


2h717
>7000.0


2h719
 600.0 ± 640.0


134.0, 646.0


2h719-2
 82.0 ± 39.0
>7000.0

196.0 ± 150.0


2h719-202
 29.0 ± 12.0


79.0 ± 29.0


2h719-203
81.0, 96.0


2h719-213
62.0, 98.0


2h719-214
66.0, 89.0


2h719-215
92.0, 91.0


2h719-218
57.0, 60.0


2h719-225
253.0, 198.0


176.0 ± 84.0 


2h719-226
164.0, 247.0


812.0 ± 53.0 


2h719-12
 358.0 ± 159.0


266.0 ± 66.0 


2h719-13
50.0 ± 8.0
659.0, 683.0,

219.0 ± 88.0 




4450.0, 1750.0


2h719-17
132.0 ± 50.0
236.0, 268.0

113.0 ± 49.0 


2h719-19
138.0 ± 31.0
202.0, >7000.0,

184.0 ± 99.0 




>7000.0, 3800.0,




5400.0


2h722
>7000.0


2h723
>7000.0


2h725
 6400.0 ± 1200.0


2h725-2
>7000.0


2h725-9
>7000.0


2h725-19
>7000.0


2h726
>7000.0


2h730
>7000.0


2h731
 5800.0 ± 2500.0


2h744
>7000.0


2h745
6400.0, 3500.0,



>7000.0


2h745-1
>7000.0


2h745-2
>7000.0


2h745-9
>7000.0


2h745-13
>7000.0


2h745-14
>7000.0


2h746
>7000.0


2h747
>7000.0


2h752
>7000.0


2h754
6600.0 ± 900.0


2h757
6400.0 ± 800.0


2h758
 5900.0 ± 1500.0


2h758-1
>7000.0


2h758-2
>7000.0


2h758-3
>7000.0


2h758-4
>7000.0


2h758-5
>7000.0


2h765
>7000.0


2h766
>7000.0


2h774
>7000.0


2h775
>7000.0


2h780
>7000.0


2h781
>7000.0


2h782
>7000.0


2h783
>2000.0


2h784
>4700.0


2h785
3700.0, >7000.0
















TABLE 6







Potency of Fc*-formatted Molecules in Various Primary Cell Assays

















CHO-


CHO-
CHO-
CHO-
CHO-



hIZCD40L-
hCD40L-


hCD40L-
hCD40L-
hCD40L-
hCD40L-



driven
driven

T-B cell
driven
driven
driven
driven



Human B Cell
Human B Cell
T-B cell
MLR
DC Activation
DC Activation
DC Activation
DC Activation



Proliferation
Proliferation
MLR
IL-6
IL-12 EC50
IL-6 EC50
IL-23 EC50
TNF EC50


Clone
EC50 (nM)
EC50 (nM)
EC50 (nM)
EC50 (nM)
(nM)
(nM)
(nM)
(nM)





2h116-1320-Fc
13.0 ± 2.0 
>130.0
244.0 ± 112.0

14.0 ± 11.0





2h503-1 Fc
4.0 ± 0.5
60.0 ± 20.0
45 ± 6 

2.8 ± 2.0


2h503-1 IgG1
4.5 ± 1.0
67.0 ± 40.0
 39.5 ± 12.04

1.4 ± 0.7


2h503-1 IgG4
2.5 ± 1.0
69.0 ± 50.0
48.3 ± 8.8 

18.1 ± 6.4 


2h572-6 Fc
0.6 ± 0.4
3.0 ± 1.0
1.9 ± 0.7

0.22 ± 0.18


2h572-6 IgG1
1.0 ± 0.4
10.0 ± 5.0 
3.1 ± 1.4
2.9 ± 1.7
0.58 ± 0.36


2h572-6 IgG4
0.9 ± 0.2
11.0 ± 5.0 
3.2 ± 1.5
1.3 ± 0.5
1.1 ± 0.5


2h572-6-CT
1.0 ± 0.5
6.0 ± 6.0
13.6 ± 9.2 
8.1 ± 3.1
3.0 ± 1.9


Long Fc


2h572-633 Fc
3.5 ± 0.6
3.0 ± 3.0
0.15 ± 0.02
0.11 ± 0.02
0.34 ± 0.17


2h572-634 Fc
3.0 ± 0.0
3.5 ± 3.0
0.23 ± 0.08
0.19 ± 0.03
0.42 ± 0.05


2h572-635 Fc
2.0 ± 0.8
2.5 ± 1.0
0.16 ± 0.09
0.11 ± 0.02
0.445 ± 0.14 


2h572-619-
1.5 ± 0.6
  2.0
0.40 ± 0.1 
 0.3 ± 0.07
1.8 ± 1.3


Ctshort Fc


2h572-619-
1.6 ± 0.5
2.0 ± 1.0
0.72 ± 0.45
0.43 ± 0.12
1.4 ± 0.6
 1.5 ± 0.36
1.5 ± 0.46
2.0 ± 0.7


Ctlong Fc


2h572-619-
0.9 ± 0 
1.0 ± 0.6
0.226, 0.216
0.1, 0.1
1.2 ± 0.6


N297Qshort Fc


2h572-619-
0.98 ± 0.05
2.0 ± 0.0
0.480, 0.474
0.22, 0.11
 1.1 ± 0.23


N297Qlong Fc


2h572-608-
 1.0 ± 0.05
2.0 ± 0.0


0.93 ± 0.4 


N297Qshort Fc


2h572-608-
2.0 ± 1.0
2.0 ± 1.0
0.468 ± 0.156
0.38 ± 0.06
 1.6 ± 0.74


CT Long Fc


2h572-614-
2.0 ± 1.0
2.0 ± 0.5
0.283 ± 0.038
0.25 ± 0.02
 1.4 ± 0.68


CT Long Fc


2h572-633-
3.0 ± 0.7
1.0 ± 1.0
0.174 ± 0.077
0.13 ± 0.07
1.9 ± 1.3
1.3 ± 0.3
1.2 ± 0.3 
 1.7 ± 0.43


CT Long Fc


2h572-633-
5.0 ± 0.5
1.0 ± 0.5
0.161 ± 0.053
0.13 ± 0.04
2.3 ± 1.5
1.5 ± 0.7

2.9 ± 1.3


CT-Fc SP5


2h572-634-
2.0 ± 1.0
1.0 ± 0.6
0.162 ± 0.029
0.13 ± 0.02
 1.5 ± 0.91


CT Long Fc


2h572-635-
3.0 ± 1.0
2.0 ± 0.6
0.149 ± 0.014
0.13 ± 0.01
 1.6 ± 0.93


CT Long Fc


2h719-2 Fc
1.0 ± 0 
0.7 ± 0.4
 6 ± 1.4

0.13 ± 0.08


2h719-2 IgG1
1.0 ± 0.5
6.0 ± 0.3
13.8 ± 10.6
2.2 ± 1.3
0.35 ± 0.23


2h719-2 IgG4
1.5 ± 0.6
16.0 ± 13.0
15.9 ± 10.9
2.1 ± 0.7
 1.1 ± 0.48


2h719-202-
1.8 ± 0.5
1.7 ± 0.7


0.66 ± 0.26


N297Qshort Fc


2h719-202-
3.0 ± 1.0
2.5 ± 0.6
1.7 ± 0.7
1.3 ± 0.3
3.1 ± 2.0


CT Long Fc





*FIG. 3 provides sequences of various Fc domains. FIG. 4 shows examples of various Fc-formatted dAbs.






Example 5
Binding Kinetics and CD40L Affinity of Various Antibodies
BMS-986004 is a dimeric fusion protein, composed of a modified Fc fragment of IgG1 linked to the C-terminus of the dAb BMS2h-572-633. Surface plasmon resonance (SPR) was used to characterize the kinetics and affinity of BMS-986004 or the monovalent component domain antibody BMS2h-572-633 binding to CD40L. The BMS-986004 values were compared to those for the benchmark antibodies 5c8-IgG1 and 5c8-CT and the monovalent component 5c8 FAB fragment. The SPR experiments utilized a hCD40L construct containing an N-terminal isoleucine zipper motif (IZ-hCD40L) which facilitates the specific assembly of the CD40L molecule into the native trimeric form. A biotinylated version of IZ-hCD40L (biot-IZ-hCD40L) with equivalent binding activity was also utilized for some SPR experiments.
The monovalent BMS2h-572-633 domain antibody binds biot-IZ-hCD40L with a Kd of 7.8 nM, compared to an affinity of 5.4 nM for the monovalent 5c8 FAB fragment, TABLE 7. Because BMS-986004 is bivalent, and the IZ-hCD40L target is trivalent, the SPR binding data are influenced by avidity regardless of whether CD40L target is on the chip surface or in solution. To estimate the avidity-influenced binding affinity, the SPR data for BMS-986004 binding to a biot-IZ-hCD40L surface was fitted to a 1:1 Langmuir model, suggesting a dissociation constant of less than 1 nM, TABLE 7. Similar results were obtained for 5c8-IgG1 and 5c8-CT.







TABLE 7







IZ-hCD40L kinetic and affinity values


as determined using SPR (Biacore)












Anti-
Temper-






CD40L
ature

ka
kd
Kd


Ab
(° C.)
Model
(M−1s−1)
(s−1)
(nM)















BMS-986004
25
1:1
2.3E+06*
2.6E−04*
0.11*




Langmuir


2h572-633
25
1:1
1.0E+06 
8.1E−03 
7.8




Langmuir


5c8-IgG1
25
1:1
5.4E+05*
2.3E−04*
0.42*




Langmuir


5c8-CT
25
1:1
5.8E+05*
1.3E−04*
0.22*




Langmuir


5c8 FAB
25
1:1
1.4E+05 
7.6E−04 
5.4


fragment

Langmuir





*Value is influenced by avidity due to analyte bivalency.






FIG. 5 shows SPR sensorgram data for the binding of 12.5-0.39 nM BMS-986004 (2:1 dilution series) to biot-IZ-hCD40L captured on a streptavidin SPR sensor chip at 25° C. Colored lines show the double-referenced sensorgram data, and black lines show the 1:1 Langmuir fit to the data, with an avidity-influenced apparent Kd value of 0.11 nM.
The affinity and thermodynamics of BMS-986004 binding to CD40L were also characterized in solution using isothermal titration calorimetry (ITC) at temperatures ranging from 15-37° C. These data suggested the presence of multiple thermodynamically distinct binding modes (FIG. 6) with Kd values for the different modes beyond the high-affinity limit of detection (Kd<2 nM) (TABLE 8), consistent with the SPR data. The affinity of the monovalent 5c8 FAB fragment for IZ-hCD40L as determined by ITC (3.5 nM) was also consistent with the value determined by SPR.







TABLE 8







IZ-hCD40L affinity as determined using ITC









Molecule in the ITC syringe
Molecule in the ITC cell
Kd (nM)












BMS-986004
IZ-hCD40L
<2


5c8-CT
IZ-hCD40L
<2


IZ-hCD40L
BMS-986004
<2


IZ-hCD40L
5c8-CT
<2


IZ-hCD40L
5c8 FAB fragment
3.5









Example 6
Fc Receptor Affinity of Various Antibodies
The Fc-domain of BMS-986004 (termed “CT”) was engineered from a wild type IgG1 Fc domain to retain the ability to bind FcRn, but to disrupt the binding to Fcγ receptors. To confirm that the engineered molecule has the desired Fc receptor binding profile, the binding affinities of BMS-986004 for human FcRn, and the human Fcγ receptors CD64 (FcγRI), CD32a (FcγRIIa), CD32b/c (FcγRIIb/c), CD16a (FcγRIIIa), CD16b (FcγRIIIb) were measured using SPR, in comparison to 5c8-IgG1 and 5c8-CT. For these experiments, BMS-986004 was captured via the domain antibody domains on a biot-IZ-hCD40L sensor surface, and the soluble Fc receptor proteins were tested for binding to the exposed Fc domain. Likewise, 5c8-IgG1 and 5c8-CT were captured on a biot-IZ-hCD40L surface via the FAB domains, with soluble FcR binding.
BMS-986004 bound FcRn with Kd of 670 nM at pH 6.0 which is the relevant pH for binding within the endosome, TABLE 9. However, binding was significantly reduced (Kd>5000 nM) at neutral pH suggesting efficient release of from FcRn under these conditions. BMS-986004 bound CD64 with a Kd of 0.6 nM, and had a statistically weak affinity for CD32a, CD32b/c, CD16a and CD16b (Kd>3000 nM). Both 5c8-IgG1 and 5c8-CT had a similar FcRn affinity as BMS-986004. 5c8-CT, which has the identical “CT” Fc region as BMS-986004, also had a similar FcγR binding properties as BMS-986004, whereas 5c8-IgG1, which has a wild type IgG1 Fc domain, bound more strongly to FcγRs, TABLE 9.







TABLE 9







Fc receptor affinity as determined using SPR (Biacore).















BMS-986004
5c8-IgG1
5c8-CT



Sample
pH
Kd (nM)
Kd (nM)
Kd (nM)

















hFcRn
6
670
590
720



hFcRn
7.1
>5000
>5000
>5000



CD64
7.1
0.6
<0.05
0.9 ± 0.4



CD32a
7.1
>3000
~10−7 M*
>3000



CD32b/c
7.1
>3000
>3000
>3000



CD16a
7.1
>3000
240 ± 40
>3000



CD16b
7.1
>3000
>3000
>3000







*CD32a binding to 5c8-IgG1 was biphasic. Kd was estimated as ~10−7 M based on steady state fit to dominant binding even. This Kd is in range of literature reported KD for CD32a binding to IgG1.






Example 7
In-Vitro Cell-Based Assays
The potency of BMS-986004 was evaluated in various primary immune cell assays to ensure robust potency across different cell types. The primary human B cell proliferation assays were conducted two ways, as described in detail above in Example 4: (1) recombinant CD40L trimer was used to drive B cell proliferation; and (2) CHO cells expressing CD40L on the membrane (CHO-CD40L) were utilized to induce B cell proliferation. The utility of CHO-CD40L cells was particularly important to ensure that signals from membrane-bound CD40L were inhibited equally well when compared to the soluble CD40L trimer. The CHO-CD40L cells were also used to drive the activation of primary human DCs differentiated from culturing PBMC-derived monocytes in presence of GM-CSF and IL-4. Similarly, the T-B MLR assay measured B cell activation driven by CD40L present on activated T cells. In all of the above described primary assays, BMS-986004 was equipotent to the benchmark 5c8 mAb: potencies ranged from was single-digit nM to sub-nM, depending on the assay (TABLE 10).







TABLE 10







Potency of BMS-986004 in Various Primary Cell Assays



















CHO-CD40L
CHO-CD40L
CHO-CD40L



Trimer
CHO-CD40L

T-B MLR
DC Assay
DC Assay
DC Assay



B cell Assay
B Cell Assay
T-B MLR
IL-6
IL-12
IL-6
TNF-a


mAb/dAb-Fc
EC50 (nM)
EC50 (nM)
EC50 (nM)
EC50 (nM)
EC50 (nM)
EC50 (nM)
EC50 (nM)





5c8
8.0 ± 3.0
2.0 ± 2.0
0.54 ± 0.37
0.23 ± 0.09
2.0 ± 1.5




5c8-IgG1
5.0 ± 1.0
2.0 ± 2.0
0.34 ± 0.13
0.21 ± 0.06
0.92 ± 0.94
0.73 ± 0.5
2.3 ± 1.3


BMS-986004
5.0 ± 0.5
1.0 ± 0.5
0.16 ± 0.05
0.13 ± 0.04
3.1 ± 1.6
 1.9 ± 0.6
3.6 ± 1.1









Example 8
Assessment of Whole Blood Receptor Occupancy (RO)
A receptor occupancy method was developed to measure CD40L target engagement by BMS-986003 in cynomolgus whole blood samples and, subsequently, in BMS-986004 in human whole blood samples. BMS-986003 is a dAb which shares the same amino acid sequence as BMS-986004, except for a non-native glycine residue at its amino-terminus.
Occupancy is measured on CD4+ T cells by flow cytometry using an anti-CD40L mAb that competes for binding to CD40L with BMS-986003/BMS-986004, and is cross-reactive with human and cynomolgus CD40L. In the presence of bound dAb, the anti-CD40L detection mAb is blocked from binding to CD40L in a concentration-dependent manner, providing a measure of target occupancy. Given that basal CD40L is expressed at low levels on resting T cells in peripheral blood, RO was assessed in both unstimulated blood samples and in samples where phytohemagglutinin (PHA) was used to induce up-regulation of CD40L on the T cell surface. Binding potency curves were generated following ex vivo whole blood treatment with BMS-986003 and BMS-986004. The average EC50 and EC90 values obtained are shown in TABLE 11.







TABLE 11







Binding Potency of BMS-986003 and BMS-986004 on CD4+


T-cells in ex vivo Whole Blood Receptor Occupancy Assay












Average EC50,
Average EC90,



n
nM
nM














BMS-986003





Human (basal)
1
0.9
3


Human (PHA-induced)
6
0.8
9


Cyno (basal)
3
0.6
3


Cyno (PHA-induced)
3
0.4
2


BMS-986004


Human (basal)
3
0.4
3


Human (PHA-induced)
3
0.7
5









The target binding potency in whole blood for BMS-986003 and BMS-986004 closely correlates between human and cynomolgus monkey. The EC50 values for BMS-986003 and BMS-986004 are also similar when bound to basal and PHA-induced CD40L. Additionally, these values are comparable to those obtained in human in vitro cell based assays (see TABLE 10). Based on the measured EC90 values, full target saturation in peripheral blood should be achieved at concentrations ≦10 nM.
To support the preclinical PK/PD profile of BMS-986003 and BMS-986004, RO was assessed in both the cynomolgus KLH study (immunization with keyhole limpet hemocyanin) with BMS-986003 and the IV bridging study with BMS-986004. Further details of these findings can be found in Examples below.
Example 9
In Vivo Pharmacology
To show efficacy of a CD40L dAb in mouse disease models, a mouse CD40L dAb 2m126-24 was formatted with mouse IgG1 Fc with D265A point mutation to further lower the Fc effector function. This mouse surrogate dAb 2m126-24-Fc shows potency comparable to BMS-986004 and MR-1, a hamster anti-mouse CD40L antibody (TABLE 12).







TABLE 12







In vitro Potency Comparison













Trimer B cell
CHO-CD40L B cell
CHO-CD40L DC



mAb/dAb-Fc
Assay EC50 (nM)
Assay EC50 (nM)
Assay IL-6 EC50 (nM)


















 5c8
8.0 ± 3.0
2.0 ± 2.0



Human
{open oversize brace}  




 BMS-986004
5.0 ± 0.5
1.0 ± 0.5
1.9 ± 0.6




 2m126-24-Fc
4.7 ± 0.9
 0.4 ± 0.06
0.5 ± 0.2


Mouse
{open oversize brace}  




 MR-1 (mAb)
1.7 ± 0.4
0.6 ± 0.2
0.6 ± 0.3









Inhibition of KLH Induced Antibody Response by the Mouse CD40L dAb
Female BALB/c mice were injected intraperitoneally (i.p.) with 250 μg KLH on day 0. Mice were dosed subcutaneously (s.c.) with MR-1 or BMS-2m-126-24-Fc at indicated doses on day −1 and day 6. Blood was collected and the serum was analyzed for anti-KLH IgM on day 7 and IgG on day 14 by ELISA. Serum from BALB/c mice collected on day 14 after immunization with KLH was pooled and used as a positive comparator, and the data is expressed as a ratio of the titre of the test serum to the titre of the pooled BALB/c serum. As shown in FIG. 7, BMS-2m-126-24-Fc demonstrated a dose dependent suppression of IgG titers with maximal effect shown at 3 mg/kg, with ED50 calculated to be 0.26 mg/kg. Both the CD40L dAb and the antibody were tested at 1 mg/kg, showing 70% vs. 30% reduction in IgG response, respectively. Similar exposure of the dAb and the antibody were observed at 1 mg/kg, suggesting that the dAb is slightly more potent than the antibody at suppressing KLH-induced IgG response. In conclusion, the CD40L dAb has demonstrated at least the same level of efficacy as the anti-CD40L antibody at inhibiting a T cell dependent antibody response.
Inhibition of TNBS-Induced Colitis by the Mouse CD40L dAb
Male SJL/J mice were intrarectally administered with 2.5 mg Trinitrobenzene sulfonic acid (TNBS) in 50% EtOH via a catheter inserted 4 cm distal to the anus. Mice were dosed once s.c. with MR-1 or BMS-2m-126-24-Fc at indicated doses 4 hours prior to TNBS injection. FIG. 8 presents the changes in the mean body weight and the percent survival of groups of mice treated with PBS/IgG or varying dose levels of MR-1 or the dAb. Abatacept was used as a positive control (20 mg/kg, i.p. every other day). A typical profile of TNBS-induced colitis was shown in the IgG control group: loss of body weight, peaking at day 3-4; colitis-related death occurring at day 3 and beyond; and the survived mice showing signs of recovery after day 4. Treatment with the CD40L dAb or the antibody (both tested at 2, 8 and 20 mg/kg) caused a dose-dependent inhibition of the body-weight loss and the increase in survival rate; both compounds at 8 mg/kg yielded a degree of efficacy that is comparable to that of Abatacept at 20 mg/kg. In conclusion, the mouse CD40L dAb BMS-2m-126-24-Fc has demonstrated comparable efficacy to the anti-CD40L antibody MR-1 in an acute TNBS-induced colitis model.
Synergistic Effect Between CTLA4 Ig and the Mouse CD40L dAb in a Mouse “Heart-to-Ear” Transplant Model
Heart grafts from neonatal (48-72 hrs) C57B1/6 mice were implanted into a subcutaneous pocket created in the ear pinnae of BALB/c mice. Mice were treated with CTLA4-Ig (i.p. 2×/wk), BMS-2m126-24-Fc (s.c. 1×/wk), or combination of both at indicated doses, with first dosing initiated the day prior to transplantation. Time to rejection was defined by the absence of cardiac contractility for three consecutive days as assessed daily by the electrocardiogram (ECG) device of allograft. As expected, without any treatment, C57BL/6 mice that received the neonatal BALB/c heart rejected the graft shortly thereafter, with median survival time (MST) of 12 days. The monotherapy with 3, 20 mg/kg of the dAb or 25 mg/kg of CTLA4-Ig had no or little impact on prolonging the survival of the allograft (MST: 12, 15 and 13 days respectively). However, in the groups treated with combination of 20 mg/kg of the dAb and 25 mg/kg of CTLA4-Ig, the graft survival was significantly prolonged showing MST of 35 days (FIG. 9). This data has provided rationale for combining CD40L dAb with belatacept in human renal transplant patients. Future transplant studies in non-human primates will further define the dose level and assess the potential effect on tolerance induction with CD40L dAb BMS-986004.
Example 10
In Vivo Nonclinical Pharmacokinetics (PK) and Pharmacodynamics (PD)
Various in vivo studies were conducted to characterize the PK and PD of BMS-986004, BMS-986003, and a mouse CD40L dAb-Fc surrogate BMS-2m-126-24-CT, in the nonclinical setting. The key findings are summarized below.
ELISA to Measure BMS-986004 dAb
Enzyme-linked immunosorbency assay (ELISA)-based bioanalytical methods were developed to support the PK studies, acute and chronic efficacy studies in mice, and exploratory PK/PD studies employing cynomolgus monkeys. In all cases, whole blood was obtained and plasma prepared in the presence of EDTA, the samples were then subjected to ELISA analysis.
Plasma concentrations of BMS-986004 were measured with an ELISA assay that utilized human CD40L antigen to capture the analyte from test samples. Test samples were thawed at 4° C., mixed well and diluted 1:100 in assay diluent composed of 1×PBS, 0.05% Tween-20, and 1% BSA (PTB). Subsequent dilutions of the sample were made using 1% normal monkey plasma/PTB as diluent. This allowed the test analyte to be assayed at several dilutions (102-105) while keeping the sample matrix at 1%.
Recombinant trimeric human CD40L was obtained from Protein Structure and Science (PSS), LVL and was bound to 96 well plates at a final concentration of 2 μg/mL. Test samples, quality control (QC) samples and the standards were detected with affinity-purified rabbit anti-heavy chain (Vh) domain framework polyclonal antibody (Covance Research Products, Denver, Pa.) diluted to a concentration of 0.25 μg/ml in PTB, followed by horseradish peroxidase-labeled donkey anti-rabbit polyclonal secondary antibody (Jackson Immunoresearch, West Grove, Pa.) with substrate (TMB—tetramethylbenzidine) added, and the enzymatic reaction stopped with 1 M phosphoric acid. Absorbance was measured at a wavelength of 450 nm. The analysis of BMS-986004 in test samples was conducted using a standard curve. Standard curve calibrators prepared on the day of each run in 1% monkey plasma were used to define the dynamic range of the bioanalytical method. The range of resulting standard curve in 100% plasma was 10-1200 ng/mL. The reference standard for BMS-986004 was obtained from Biologics Process and Product Development (BPPD), HPW. The reference standard material was representative of the manufacturing batch and was used in the study protocol. Standard curves and QCs were evaluated using criteria for accuracy and precision of ≦20% which was considered to be acceptable for assay performance. Test samples were quantified using a 4-parameter logistic fit regression model weighted by reciprocal concentration (1/x) derived from the calibrators.
Performance of the QC samples, measured by the deviation of the calculated concentration from its nominal value indicated the reference material was stable in neat monkey plasma at concentrations of 30-1000 ng/ml when stored at −70° C. for over 2 months.
ELISA to Measure a Mouse Surrogate dAb
Mouse CD40L-specific dAb BMS-2m-126-24-CT was measured in mouse plasma samples to provide exposure data in support of several acute and chronic efficacy studies as well as PK assessment.
While the assay format for mouse dAbs was quite similar to that for human dAbs in monkey samples, there were a few differences. The mouse plasma matrix was diluted to 1:10 (10%) in assay diluent, and all subsequent dilutions of test samples were made using 10% mouse matrix. Likewise, all standards and QCs were also incubated on ELISA plates in 10% mouse plasma. The concentration of BMS-2m-126-24-CT in test samples from mice was measured using mouse CD40L to capture the analyte. As the mouse dAb has Vk framework, all test samples, QCs, and the standards were detected with affinity purified rabbit anti-kappa (Vk) domain polyclonal antibody (Covance Research Products, Denver, Pa.) diluted to a concentration of 0.5 μg/mL in PTB. The rest of the assay and analysis procedure was similar to the procedure for the analysis of human CD40L dAbs. Acceptance criteria for back-calculated concentrations of standards and QCs were also similar to those for human CD40L dAbs. The quantitative range of BMS-2m-126-24-CT as determined from the standard curve was 12.5 to 600 ng/mL in neat sample matrix.
Nonclinical Pharmacokinetics
TABLE 13 summarizes the PK parameters for BMS-986004, BMS-986003, and BMS-2m-126-24-CT in nonclinical animal species.







TABLE 13







Single-dose PK Parameters (mean ± SD) from Two Nonclinical Animal Species




















Dose
Cmax
Tmax
AUC0-inf
T1⁄2
CLTp
Vss
F


Species
dAb
Route
(mg/kg)
(μM)
(h)
(μM · h)
(h)
(mL/h/kg)
(L/kg)
(%)




















Mouse
BMS-2m-
IV
 1
—
—
6.9
101
1.85
0.26 
—



126-24-CT

(N = 3)




SC
 1
0.063
24
10
100
—
—
100 





(N = 3)





10
0.68 
24
114
120
—
—
100 





(N = 3)


Monkey
BMS-986003
IV
 2
—
—
40
106
0.67
0.067
—





(N = 2)




SC
  0.2
0.019 ± 0.004
60 ± 72
4.0 ± 2.7
85 ± 29
—
—
88





(N = 4)





 2
 0.22 ± 0.075
33 ± 43
29.7 ± 4.9 
68 ± 11
—
—
74





(N = 4)





20
1.48 ± 0.34
11 ± 9 
175 ± 27 
105 ± 18 
—
—
44





(N = 4)



BMS-986004
IV
11
—
—
241 ± 18 
124 ± 12 
0.59 ± 0.04
0.098 ± 0.01
—





(N = 4)



5c8-IgG1
IV
20
—
—
1800 ± 74 
400
 0.074
0.042





(N = 4)









BMS-986004 and BMS-986003 exhibited comparable PK profiles in monkeys (FIG. 11A and FIG. 11B). After IV administration, the plasma concentrations of BMS-986004 and BMS-986003 exhibited a bi-exponential decline up to 504 and 408 h, respectively. Accelerated clearance was observed afterward in 50% of monkeys enrolled in both studies. Immunogenicity testing of the plasma samples collected at 38 d after BMS-986004 treatment suggested that all monkeys developed anti-drug antibody (ADA); and that the monkeys with higher ADA levels showed faster clearance. Although no immunogenicity test was conducted for the IV PK study with BMS-986003, a similar level of immunogenicity was observed in monkeys after subcutaneous dosing with BMS-986003 in the PK/PD study, suggesting both proteins were immunogenic in monkeys. The terminal half-life (T1⁄2) of 124 and 106 h for BMS-986004 and BMS-986003 was, therefore, determined using the exposures collected up to two weeks (336 h) only. The steady-state volume of distribution (Vss) of BMS-986004 and BMS-986003 was 0.098 and 0.074 L/kg, respectively. The values are greater than the plasma volume (0.06 L/kg) but less than the volume of extracellular fluid (0.2 L/kg), suggesting that the proteins largely reside in the extracellular space. The total body plasma clearance (CLTp) of BMS-986004 and BMS-986003 was 0.59 and 0.65 mL/h/kg, respectively.
The PK parameters of BMS-986004 in monkeys were compared to those of abatacept, a similar size protein (78.5 vs 78-kDa BMS-986004, based on amino acid sequence), with the same modified human IgG1 Fc format. As expected, the parameters of BMS-986004 were nearly identical with those of abatacept (CLTp of 0.6 mL/h/kg, Vss of 0.087 L/kg, T1⁄2 of 5 d), suggesting the humans PK of BMS-986004 and abatacept is likely to be similar.
The absorption of BMS-986003 after subcutaneous (SC) administration was evaluated in the monkey PK/PD study. The monkeys were administered with BMS-986003 as single subcutaneous doses of 0 (vehicle control), 0.2, 2 and 20 mg/kg, at 24 h prior to the immunization with keyhole limpet hemocyanin (KLH), a T cell-dependent antigen. After dosing, BMS-986003 was slowly absorbed, with a Tmax ranging from 6-96 h (FIG. 12). The exposure of BMS-986003 appeared to be less than dose-proportional across all dose levels. With a dose ratio of 1:10:100, the average Cmax and AUC0-inf ratios were 1:12:80 and 1:7:44, respectively. With the exposure following the IV dose (2 mg/kg) as reference, and assuming linear PK after IV dosing, the SC bioavailability of BMS-986003 was 88%, 74%, and 44% at 0.2, 2, and 20 mg/kg, respectively. The terminal T1⁄2 was confounded by the immunogenicity observed with most of the monkeys at 2 to 5 weeks after dosing. Therefore, the T1⁄2 was estimated to be 85, 66, and 105 h at 0.2, 2 and 20 mg/kg, respectively.
The PK of 5c8-IgG1, an anti-human CD40L monoclonal antibody used as a positive control in the PK/PD study, was evaluated after IV administration at 20 mg/kg (FIG. 12). 5c8-IgG1 exhibited 10-fold higher plasma exposures and 4-fold longer T1⁄2 when compared to BMS-986003 given SC at the same dose (TABLE 13).
The PK of the mouse surrogate dAb-Fc fusion protein, BMS-2m-126-24-CT, was evaluated in mice following single IV and SC administration (TABLE 13). After a single IV (1 mg/kg), the plasma concentrations followed a mono-exponential decline with a terminal T1⁄2 of 101 h (FIG. 13). The CLTp was 1.85 mL/h/kg; and the Vss was at 0.26 L/kg, indicating extracellular distribution. After single SC doses of 1 and 10 mg/kg, BMS-2m-126-24-CT was slowly absorbed with a Tmax of 24 h. The systemic exposures increased in a dose-proportional manner. With a dose ratio of 1:10, the Cmax and AUC0-inf increased in the proportion of 1:11. The terminal T1⁄2 was 100 and 120 h at 1 and 10 mg/kg, respectively. The ratio of the dose-adjusted exposure (AUC0-inf) after SC and IV administration was greater than 1, suggesting complete absorption after SC administration.
Pharmacokinetic/Pharmacodynamic Modeling
The PD of BMS-986003 was measured as the suppression of anti-KLH antibody response in the PK/PD study. BMS-986003 suppressed 70% the antibody response to KLH




  (
  
    
      %
      ⁢
      
        
      
      ⁢
      response
      ⁢
      
        
      
      ⁢
      suppressed
    
    =
    
      
        (
        
          1
          -
          
            
              
                AUEC
                
                  0
                  ⁢
                  
                    -
                  
                  ⁢
                  1008
                  ⁢
                  h
                  ⁢
                  
                    
                  
                  ⁢
                  IgG
                  ⁢
                  
                    
                  
                  ⁢
                  titers
                
              
              ⁢
              treatedgroup
            
            
              
                AUEC
                
                  0
                  ⁢
                  
                    -
                  
                  ⁢
                  1008
                  ⁢
                  h
                  ⁢
                  
                    
                  
                  ⁢
                  IgG
                  ⁢
                  
                    
                  
                  ⁢
                  titers
                
              
              ⁢
              vehicle
              ⁢
              
                
              
              ⁢
              group
            
          
        
        )
      
      *
      100
    
  
  )




at the highest dose of 20 mg/kg. Marginal (15%) and no suppression of the antibody response occurred at 2 and 0.2 mg/kg. In comparison, 5c8-IgG1 exhibited 10-fold higher plasma exposures and 4-fold longer T1⁄2 than BMS-986003 at the same dose level (20 mg/kg). As a result, 5c8-IgG1 suppressed 97% anti-KLH antibody response. In order to compare the in vivo potency between BMS-986003 and 5c8-IgG1, PK/PD modeling was performed using SAAM II (version 1.2.1, Seattle, Wash.). The plasma concentrations of BMS-986003 following SC administration were described using a first-order absorption kinetics coupled with a 2-compartment model, where the elimination occurred in both central and peripheral compartments. Because of complications from immunogenicity and possible nonlinear absorption, the PK data were fitted individually at each dose.

For 5c8-IgG1, a two-compartment model with central elimination was used. The anti-KLH antibody response, expressed as the average value of IgG titers, was modeled using a 6-compartment signal transduction model. The kinetics of KLH in the body was assumed to be a 1-compartment model. The inhibition of the IgG production by BMS-986003 and 5c8-IgG1 was described using an Imax model, with a maximum inhibition equal to 100%. As shown in FIG. 14, the model-fitted curves were able to describe both the PK and PD profile. The plasma IC50 of BMS-986003 and 5c8-IgG1 for the suppression of KLH-induced IgG production was estimated to be 74±14 and 60±18 nM, respectively. These results demonstrated that the potency of these two molecules was comparable in vivo.
The CD40L receptor occupancy (RO) of BMS-986004 was measured in the IV PK study. Following IV administration of 11 mg/kg, the RO of BMS-986004 on the peripheral-blood mononuclear cells (PBMC) was time- and concentration-dependent. PK/PD modeling was performed to estimated an RO EC50. The plasma concentrations were modeled using a modified two-compartment model with an additional ADA-mediated first order elimination constant introduced at 504 h after dosing; and the RO was modeled using an Emax model




  
    (
    
      
        RO
        ⁢
        
          
        
        ⁢
        %
      
      =
      
        
          E
          ⁢
          
            
          
          ⁢
          
            
              max
              *
            
            ⁢
            
              Cp
              γ
            
          
        
        
          
            EC
            ⁢
            
              
            
            ⁢
            
              50
              γ
            
          
          +
          
            Cp
            γ
          
        
      
    
    )
  
  .




As shown in FIG. 15, the fitted curves were able to describe both exposure and RO, with an estimated RO EC50 of 3.4±0.3 nM and the γ (hill factor) of 3.1±0.1. In comparison, the RO EC50 was  ̃22-fold lower than the anti-KLH antibody response IC50 of 74±14 nM, suggesting that >95% RO is required in order to achieve appreciable (>50%) anti-KLH antibody suppression.

Example 11
Nonclinical Toxicology Single-Dose PK/PD Study
The objectives of this study were to 1) determine the tolerability of BMS-986003, including its potential immunogenicity, when given subcutaneously as a single dose to monkeys; 2) evaluate its PD (e.g., inhibition of the antibody response to T-cell-dependent antigen) and PK profiles; 3) evaluate the receptor occupancy of BMS-986003 and peripheral T-cell counts following subcutaneous dosing; and 4) aid dose selection for renal transplant studies and first-in-human dosing.
BMS-986003 was administered s.c. in the posterior thorax as single doses of 0 (vehicle control), 0.2, 2, or 20 mg/kg to groups of 2 cynomolgus monkeys per sex. An additional two monkeys/sex received a single intravenous dose of 20 mg/kg 5c8-IgG1, a monoclonal antibody to human CD40L that was used as a positive control in this study. All doses were administered at 2 mL/kg in the vehicle (PBS; pH 7.2). To assess the effects on the T-cell dependent antibody response, animals were immunized at approximately 24 hours after dosing with test article or immediately after dosing the positive control with 10 mg of KLH by intramuscular injection (posterior quadriceps or caudal thigh). Criteria for evaluation included survival, PK, immunogenicity, PD (inhibition of the antibody response to the T-cell-dependent antigen, KLH), clinical signs, body weights, food consumption, peripheral-blood immunophenotyping, receptor occupancy, and clinical-pathology evaluations (hematology, serum chemistry, and coagulation). Animals were returned to stock following a 6-week post-dose observation period.
At doses ≦20 mg/kg, BMS-986003 was slowly absorbed (Tmax=6-96 h) and Cmax and AUCtot values increased in a less than dose-proportional manner across all dose groups and there were no apparent gender differences. The T1⁄2 values estimated ranged from 69-104 h across all doses. BMS-986003 was substantially immunogenic; all monkeys developed a positive anti-drug antibody (ADA) response during the 6-week post-dose period. At 0.2 and 2 mg/kg, the mean group total ADA response peaked at Day 22 at mean group end point titers (EPT) of 4203 and 6469, respectively. At 20 mg/kg, the ADA response, while positive, was somewhat delayed and partially suppressed, consistent with target pharmacology, peaking at Day 36 at a mean group EPT of 1828. Further characterization of the antibodies demonstrated the majority of binding to the dAb (non-Fc) portion of the molecule and these antibodies were shown to block the binding of BMS-986003 to CD40L in 2 different immunoassay formats suggesting that the ADA were neutralizing. In addition, the formation of ADA appeared to accelerate the elimination of BMS-986003 in several monkeys.
Mean PK parameters for BMS-986003 are presented in TABLE 14.







TABLE 14







Pharmacokinetic Summary










BMS-986003
5C8-IgG1



SC
IV











Mean
0.2 mg/kg
2 mg/kg
20 mg/kg
20 mg/kg


Parameter
(N = 4)
(N = 4)
(N = 4)
(N = 4)





Gender
Male/Female
Male/Female
Male/Female
Male/Female


AUC(0-inf)
219/407
2165/2477
14195/13114
267750/272250


μg · h/mL


CLTp
Not
Not
Not
  ND/0.074


mL/h/kg
applicable
applicable
applicable


T1⁄2 h
 69/101
68/69
107/104
ND/400


Cmax
 69/101
45/49
88/91
Not


μg/mL



applicable


Tmax h
24/96
51/15
 6/15
Not






applicable





Molecular weight used for conversion was 78104 Da for BMS-986003, 150000 Da for 5c8-IgG1 mAb.


ND = not determined,;


AUCextra for males was above 20%, therefore the T1⁄2 was not reported.






There were no BMS-986003- or 5c8-IgG1-related clinical observations or effects on body weights or clinical pathology parameters except 1 male treated with 5c8-IgG1 had decreased red blood cells (0.74×control), hemoglobin (0.73×predose), and hematocrit (0.75×predose) on Day 8, and 3 of 4 monkeys receiving 5c8-IgG1 had decreased lymphocytes (0.53× to 0.65×predose) on Day 8, suggestive of lymphocyte depletion.
CD40L receptor occupancy was generally time- and dose-dependent and more sustained following administration of 20 mg/kg BMS-986003, consistent with higher and more sustained exposures at this dose and PD activity. For BMS-986003, mean peak receptor occupancy on peripheral-blood mononuclear cells (PBMC) was achieved at 24 hrs (97%), 6 hrs (99%) or 48 hrs (99%) post-dose, decreasing to <90% occupancy at 240, 360, or 696 hrs and to <50% occupancy at 360, 696, or 1032 hrs, at 0.2, 2, or 20 mg/kg, respectively. In comparison, for 5c8-IgG1 at 20 mg/kg, mean peak receptor occupancy on PBMC was achieved at 48 hours 100%), and was sustained at ≧97% for the entire study (1032 hr or through Day 44).
BMS-986003 suppressed the antibody response to KLH only at the high dose of 20 mg/kg. On Days 8-30 at 20 mg/kg, there was a 69 to 83% suppression of the geometric group mean antibody response to KLH, relative to the control group, with a peak suppression of 83% occurring on Day 16. No suppression of the antibody response occurred at 0.2 or 2 mg/kg BMS-986003. These data demonstrate that BMS-986003 at a sustained receptor occupancy of >90% for at least 1 month and at sustained plasma concentrations above  ̃10 μg/mL through Day 11 is able to inhibit a T-cell dependent antibody response in cynomolgus monkeys. For the positive control antibody, 5c8-IgG1, suppression of 74-97% of the geometric group mean antibody response to KLH occurred on Days 8-30, with peak suppression of 97% by Day 16 which was generally sustained through Day 30.
No biologically relevant BMS-986003 related changes in absolute numbers of B cells (CD45+, CD20+, CD3−), total T (CD45+, CD3+) cells, helper T (CD45+, CD3+, CD4+, CD8−) cells, cytotoxic T (CD45+, CD3+, CD4−, CD8+) cells, or natural killer (CD45+, CD3−, CD16+) cells occurred during the study, which confirmed lack of any Fc effector function. However, on Day 8, 3 of 4 monkeys treated with 20 mg/kg 5c8-IgG1 had decreased T-lymphocytes (0.53×-0.66×predose), both helper T-cell (0.64× to 0.77×predose) and cytotoxic (0.40× to 0.61×predose) T-cell populations, suggestive of depletion.
In conclusion, BMS-986003 administered as single SC doses of 0.2, 2, or 20 mg/kg (AUC≦14195 μg*hr/mL) was well tolerated in cynomolgus monkeys with no adverse drug-related effects. The positive control, 5c8-IgG1, at a dose of 20 mg/kg, resulted in complete, sustained inhibition of the antibody response to KLH and sustained receptor occupancy of nearly 100% through 30 days post-dose. Mild depletion of T-cells was also noted by Day 8 in monkeys receiving 5c8-IgG1 (0.40× to 0.77×predose), which was not observed with BMS-986003. BMS-986003 was able to suppress an antibody response to KLH at 20 mg/kg (peak suppression of 83%) following KLH immunization on Day 1 and had sustained receptor occupancy of ≧90% through Day 22 and ≧50% through Day 29. Similar dampening of the immunogenicity to BMS-986003 occurred at 20 mg/kg. However, lower BMS-986003 doses of 0.2 and 2 mg/kg did not suppress the antibody response to KLH or the anti-drug antibody response. The lack of pharmacology at the lower doses also correlated with decreasing receptor occupancy (i.e., <90% by Day 11 [0.2 mg/kg] or 16 [2 mg/kg]; <50% by Day 16 [0.2 mg/kg] or 30 [2 mg/kg]) and accelerated clearance, presumably due to the formation of ADA. The inhibition of TDAR is consistent with the mechanism of action of this compound and was not considered adverse.
Example 12
Evaluation of the Risk for TE/Thrombosis
It has been hypothesized that the TE associated with administration of the anti-CD40L monoclonal antibodies is mediated by anti-CD40L mAb-CD40L immune complex (IC)-mediated cross linking of platelets, facilitated by IC binding to FcgRIIa, an IgG Fc receptor, causing activation and aggregation (FIG. 10). Blocking the interaction of Fc moiety of IgG with FcgRIIa is, therefore, expected to mitigate platelet cross linking and thrombosis. The following methods and approaches were designed to evaluate the risk of TE and/or thrombosis.
In Vitro Platelet Activation Assays
Several in vitro assays were conducted to test the hypothesis that platelets are activated by CD40L mab/sCD40L IC in a FcgRIIa-dependent manner. The positive control 5c8-IgG1 was used to validate the assays prior to testing BMS-986003 and BMS-986004. Blood from human donors or mice expressing hFcgRIIa receptor on platelets were used for these studies. Platelet activation was detected by flow cytometry using antibodies against the well-validated platelet activation markers P-selectin (CD62P) and PAC-1 (activated GPIIb/IIIa). Briefly, blood was diluted 1:25 in modified Tyrodes-HEPES containing 1 mM CaC12 to which detection antibodies and test reagents was added, incubated, and analyzed for platelet activation. Initial experiments determined that sCD40L or 5c8IgG1 alone did not activate platelets, but different immune complex ratios of 1:1 to 1:8 of 5c8:sCD40L significantly activated platelets. Subsequent experiments used 5c8-IgG1 or 5c8-mIgG2a IC, mostly at a 1:3 molar ratio of 5c8:sCD40L.
Platelet Activation by 5c8/sCD40L IC can be Blocked by Anti-FcgRIIa Antibody
Studies were conducted with the FcgRIIa blocking antibody IV.3 to test whether activation of platelets by 5c8/sCD40L IC was indeed FcgRIIA-mediated. Blood from human donors was pre-incubated with 0.5 μg/μl of the FcgRIIa blocking antibody IV.3 prior to dilution and incubation with detection antibodies as described above. Adenosine diphosphate (ADP), a platelet activator via a different mechanism, was used as a positive control. As illustrated in FIG. 16, platelet activation by 5c8/sCD40 IC was completely blocked by IV.3, while activation by ADP was not inhibited by the blocking antibody, indicating that activation by the IC is FcgRIIa-mediated.
Selection of Inert Fc Tails
A requirement for potential candidate molecules was absence of binding to FcgRIIa to prevent potential platelet activation. Several 5c8 constructs containing different mutations derived from IgG1 (e.g. 5c8-CT and N297Q) or IgG4 (e.g., 5c8-S228P) were expressed and screened for Fc tails that did not activate platelets using different molar ratios of sCD40L to mAbs. Wild-type and most mutated constructs activated platelets except for 5c8-CT and 5c8-N297Q (FIG. 17). Absence of Fc (5c8-Fab2) also did not activate platelets further confirming that IC-platelet activation is Fc-mediated. The CT tail was chosen to format the dAb candidates BMS-986003 and BMS-986004.
Effect of FcgRIIa Polymorphism on Platelet Activation
The gene for FcgRIIa is variable at codon 131, resulting in His-Arg (CAT/CGT) polymorphism. The genotype distribution in approximately 100 individuals with about equal distribution of Caucasians and African Americans was A/A (His homozygous; 14%), A/G (His/Arg heterozygous; 60%), and G/G (Arginine homozygous; 26%) for Caucasian Americans and A/A (30%), A/G (51%), and G/G (19%) for African-Americans. Reilly et al., Clin. Diagn. Lab. Immunol. 1: 640-644 (1994). Fc-dependent platelet aggregation was noted in samples from R131 individuals when treated with anti-CD9 in mIgG2 or mIgG1 Fc format, while platelets from H131 individuals aggregated only with anti-CD9 as mIgG2 format; this suggests that Fc-dependent aggregation with an IgG1 mAb could potentially segregate a patient population into low and high responders, which has previously been reported with this polymorphism. Tomiyama et al., Blood 80: 2261-2268 (1992). To address any potential differences in platelet activation with the IgG1 and CT Fc tail, 19 donors were genotyped for hFcgRIIa polymorphism and samples tested for platelet activation. The donor pool polymorphism (RR; 42%, HH; 21%, HR; 37%) was sufficient to evaluate any potential differences in platelet activation to the IgG1 format. Representative of literature reports, platelet activation with 5c8-IgG1/sCD40L IC was similar across all genotyped individuals. No activation was found with 5c8-CT/sCD40L IC (FIG. 18), suggesting no or minimal risk of increased TE in a patient population with an antibody formatted with the CT tail.
BMS-986004: Platelet Activation in Human Blood Donors
The experiments described above using 5c8, supported selection of the CT-tail as the best format for BMS-986004 (also called BMS2h-572-633-CT-L2). Blood obtained from 6 donors was treated with 5c8-IgG1, 5c8-CT, F(ab)2, and BMS-986004. Platelets were activated by 5c8-IgG1 but not by any of the other constructs, including BMS-986004 (FIG. 19), suggesting that this dAb has no or low risk for causing platelet activation and TE in clinical studies.
BMS-986003: Platelet Activation in Blood from Mice Expressing hFcgRIIa
To further confirm that activation of platelets by anti-CD40L antibodies was mediated by FcgRIIa receptor, blood from transgenic mice expressing the human receptor (R131 genotype) was treated with 5c8-IgG1, 5c8-IgG2a, dAb-IgG1, 5c8-CT, and BMS-986003 (also called BMS-2h572-633-CT). Platelets were specifically activated by 5c8-IgG1, 5c8-IgG2a, and dAb-IgG1/sCD40L IC in blood from mice expressing hFcgRIIa, but not wild-type littermates. 5c8-CT and BMS-986003 did not activate platelets, further confirming a low risk for TE with the presently disclosed antibodies (FIG. 20).
Example 13
Epitope Binding Experiments
FIG. 25 shows SPR sensorgram data for experiments designed to test whether or not monovalent dAb molecules BMS2h-503-1, BMS2h-572-6, BMS2h-719-17, and the monovalent anti-CD40L 5c8 Fab fragment compete with each other for binding to CD40L. Experiments were performed using biotinylated CD40L (biot-IZ-hCD40L) that was captured on a streptavidin sensor chip surface. The tests involved the sequential injection of a specified molecule (phase “a”), immediately followed by injection of the same molecule in the presence of a second specified molecule (phase “b”), followed by dissociation (phase “c”). Competition for binding is identified as a reduction (blocking) of the binding signal for the second molecule in the presence of the first, with the level of blocking being governed by the association and dissociation kinetics of each molecule. For each pair of molecules tested, the binding of the second molecule was shown to be reduced when the first molecule was present. These result suggest that BMS2h-503-1, BMS2h-572-6, BMS2h-719-17, and 5c8 Fab compete with each other for binding to biot-IZ-hCD40L.
FIG. 26 shows SPR sensorgram data for binding of the indicated dAb-CT-long and the 5c8-CT-long molecules to either human CD40L monomer (triple CD40L mutant (T211E, S222Y, H224K, [108-261])) or to CD40L trimer (IZ-hCD40L). The dAb-CT-long and the 5c8-CT-long molecules were captured via their “CT-long” Fc-domain on an immobilized anti-human IgG Fc (Biacore, GE Healthcare) antibody sensor chip surface. The data in the top 3 panels show that human CD40L monomer binds specifically to BMS2h-719-202-CT-long and 5c8-CT-long, but does not bind to any of the indicated dAb-CT-long molecules that contain dAbs from the BMS2h-572-6 lineage. In contrast, the bottom 3 panels show that CD40L trimer (IZ-hCD40L) binds strongly to all the tested dAb-CT-long molecules from the BMS2h-572-6 lineage, as well as to BMS2h-719-202-CT-long and 5c8-CT-long. These results suggest that the molecules from the BMS2h-572-6xx-CT-long lineage are specific for an epitope that is only present on the CD40L trimer and not present on monomeric human CD40L, whereas BMS2h-719-202-CT-long and 5c8-CT-long bind to an epitope that is present on both the CD40L monomer and trimer.
Although the present embodiments have been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of these embodiments, and would be readily known to the skilled artisan.

## Claims

1. An isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO: 1, wherein the first variable domain comprises
(a) a CDR1 region having a sequence Trp-X1-Leu-Met-Gly (SEQ ID NO: 2), wherein X1 is Glu or Gln,
(b) a CDR2 region having a sequence Gly-Ile-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQ ID NO: 3), and
(c) a CDR3 region having a sequence Lys-X2-Y2-Z2-Ser-Asp-Tyr (SEQ ID NO: 4), wherein X2 is Asp or Glu, Y2 is Ala or Ser, and Z2 is Lys, Asn, or Arg.

2. The antibody polypeptide of claim 1, wherein the first variable domain comprises the amino acid sequence of:
BMS2h-572-10 (SEQ ID NO: 225), BMS2h-572-11 (SEQ ID NO: 226), BMS2h-572-12 (SEQ ID NO: 227), BMS2h-572-14 (SEQ ID NO: 229), BMS2h-572-15 (SEQ ID NO: 230), BMS2h-572-22 (SEQ ID NO: 237), BMS2h-572-23 (SEQ ID NO: 238), BMS2h-572-6 (SEQ ID NO: 243), BMS2h-572-604 (SEQ ID NO: 247), BMS2h-572-607 (SEQ ID NO: 250), BMS2h-572-608 (SEQ ID NO: 251), BMS2h-572-609 (SEQ ID NO: 252), BMS2h-572-610 (SEQ ID NO: 253), BMS2h-572-611 (SEQ ID NO: 254), BMS2h-572-612 (SEQ ID NO: 255), BMS2h-572-613 (SEQ ID NO: 256), BMS2h-572-614 (SEQ ID NO: 257), BMS2h-572-616 (SEQ ID NO: 259), BMS2h-572-619 (SEQ ID NO: 262), BMS2h-572-630 (SEQ ID NO: 271), BMS2h-572-631 (SEQ ID NO: 272), BMS2h-572-632 (SEQ ID NO: 273), BMS2h-572-633 (SEQ ID NO: 274), BMS2h-572-634 (SEQ ID NO: 275), BMS2h-572-635 (SEQ ID NO: 276), BMS2h-572-8 (SEQ ID NO: 278), or BMS2h-572-9 (SEQ ID NO: 279).

3. The antibody polypeptide of claim 1, wherein the first variable domain comprises the amino acid sequence of BMS2h-572-633 (SEQ ID NO: 274).

4. The antibody polypeptide of claim 1, wherein the antibody polypeptide is a domain antibody (dAb).

5. The antibody polypeptide of claim 1, wherein the antibody polypeptide is a fusion polypeptide comprising the first variable domain and an Fc domain.

6. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises an IgG4 Fc domain.

7. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises an IgG1 Fc domain.

8. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises a CT-Long domain (amino acids 139 to 370 of SEQ ID NO: 1362).

9. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises a CT-short domain (amino acids 138 to 362 of SEQ ID NO: 1363).

10. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises a N297Q Long Fc domain (amino acids 139 to 370 of SEQ ID NO: 1364).

11. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises a N297Q Short Fc domain (amino acids 138 to 362 of SEQ ID NO: 1365).

12. The antibody polypeptide of claim 1, wherein the antibody polypeptide further comprises a second variable domain that specifically binds a second antigen, wherein the second antigen is an antigen other than human CD40L.

13. The antibody polypeptide of claim 12, wherein the second antigen is a cluster of differentiation (CD) molecule or a Major Histocompatibility Complex (MHC) Class II molecule.

14. The antibody polypeptide of claim 12, wherein the second antigen is serum albumin (SA).

15. A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of claim 1 and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15, further comprising an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.

17. A method of antagonizing CD40L activity in a patient with an immune disease in need of such treatment, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 15.

18. The method of claim 17, wherein the isolated antibody polypeptide is administered in combination with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.

19. The method of claim 17, wherein the immune disease is an autoimmune disease or a graft-related disease.

20. The method of claim 17, wherein the immune disease is a graft-related disease.

21. The method of claim 20, wherein the graft-related disease comprises solid organ, tissue and/or cell transplant rejection.

22. The method of claim 20, wherein the graft-related disease is graft versus host disease (GVHD).

23. The method of claim 20, wherein the graft-related disease is an acute transplant rejection.

24. The method of claim 20, wherein the graft-related disease is a chronic transplant rejection.

25. The method of claim 20, wherein the isolated antibody polypeptide is co-administered with a CTLA4 mutant molecule.

26. The method of claim 25, wherein the CTLA4 mutant molecule is L104EA29Y-Ig (belatacept).

27. The method of claim 17, wherein the immune disease is selected from the group consisting of Addison's disease, allergies, ankylosing spondylitis, asthma, atherosclerosis, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes, including Type 1 and/or Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products, systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, alcohol addiction, and drug addiction.

28. The method of claim 17, wherein the immune disease is selected from the group consisting of myasthenia gravis, idiopathic thrombocytopenic purpura, and systemic sclerosis.

29. An isolated antibody polypeptide comprising a first variable domain, wherein said antibody polypeptide specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO: 1, wherein the antibody polypeptide competes with the binding of BMS2h-572-633, and wherein the antibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM.

30. The isolated antibody polypeptide of claim 29, wherein the first variable domain comprises the amino acid sequence of one of the antibody polypeptides selected from the lineage group consisting of BMS2h-572, BMS2h-719, BMS2h-503, and BMS2h-116.

31. The isolated antibody polypeptide of claim 30, wherein the first variable domain comprises an amino acid sequence at least 95% identical to BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313, or BMS2h-116-1320.

32. The isolated antibody polypeptide of claim 31, wherein the first variable domain comprises the amino acid sequence of BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313, or BMS2h-116-1320.

33. The antibody polypeptide of claim 5, wherein the amino acid sequence of the fusion polypeptide is set forth in SEQ ID NO: 1355.

34. The antibody polypeptide of claim 5, wherein the fusion polypeptide comprises the first variable domain consisting of the amino acid sequence of BMS2h-572-633 (SEQ ID NO: 274) and an Fc domain consisting of the amino acid sequence of amino acids 139 to 370 of SEQ ID NO: 1362.

35. The antibody polypeptide of claim 34, wherein the first variable domain and the Fc domain are linked by an amino acid sequence selected from the group consisting of: AS, AST, TVAAPS (SEQ ID NO: 13), TVA, ASTSGPS (SEQ ID NO: 14) and (GGGGS)n (SEQ ID NO: 12) wherein n is 1, 2, 3, 4, or 5.

36. The pharmaceutical composition of claim 15, comprising the antibody polypeptide of claim 34.

37. The pharmaceutical composition of claim 15, comprising the antibody polypeptide of claim 35.